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Abstract
African trypanosomes are blood dwelling eukaryotic parasites infecting a wide range of
mammals in sub saharan Africa, causing significant disease in humans and cattle. The
predominant route of transmission is by the bite of an infected tsetse fly, which represents
the main vector between mammalian hosts. The disease, termed African Sleeping Sickness
in humans and Nagana in cattle, is often characterised by a chronic infection profile, and
the chronicity is due largely to a dedicated system of immune evasion termed antigenic
variation. African trypanosomes are shielded by a homogeneous glycoprotein coat whose
main component is the Variant Surface Glycoprotein (VSG). This protein is highly
immunogenic and targeted by host antibodies. Escape is achieved by switching to a non-
cross reactive VSG isoform, by either transcriptional or recombinational mechanisms.
Repeated switching allows continual escape from antibodies, and the "directionality" of
this process is achieved by interaction with the immune response: VSGs have been shown
to have different activation probabilities depending on their locus, so in the absence of
antibodies only antigens with the highest activation probabilities would be detected. VSGs
are transcribed from telomeric expression sites, and telomere-proximal silent alleles (-200)
are known to be expressed early in infection: ease of sequence interaction and extensive
homology results in such gene conversion events to be favoured. Most alleles (-1000) are
located on megabase chromosomes, in arrays that have been recently defined to be
subtelomeric. These alleles have lower activation probabilities and appear later in
infection, enhancing the chronicity of the disease and therefore its transmission and
persistence.
The aim of this thesis was to further our knowledge about the contribution of silent alleles
on megabase chromosomes to the late stages of trypanosome infection and test the
hypothesis that this contribution takes shape in a hierarchy of expression due to differences
between alleles in terms both of flanking regions and coding sequence. This was achieved
through a combination ofbioinformatics and molecular studies. The initial approach was
to undertake an extensive manual curation of the available VSG archive; this endeavour
resulted in establishment of a fertile collaboration with the Trypanosoma brucei genome
sequencing project (http://www.sanger.ac.uk/Projectsff bruceiD, and in creation, with the
aid of P. Ward and S. Menon, of a dedicated web-based tool to handle and query curated
VSG genes (http://www. vsgdb.orgD. Out of an updated estimate of -1600 VSG genes, 940
(between half and three quarters) were annotated and shown to be arranged in subtelomeric
arrays and to be largely present as pseudogenes (-90%). By considering separately the
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hypervariable N-terminal domain (three types, A, B and C) and the more conserved C-
terminal domain (types 1 to 4, with two additional types identified in this study), it
appeared that most of the degeneracy lied in the C-terminal domain. This suggested that
N-terminal domains (one third of them being intact) would be utilised by a process of
segmental gene conversion yielding hybrid genes, by recombination with functional C-
terminal ends resident at the expression site. Under the assumption that "order" within the
genome (the presence of patterns within the VSG archive) helps inform "order" in VSG
expression (a hierarchy based on different activation probabilities), itwas somewhat
surprising to detect little evidence of clear sub structuring within the archive: no "classes"
of VSGs could be identified, based on coding sequence and flanking sequence features. In
keeping with the observed high level of divergence within the VSG archive, clear
orthologue groups (here defined as alleles sharing >60% amino acid sequence identity)
were found not to include more than three to four members and to be scattered at random
across the arrays. Putative functional genes could not be separated into groups based on
expected differences in activation probabilities, such as a different number of upstream 70-
bp repeats, shown to be involved in copying silent alleles to the expression site.
Due to the lack of order found in the VSG archive, the "simple" hypothesis that led to the
planning of an in vivo experiment was that mosaic gene formation would give rise to a
significant fraction of late appearing variants. A chronic mouse infection involving eleven
animals was conducted, and this allowed gDNA and RNA from different timepoints to be
obtained, between day 3 and day 28 (each mouse was terminally sampled). Expressed
VSG genes were amplified from cDNA, then cloned and sequenced; the sequences
obtained were then queried against the T. brucei genome database
(http://www.genedb.org/genedb/tryp/index.jsp). Indeed, it appeared that mosaic genes
represented a high proportion (five out of eight) of variants detected in the two infections
at day 28. Two of the putative mosaics were confirmed experimentally by PCR. In
addition, a significant number of point mutations were observed between putative donor
and cDNA sequences and found to correlate with regions of reduced protein secondary
structure potential, possibly representing surface loops and epitopes. Mutations were more
numerous later in the infection, showing a timing of appearance similar to that of mosaic
genes. These novel fmdings pose two major questions as to the kinetics of late stage
antigenic variation: firstly, to what extent is a hierarchy present late in infection, and to
what extent order is abandoned, allowing a different infection profile to emerge. Secondly,
whether further variation within expressed mosaic genes and accumulation of point
mutations contribute to the process of antigenic variation or are important only when
considering long-term archive diversification. Detailed discussion of the data leads to the
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proposal that a mutator phenotype might be selected for late in infection, as this might
increase the frequency of these heretofore underestimated sequence variation mechanisms.
An additional and unexpected finding was the detection of the novel gene family of VSG-
related genes. Bioinformatic analysis showed that its -30 alleles are genetically and
physically separate from T. brucei VSGs. Although N-terminally they resemble very
closely type B VSG N-terminal domains, their C-terminal end is divergent, bearing closer
similarity to that of T. congo/ense VSGs. Their expression was shown to be unlinked to the
monoallelic expression of VSGs, and it appears that several members of this family are
expressed at the same time, in all likelihood from their own loci. The presence of a signal
peptide and the potential for GP! anchoring (at least in some of the alleles) suggests that
VSG-related genes might encode surface receptors, adding to the diversity of the VSG
superfamily. This already includes, apart from VSGs themselves, the receptor for host
transferrin (ESAG6 and ESAG7 genes) and a gene associated with human serum resistance
in a subset of human infective T. brucei strains (SRA gene). Whether a similarly important
role can be ascribed to VSG-related genes remains to be established.
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1CHAPTER 1
INTRODUCTION
21.lntroduction
1.1 African trypanosomes
"The trypanosomes of man have neither abandoned their evolutionary cradle nor reached their
ultimate parasitological destination; they still pursue the protracted odyssey which a parasite must
follow during the hazardous traverse from an ancient host to a new one, and the consequences of
human infection betray the insecurity of an undecided relationship" (Duggan, 1970)
African trypanosomes are unicellular eukaryotes constituting the Salivarian branch of
trypanosomes, a monophyletic group branching from the order kinetoplastida' 400 mya
(Simpson et al., 2006). One of their distinguishing features is the evolution of a complex
form of immune evasion termed antigenic variation, which enables them to sequentially
activate different non cross-reactive copies of their surface antigen (VSG, Variant Surface
Glycoprotein), thereby establishing a chronic infection in their vertebrate hosts, causing an
often fatal disease that in humans is termed African Sleeping Sickness and in cattle is
termed Nagana. Many different aspects of antigenic variation have been studied. Broadly
speaking, there are biological studies, in which the course of an infection is monitored and
the growth patterns of trypanosome variants are studied in relation to the immune response.
There are also biochemical and molecular studies concerning VSG protein structure and
organisation of VSG genes, their transcription and the mechanisms of switching from one
gene copy to another (Turner, 1999). All these studies are interrelated and overlapping,
with molecular and biochemical results feeding into the overall understanding of infection,
and general biological considerations providing the framework for testing hypotheses at
the molecular level.
Firstly, the species and life cycle of African trypanosomes will be presented, followed by
general features of genome organisation, replication, transcription and translation.
Secondly, an overview of the cell surface of these parasites will be given, leading to the
VSG system, looking at the VSG coding sequence, its diversity and its features at the
protein level. Thirdly, the mechanisms by which VSGs are expressed and expressed VSGs
are replaced by other VSG copies will be considered, with the aim of conveying the current
1Kinetoplastids are defmed as flagellated protozoa with an unusually organised mitochondrial genome,
termed kinetoplast or kDNA (Lukes et al., 2005). Within this group other important organisms are
Trypanosoma cruzi and Leishmania species.
3understanding of antigenic variation at the molecular level. Lastly, the broader issue of
VSG divergence and evolution will be addressed, and antigenic variation strategies of other
parasites will be considered, to put African trypanosomes into perspective.
1.1.1 Species
There are three main species of African trypanosome: Trypanosoma brucei, Trypanosoma
congolense and Trypanosoma vivax; most research has been conducted on T. brucei, as it is
the only one to infect humans and grows more easily than the others in laboratory
conditions. The remaining two are important livestock parasites, T. congolense being the
most widespread and T. vivax being the most pathogenic. While keeping T. brucei as the
main focus, information on antigenic variation will be given, where appropriate and if
available, on studies conducted on T. vivax and T congolense. Table 1.1 gives a brief
summary of the species within the Salivaria.
Table 1.1: African trypanosomes (Hoare, 1970).
SPECIES VERTEBRATE VECTOR DISTRIBUTION
HOST ffRANSMISSION
A) Duttonella Development only in
proboscis'
T. vivax Cattle, sheep, goats, Tsetse fly (Africa); Africa, South America
equines, camels tabanid flies (South
America)
B) Nannomonas Development in
midgut and proboscis'
T. congolense Cattle, sheep, Tsetse fly Equatorial Africa
goats
T. simiae Pigs Tsetse fly Central and East Africa
C) Trypanozoon Development in
midgut and salivary
glands'
T. bruce; Equines, sheep, Tsetse fly Equatorial Africa
goats, humans
T. evansi' Equines, camels Tabanid flies Africa, Middle East, Asia
(mechanical and Latin America
transmission)
T. equiperdum Equines Transmitted by Africa, Middle East
venereal contact
2 This refers only to tse tse infections, mechanical transmission by tabanid flies does not involve any
development of parasites in the vector (see Section 1.1.2).
3 T. evans;is thought to have evolved recently from T. bruce;on the northern extremity of the tsetse belt
following infection of camels by tsetse, then to have been propagated by mechanical transmission by tabanid
flies. Ithas spread to the Middle East, Asia and Latin America.
4Within the subgenus Trypanozoon are T brucei together with its close relatives
Trypanosoma evansi and Trypanosoma equiperdum, which have separated by developing
alternative modes of transmission, allowing them to spread beyond the tsetse equatorial
habitat (see Table 1.1). T brucei has been classified into three subspecies, T brucei
brucei, T brucei gambiense and T brucei rhodesiense. The differences between
subspecies are thought to be relatively small: the human-infective subspecies can be
identified because, unlike T brucei brucei, they are resistant to lysis in vitro by human
serum. The distinction has been found to be not so clear-cut, as together with sensitive and
resistant T brucei, a third groups of strains with an intermediate phenotype has recently
been characterised: this latter group, of which strain T brucei 927 is an example, shows
slower kinetics of lysis, compatible with growth in the presence of human serum (at least
in vitro), and, unlike sensitive strains, has the ability to develop resistance upon prolonged
exposure to human serum (Turner et al., 2004). A further complication in defining these
subspecies is due to the fact that genetic exchange can readily occur between them (see
section 1.1.2), which in turn could cause spread and modification of serum resistance traits.
The extent as to which this happens in the wild has not been ascertained, as population
studies have so far established the pattern of exchange within, rather than between
subspecies (A. MacLeod, pers. comm.). The three phenotypes detected with regards to
lysis in the presence of human serum have been ascribed to the action of a limited number
of genes (Turner et al., 2004), one of which, SRA (Serum Resistance-Associated gene),
present in T. rhodesiense, has been extensively characterised (Oli et al., 2006). Basic
features of the three T brucei subspecies are given in Table 1.2.
Table 1.2: T. bruce; species (Hoare, 1970).
Species VERTEBRATE HOST/ DISTRIBUTION COMMENTS
VECTOR
T. brucei Cattle, pigs, horses, sheep, All equatorial Africa Lack of human
brucei goats; game animals / where tsetse flies are infectivity is main
Glossina morsitans (main present distinguishing trait'
vector)
T. brucei Humans, reservoir host First appeared in Anthropozoonosis;
rhodesiense overlapping with T brucei Zambia; spread across Causes acute Sleeping
brucei I Glossina East Africa (savanna) Sickness
morsitans (dry fly)
T. brucei Humans; non-human West and central Anthroponosis; causes
gambiense reservoir secondary / Africa (rivers) chronic Sleeping
Glossina palpalis (wet fly) Sickness
4 See text above and (Turner et al., 2004) for caveat on this statement.
1.1.2 Life cycle
Trypanosomes are transmitted to their vertebrate host by the bite of an infected tsetse fly,
injected below the skin tissue as the fly takes a blood meal. The developmental stage of
the initial infecting trypanosome population (10-10000 trypanosomes) is termed
metacyclic: it develops in the salivary glands of the tsetse and is already expressing a VSG
coat (Tetley et al., 1987) (see Figure 1.1 for a life cycle outline). Non-dividing metacyclic
trypanosomes evolve into what has been described as the long slender bloodstream form
(BSF), the growth of which results in peaks of parasitaemia corresponding to antigenically
distinct VATs' emerging (Capbem et al., 1977). The mechanics of the process will be
explained later in this chapter, for now suffice it to say that at each peak of growth a
density-dependent differentiation into the cell-cycle-arrested short stumpy BSF occurs, the
latter being responsible for infecting the tsetse fly (Gruszynski et al., 2006). As
demonstrated by laboratory studies, only a small proportion of flies becomes infected (T.
brucei has the lowest fly infection rate amongst the Salivaria, T. congolense and T. vivax
showing a higher adaptation to the insect vector), and trypanosomes undergo several
population bottlenecks as they develop from the midgut of the fly to the salivary glands,
over the course of at least two weeks (Gibson and Bailey, 2003). Both infection rate and
length of cycle have been shown to be temperature dependent, higher physiological
temperatures (up to 37°C) resulting in a higher infection rate and a faster cycle through the
fly (Hoare, 1970). In the midgut of the fly, the trypanosome becomes the pro cyclic form
(PF), with a coat presumably more suitable to the new environment, made of a small set of
proteins called procyclins (Liniger et al., 2004). The procyclic trypanosome then
undergoes a process of maturation, involving further rounds of differentiation, as it makes
its way to the salivary glands (Urwyler et al., 2005), to the epithelium of which it becomes
attached. Attachment is accompanied by development into the epimastigote stage, a
replicating stage that gives rise to the next metacyclic trypanosome population, leading to
completion of the life cycle (see Figure 1.1).
S Variable antigen type CVAT) is referred to as a population oftrypanosomes expressing the same VSG at a
given time. Different subpopulations express different VSGs during the course of infection. MVAT is a
population of metacyclic trypanosomes expressing a given VSG. A BVAT is the bloodstream equivalent.
6Figure 1.1: Life cycle of T. brucel (Barry and McCulloch, 2001).
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71.1.3 Genome organisation
The diploid genome of T. brucei strain 92714 (haploid size 26 Mb) has been shown to
contain 9068 predicted genes, including -900 pseudogenes and -1700 T. bruce i-specific
genes, the remainder being shared with the other sequenced kinetoplastids, Leishmania and
Trypanosoma cruzi (Berriman et al., 2005). The genes of T. brucei are tightly packed and
oriented unidirectionally over long regions, as it is probable that they are transcribed
polycistronically. These polycistrons are found to be very conserved across kinetoplastids,
highlighting the fact that key housekeeping functions have been retained. In addition,
regions of discontinuity appear at strand switches between polycistrons, suggesting in the
case of T. brucei that the current chromosomes have originated from several chromosome
fusion events (Ghedin et al., 2004). Early analysis of cosmid clones suggested clustering
of VSGs in arrays in the genome (Van der Ploeg et al., I982b): this has been confirmed
bioinformatically, and the location of these clusters has been shown to be predominantly
subtelomeric (see Chapter 3).
The diploidy of T. brucei is not typical, as it has been demonstrated so far only for the 11
megabase (1-6 Mb) chromosomes and not for the several (between one and five")
intermediate (200-900 kb) chromosomes and around 100 minichromosomes (50-150 kb)
(Ersfeld et al., 1999); triploidy occasionally arises as a result of mating in the fly, but is
considered to be rare and to occur mostly between subspecies (Gibson and Stevens, 1999;
Hope et al., 1999). Furthermore, VSG genes and VSG expression sites appear to be
haploid, as often only single copies of VSG genes are recovered (Morrison et al., 2005);
haploidy has been shown for the expression site (VSG transcription unit, see section 1.3.1)
on chromosome (chr) 1 (El Sayed et al., 2000) and for the VSG arrays on chr 8 (Berriman
et al., 2005), chr 5 and chr 11 (Berriman, pers. comm.). Intermediate chromosomes and
minichromosomes have been shown to harbour only VSGs and VSG expression sites
(which contain also other genes, see section 1.3.1) and to be present only in small numbers
in T. vivax, suggesting a potential expansion of the VSG archive in T. brucei and T.
congolense (Barry and McCulloch, 2001; Wickstead et al., 2004).
Strains of T. brucei differ by as much as 25% in their haploid DNA content (compared
with the genome strain) (El Sayed et al., 2000) and within each strain there are large size
differences between pairs ofhomologues (up to fourfold, assessed by pulsed field gel
electrophoresis) (Gottesdiener et al., 1990). Whereas comparison of chr la ofTREU 927/4
6 two in the 927/4 genome strain (Hom and Barry, 2005).
8with chr 1 of STIB 247 showed that differences were also due to the presence of variation
in the core region of the chromosome (source unknown, but possibly involving tandemly
repeated genes' and variation at strand switch regions), it appears that differences between
chr la and the homologue 1b were largely due to differences in the subtelomeric repetitive
region (Melville et al., 1999). This subtelomeric repetitive region had been associated with
the retrotransposon INGI and can now be safely assumed to correspond to VSG arrays, as
revealed by the genome project (further considerations on this matter will be made in
Chapter 3, and section 3.2.1 in particular).
1.1.4 Transcription and translation
In all kinetoplastids studied, transcription is polycistronic, with up to 90 genes in a single
transcription unit in the case of T. brucei; these polycistrons are composed of genes that
appear largely unrelated in function (El Sayed et al., 2003). It has been reported that genes
within the same polycistron can differ in the levels of transcript they yield and in the
developmental stage in which they are expressed (Belli, 2000). If each gene has an upper
limit of transcript abundance dependent on basal polycistronic transcription, genes
encoding abundant proteins are likely to be present in multiple copies, and this is indeed
the case for the tubulin genes, for which an array of -15 copies is present. Some tandem
duplications have also led to diverged copies of the original genes, possibly when the
constraints of high expression were not great; the current estimate is that unique genes
represent around 50% of the total number, this figure broadly reflecting the common
occurrence (and importance) of duplications (H. Renauld, pers. comm.).
In order to produce mature mRNA from the polycistronic transcript, each gene, as
transcribed, is individually processed with a 39 nt leader sequence (miniexon) spliced in
trans to the 5' end. This spliced leader sequence supplies the mRNA cap and its acceptor
site is the first AG dinucleotide following an 8-25 nt polypyrimidine tract.
Polyadenylation occurs as a coupled reaction, dependent on trans-splicing of the
downstream gene, as no "autonomous" consensus signal for polyadenylation is to be found
at the 3' end of the nascent transcript (Benz et al., 2005). Trans-splicing results in what
has been termed discontinuous transcription and has been found to occur also in nematodes
and several other protozoa and lower chordates, but in kinetoplastids alone it is the only
system available for gene expression (Das and Bellofatto, 2003).
, Polymorphism in copy number has been shown for several genes, including those encoding tubulin, actin
and the glucose transporter THT-l (Barrett et al., 1996).
9Gene regulation therefore seems to occur mostly at various post-transcriptional levels, with
mechanisms possibly including mRNA processing (trans-splicing and polyadenylation),
nucleocytoplasmic export, mRNA stability, antisense mRNA, translational control and post
translational turnover of proteins' (D'Orso et al., 2003). It has been speculated that the 3'
VTR of each gene would be the most important cis element allowing developmental
regulation of transcribed genes, based on studies conducted on EP-procyclin 3' VTR
(Matthews et al., 2004). As for trans-acting factors involved in post-transcriptional
regulation, to date (literature search updated to 2006), only proteins involved in trans-
splicing and mRNA turnover have been identified (D'Orso et al., 2003).
Eukaryotic transcription is mediated by three types of polymerase (pol), of which poll
generates rRNA, polII yields mRNA and some small nuclear RNA, and polIII synthesizes
tRNA and some other small nuclear RNA. In T. brucei there is a lack of recognisable
promoter elements for polII upstream of individual polycistrons, the only polII promoters
found being those associated with the 39 nt spliced leader sequence (Palenchar et al.,
2006). PolII appears to be the sole polymerase responsible for constitutive transcription of
polycistrons, as knockdown of one of its subunits resulted in transcription being restricted
to the nucleolus, where poll operates (Devaux et al., 2006). Another unusual feature of
transcription in T. brucet is that the stage-regulated procyclic and bloodstream surface coat
proteins (procyclins and VSGs) are transcribed from expression sites that are driven by
poll. This is the only example of poll transcribing mRNA, possibly to allow high levels of
transcription for these very abundant proteins (Gunzl et al., 2003): VSG mRNA levels are
comparable to those of the tubulin gene, which is polII-transcribed but is present in -15
copies (Kooter and Borst, 1984).
An important aspect when considering transcription is also the level of compaction of the
DNA substrate into organised chromatin. T. brucei appears not to have as wide a range of
chromatin states as do other organisms. This possibly is due to the linker histone HI
protein being shorter than usual in trypanosomes, resulting in highly condensed
chromosomes not being visible at mitosis (Hom, 2001). A role in chromatin condensation
has been nevertheless ascribed to histone HI. The fact that chromatin appears to be more
condensed in the bloodstream form than in the procyclic form positively correlates with a
higher level of expression of histone HI in the bloodstream form (Belli, 2000). Chromatin
8 Transcriptional elongation has been shown to be an important stage of gene regulation in the case of VSG
expression sites (see section 1.4.1), but it is not known whether it could be of importance for housekeeping
genes.
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is likely to playa role in the regulation of cell surface protein genes that are
developmentally regulated at the level of transcription (see section1.4.1).
1.2 Antigenic variation: the VSG gene and the
trypanosome cell surface
Having presented the core features of African trypanosomes, and before moving on to the
mechanisms by which they conduct antigenic variation, it is important to discuss more
closely the features of the antigen, the Variant Surface Glycoprotein, or VSG.
1.2.1 VSG archive
Considering the full potential of immune evasion of African trypanosomes leads to the
question of how many VSG gene silent copies are present: this silent potential will be
referred to as the VSG archive. Up to -200 VSGs are expected to be located at telomeres in
all chromosome classes (especially in minichromosomes), but the majority of them are to
be found in long arrays located subtelomerically in the megabase chromosomes,
accounting for -20% of the whole genome sequence (Berriman et al., 2005). The number
of VSGs had previously been estimated to be around 1000 (Vander Ploeg et al., 1982b),
but is now thought to vary greatly depending on the trypanosome strain, due to the
plasticity ofT. brucei subtelomeres (see section 1.1.3 and 3.2.1 for more details). The
archive composition of different strains can vary significantly, as only a few common
VSGs have been found (Bernards et al., 1986); the precise degree of overlap between T.
brucei strains is currently unknown, and a larger set of genes would have to be considered
and compared in order to draw more definite conclusions (see Chapter 5, section 5.3.1 for
an additional discussion on this matter).
1.2.2 VSG structure and function
VSG domains, post-translational modifications and folding will now be considered, leading
to a description of the trypanosome cell surface. The information below and in the rest of
this chapter attempts to summarise the vast amount of data generated since the early 1980s,
dealing with the molecular mechanisms of antigenic variation and, directly or indirectly,
with VSG structure. It includes a survey of full-length VSG sequences deposited in the
online databases (ncbi, http://www.ncbi.nlm.nih.gov/gquery/gguery.fcgi?itool=toolbar;
expasy, http://us.expasy.org!, January 2006), which yielded 97 distinct variants, all but one
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derived from mRNA transcripts. Eighty-six are from the Trypanozoon subgenus (T.
brucei, evansi, equiperdum), 10 are from T. congolense and one is from T. vivax. A table
(Table 7.1) with all sequences listed with accession number and key reference is provided
in the Appendix, and Figure 1.2 summarises the primary sequence features and diversity of
these sequences.
T. brucei VSGs are 400-500 amino acids (aa) long and are composed of an N-terminal
(350-400 aa) and a C-terminal (100-150 aa) domain (see Figure 1.2). The domains are
separated by a "hinge" region that is sensitive to proteolysis (Johnson and Cross, 1979),
recently defined to be -15 amino acids long (Chattopadhyay et al., 2005). There are three
N-terminal domain types (A-C) and four C-terminal domain types (1-4) (Carrington et al.,
1991) and these can be identified by the pattern of cysteines along the length of the protein,
forming an N- and a C-terminal cluster. A notable difference between the two domains is
the level of sequence conservation, which is much higher in the C-terminal domain (40%
identity between domains is common), while the N-terminal domain tends to be
hypervariable (17-22% identity) (Rice-Ficht et al., 1981). T. congolense and T. vivax
VSGs are shorter (between 350 and 410 aa long), mainly due to the absence of a defined
C-terminal domain, and all known VSGs of these trypanosome species have homology
only with the T. brucei type B N-terminal domain. The C-terminal end of T. congolense
VSGs has been found to be proline-rich (Rausch et al., 1994), possibly resulting in
formation of a rigid elongated structure that might increase the height of these shorter
VSGs (Carrington and Boothroyd, 1996).
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Figure 1.2: Primary structure features of known expressed VSGs, with cysteine pattern
highlighted.
Cysteine residues are depicted as full-length vertical bars. Half-length vertical bars indicate
the GPI signal cleavage site, if known. Example VSGs are given for each domain
combination found, ordered based on the N-terminal domain. The number of VSGs falling
into each category is given to the right. N- and C-terminal domains are divided by a vertical
dashed line, apart from the case of T. congo/ense and T. vivax, which do not have such
distinct C-terminal domains (see text for discussion). C-terminal domains type 1, 2 and 3
are boxed in green, purple and blue respectively. VSG sequences underlined in red
correspond to the types for which tertiary structure has been determined by
crystallographic studies.
There are several steps leading to the VSG becoming a surface glycoprotein. Initially,
around 20 hydrophobic amino acids (signal peptide) are removed by a type I signal
peptidase, directing the VSG to the secretory pathway through the endoplasmic reticulum
(ER) and Golgi, where VSG folding and further post-translational modifications occur.
The tertiary structure ofVSGs has been solved for two T brucei type AN-terminal
domains (ILTat 1.24 (Blum et al., 1993); MITat 1.2 (Freymann et al., 1990)), and for a
type 2 C-terminal domain (MITat 1.2 (Chattopadhyay et al., 2005)). It appears that VSGs
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with very different primary sequence have a remarkably similar N-terminal domain fold,
termed the VSG fold, consisting of two antiparallel alpha helical regions (helix A and helix
B in Figure 1.3) followed by loops and smaller helices. The structure is held together by
four cysteines forming two disulphide bridges, only one of which is thought to be essential,
as there is an example of an expressed VSG (MYATS) with only three cysteines (Blum et
al., 1993). A comparison of the two N-terminal domains for which the structure has been
solved shows that structural identity reaches 60% (over 207 residues), and that residues
with identical structure show only 16% sequence identity (Blum et al., 1993). The N-
terminal domain is also responsible for the dimerisation of the protein (Auffret and Turner,
1981). Type B domains appear to share with type A the position of the first cysteine at the
beginning of the domain and sequence analysis (detection of hydrophobic heptad repeats)
suggests the presence of two antiparallel alpha helices separated by a region containing
glycine and/or proline; although the pattern of cysteines differs, it is therefore likely that
type B domains share the same VSG fold as type A (Blum et al., 1993). The same heptad
repeat pattern has also been found in T congolense VSGs (Rausch et al., 1994). These
findings rendered obsolete a previous hypothesis envisaging antigenic variation deriving
from multiple folding patterns (see for example Strickler et al. (1987».
ILTat 1.24 (Ai)
I I I IIII IIIIIull~I~1 t~__~I ~I~I~I~I~lllll~I~~ ~1 2D crystal data
cc:n:::=:::::n~=:::c======:::::::c:::r::c::J:J:[]::r::::=C=::C::::====::=:J Jpred
MiTat 1.2 CA2)
I I I I It!I IIf I IIII 2D crystal data
Jpred
o 100 200 300 400 500 Aminoacids
Helix Helix
a b
Surface
loops
Helix S + glycine
+ proline
Figure 1.3: VSG secondary structure representation for MITat 1.2 (N-terminal domain type A,
C-terminal domain type 2) and ILTat 1.24 (N-terminal type A), the two VSGs for which the
crystal structure has been solved in detail.
Regions in red indicate alpha helices; crystallographic data is plotted into the first linear
diagram for each of the two genes, whereas the second narrower plot represents the output
of the secondary structure prediction program Jpred
(http://www.compbio.dundee.ac.ukl-www-jpredJ). used in Chapters 3 and 4 to present
putative secondary structure of VSG sequences obtained in this study (the output is shown
here for validation purposes).
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The C-tenninal domain has either four (domain types 2 and 4) or eight cysteines (types 1
and 3) (see Figure 1.2), with very few exceptions: four instances in three different strains
of a domain with a type 2 GPI signal, but devoid of cysteines (accession numbers
AAN78184, AF335471, AF335472 and ILTat 1.68, unpublished). The C-tenninal domain
is rich in lysine and glutamic acid and therefore hydrophilic, and this is thought to facilitate
interactions with the polar head of phospholipids on the plasma membrane (Allen et al.,
1982). Modelling the known crystal structure of the MITat 1.2 C-tenninal domain onto
other type 2 domains suggests that, as in the case ofN-tenninal domains, C-tenninal
domains share more higher order structure than primary sequence (Chattopadhyay et al.,
2005). Their sequence variation is high (especially due to short indels), although not as
high as between N-tenninal domains. An extra cysteine is sometimes present upstream of
the four or eight cysteines (hinge region), and this appears to be responsible for disulphide-
linked dimerisation in solution and may have similar properties in vivo, strengthening the
VSG dimer (Carrington et al., 1991; Blum et al., 1993). There appear not to be any major
constraints in domain combinations between different N- and C-tenninal domain types", as
can be seen from the variety of domain combinations found in expressed VSGs (see Table
7.1 in Appendix) and by the finding that VSGs with closely related N-tenninal domains
may have different C-tenninal domains (Hutchinson et al., 2003).
In the process of polypeptide maturation, within a minute from initial polypeptide
production (Ferguson et al., 1986), at least one N-linked oligosaccharide is added to most
C-tenninal domains, and another one to three may be added to the N-tenninal domain
(Carrington et al., 1991). The type of glycosylation varies and the pattern of glycosylation
is determined mainly by tertiary structure of the "acceptor" VSG (Zitzmann et al., 2000):
comparison of tertiary structure of the two crystallised N-tenninal domains suggested that
N-glycosylation in MITat 1.2 had the same structural role as a helix in ILTat 1.2 (Blum et
al., 1993). The contribution of glycosylation to VSG structure stability varies: by use of
the N-glycosylation inhibitor tunicamycin, this post-translational modification was shown
to be a requirement for correct cell surface expression ofVSG MITat 1.5, but not of MIT at
1.2 and MITat 1.4 (Ferguson et al., 1986). In addition, it was noted that six out of seven
type A N-tenninal domains that combined with type 1 C-tenninal domains were devoid of
N-glycosylation sites (Carrington et al., 1991), further suggesting that N-glycosylation
plays an important ancillary structural role and might be a factor in determining whether
specific domain combinations are viable. Further experimental evidence tends to support
this view, at least in one in vitro study where the N-glycosylation site was mutated (Wang
9 different N-glycosylation patterns might constitute a constraint to domain combinations, see next paragraph.
~-,,~c-~ _
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et al., 2003). N-glycosylation is not present in the only studied T. vivax VSO (Oardiner et
al., 1996).
While still in the ER, the hydrophobic C-terminal extension (17-23 aa) is replaced via a
transamidation reaction by a glycosylphosphatidylinositol (OPI) lipid anchor, which is in
turn extensively modified by galactose. OPI signals in expressed VSOs appear to be very
conserved, most being either 17 or 23 amino acids long (type 2 and types 1,3 and 4 C-
terminal domains respectively). Mutational analysis suggests that in vitro the sequence
requirements may not be as stringent as might have been expected from known expressed
VSOs (Bohme and Cross, 2002), although there is no in vivo proof to support this claim.
On the other hand, the transamidation reaction is an absolute requirement even in vitro:
failure to add the anchor due to OPI signal cleavage site mutations results in ER retention
and degradation (Bohme and Cross, 2002). VSO secretion appears to be determined also
by its structure, as OPI-reporter constructs using other proteins with VSO signals were not
secreted (Bohme and Cross, 2002). There is evidence that T. congolense VSOs are OPI-
anchored, but the anchor site has not been determined experimentally for any variant
(Rausch et al., 1994). A OPI anchor site was suggested for one VSO (YNat 1.1) (Strickler
et al., 1987) by comparing amino acid and cDNA data, but there appears not to be the
degree of sequence conservation that occurs amongst T. brucei OPI signals, so it has been
difficult to extend this finding to other T. congolense variants.
When the VSO reaches the surface it covers the trypanosome in its entirety, forming what
has been defined as the "VSO coat" (see section 1.2.3 and Figure 1.4 for more
information). The C-terminal domain is buried within the coat, whereas the N-terminal
domain alpha helices project outwards, with the loops between helices predicted to occupy
the uppermost part of the protein, exposed to the immune system of the host. The pressure
for divergence therefore is acting most strongly on the N-terminal domain, with divergence
operating within the constraints of maintaining 3D structure". In contrast to the N-
terminal domain, definition of the role of the C- terminal domain remains problematic, as it
is not present in T. congolense or T. vivax. It was suggested to enhance the diffusion
barrier properties of the VSG by elongating its structure (Ziegelbauer and Overath, 1993),
although current modelling suggests that its compact structure may not warrant this role,
but rather increase packing horizontally in the monolayer (Chattopadhyay et al., 2005)11.
10 VSG divergence will be considered in more detail in subchapter 1.4.
11 This statement was made with reference to the solved type 2 C-terminal domain structure, with only four
cysteines. Whether packing alters significantly in the presence of an eight-cysteine domain remains to be
determined.
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In the same line of thought, N-glycosylation might have, together with its ancillary
structural role, a space-filling role to hinder immunoglobulin penetration in the monolayer
(Mehlert et al., 2002).
1.2.3 The trypanosome cell surface and VSG recycling
The primary function of the trypanosome cell surface appears to be that of immune
evasion, as VSGs account for 15-20% of total cell protein and >95% of surface proteins
(Barry and Carrington, 2004). The VSG protein is thought to form dimers on the cell
surface (Strickler and Patton, 1982) with 5.5 x 106 dimers per cell, resulting in the
production of a 12-15 nm thick coat (Vickerman, 1969) (see Figure 1.4), extending also
within the flagellar pocket, a specific membrane invagination at the base of the flagellum
where receptor-mediated endocytosis takes place (Carrington et al., 1991).
IgG2
antibody
Transferrin
Transferrin
receptor
VSG
dimer
VSG coat
I
14.5 nm
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Figure 1.4: The trypanosome VSG surface coat.
To the left is a cross section of the parasite and its flagellum (f). The electron dense surface
coat (sc) can be seen very clearly. The second cross section, to the right, shows antibody
binding to the surface coat, by gold immunolabeling (20nm gold coupled to anti-VSG
(AnTat7.1) antibodies, image kindly provided by L. Tetley). The relative size of coat
components is given in the diagramatic illustration to the right, with the addition of the
structure of the IgG2 antibody and host transferrin (adapted from Borst and Fairlamb
(1998».
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Buried within the VSG coat, and therefore potentially shielded from the immune system,
are invariant molecules. They generally are not detected by antibodies on living
trypanosomes (Ziegelbauer and Overath, 1992) and include membrane transporters,
proteases and receptors (Chung et al., 2004). Two bloodstream form-specific invariant
surface glycoproteins of unknown function, ISG65 and ISG75, are present at respectively
70 000 and 50 000 molecules/cell (Ziegelbauer and Overath, 1992; Ziegelbauer and
Overath, 1993). An in vitro study has led to speculation that ISG65 could be involved in a
signalling pathway, due to its very short half-life, a feature that is frequently associated
with this type of function in other eukaryotes. In addition, it appears to be recognised by
antibodies, although it is currently unknown whether this has any in vivo significance
(Chung et al., 2004). Another key surface molecule acting in the bloodstream stage is the
transferrin receptor, a GPI-anchored heterodimer made up of proteins ESAG6 and ESAG7
(Salmon et al., 1997), present at 3000 molecules/cell, around the flagellar pocket
(Steverding et al., 1995; Steverding et al., 1994). It has been shown that both its steady
state location in the flagellar pocket and its shorter half life (7 h) compared with that of
VSGs (30 h) is due to the fact that it has a single GPI anchor on ESAG6, as opposed to the
two GPI anchors of the VSG homodimer (Gruszynski et al., 2006). Other surface
molecules such as ISG65 are transmembrane proteins and are recycled through the same
endosomal compartment as GPI-anchored proteins, suggesting the presence of multiple
and overlapping mechanisms for surface molecule recycling (Chung et al., 2004). It is
remarkable that ISG65, ISG75, ESAG6 and ESAG7, together with the PAGI (procyclin
associated gene) product, expressed in procyclic trypanosomes (Koenig-Martin et al.,
1992), probably all share the N-terminal domain type A VSG fold (Carrington and
Boothroyd, 1996). It is suggested that tertiary structure provides an elongated scaffold for
a variable active site at the tip of these molecules, reminiscent of the immunoglobulin gene
family (Carrington and Boothroyd, 1996). The VSG type B N-terminal domain possibly
also has a relative in PSSAl, a surface protein found in procyclic trypanosomes, but the
crystal structure for type B VSGs is unknown, making this comparison more tentative.
The C-terminal domain of VSGs does share similarity (although very localised) with part
of the N-terminal region ofa transmembrane surface protein, the hexose transporter
(Carrington and Boothroyd, 1996); the significance of this similarity awaits tertiary
structure comparison.
The question as to how invariant surface antigens are protected by the VSG coat is still at
least partially unanswered and requires further investigation. The easiest explanation is
that VSGs are more elongated in structure, hiding the other surface proteins, although this
could be proven only by a crystal structure of these other molecules, as they appear to be of
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similar molecular weight, and therefore possibly of similar height (Carrington and
Boothroyd, 1996). In addition, more needs to be elucidated in terms of antibody responses
against invariant antigens in vivo.
Another important aspect of VSG expression is that of VSG recycling, which occurs at the
flagellar pocket, implicated as the only site of exocytosis and endocytosis. A steady state
is reached between the internalised (endosomal) and surface VSG pools, with the
endosomal pool amounting to -9% of total VSG protein. Recycling is very rapid, 12
minutes allowing cycling of one coat equivalent (Engstler et al., 2004). As the half-life of
VSG molecules has been estimated to be -30 hours (Seyfang et al., 1990), this suggests
repeated cycling ofVSG protein with only limited replacement. Upon differentiation from
bloodstream long slender to the non-dividing short stumpy form, VSG transcription is
repressed (Amiguet-Vercher et al., 2004): as the halflife of the latter form is 48-72 hours
(Turner et al., 1995), there might also be compensatory mechanisms to enhance stability of
the VSG coat (halflife of 30 hours), such as reduced surface turnover, ensuring
trypanosome survival. When short stumpy trypanosomes develop to the procyclic stage,
procylin expression commences and VSG expression is further repressed: it takes 12 hours
for the VSG coat to be completely replaced by procyclin, through an active process
involving GPI hydrolysis and proteolytic cleavage (Gruszynski et al., 2006). With regards
to the suggestion that the rapid recycling could eliminate antibodies bound to the cell
surface if antibodies were at low concentration, contributing to immune evasion (Engstler
et al., 2004), there is no conclusive evidence supporting this. One study analysed
agglutination oftrypanosomes in the presence of antibody and reported disaggregation of
trypanosome-antibody complexes leading to fully motile dividing trypanosomes, likely to
be due to endocytosis of the bound VSG-antibody complex (OBeirne et al., 1998); this has
been confirmed more recently and antibody degradation has been shown to proceed
rapidly, in less than one hour (pal et al., 2003). While the explanation for the in vitro
"survival" oftrypanosomes exposed to antibodies was derived from what appears to be an
internally consistent experiment, its relevance is unclear because immune lysis, which
would be likely to kill trypanosomes during the incubation, would not occur in the reported
absence of added complement (the labile nature of this factor requires exogenous
complement to be added in vitro). Due to this shortcoming, it is not yet possible to support
a model inwhich endocytosis of antibodies promotes immune evasion.
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1.3 Antigenic variation: VSG gene activation and
switching
1.3. 1 VSG expression sites and VSG transcription
The process of VSG transcription is highly regulated, such that VSGs are exclusively
transcribed when present in an active telomeric expression site (ES), and transcription is
stage-specific and mediated by RNA poll (see section 1.1.4). There are two types of
expression site (ES), metacyclic (MES) and bloodstream (BES): whereas the MES locus is
relatively simple, the only documented example in kinetoplastids of monocistronic
transcription, except for the case of the spliced leader genes, BESs are more complex,
consisting of a 30-60 kb long polycistronic unit containing, besides the VSG, several
ESAGs (expression site associated genes) (See Figure 1.5) (Xong et al., 1998).
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Figure 1.5: Sequenced VSG expression sites of T. brucei, modified from Berriman et al.
(2002).
Promoters are indicated with flags, and ESAGs with numbered boxes (ESAG genes 1 to 11).
The VSG is indicated with a white box. 50-bp and 70-bp repeat arrays (not drawn to scale)
are Indicated with striped boxes. Putative pseudogenes are Indicated with",. The strain
from which the expression sites were sequenced is indicated to the left. The SRA gene
found in the r.b. rhodesiense expression site is labelled "SRA".
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A puzzling feature of VSG expression sites is that they are present in multiple copies in the
genome: -20 BES are present in strain 427, as detected by probing at high stringency with
sequences from the 221 VSGES (Zomerdijk et al., 1990). In a more recent study in the
same strain, isolation and PCR analysis of telomere containing clones has confirmed the
previous estimate, yielding a value of 17 BES (Becker et al., 2004). There might be
variation in BES numbers between strains, as the existence of as many as 40-50 BES has
been suggested based on unique RT-PCR expression site products in strains AnTat 1 and
ETat 1 01anhamme et al., 2000). ES are mostly located at telomeres in the megabase
chromosomes (de Lange and Borst, 1982; Raibaud et al., 1983), but have also been found
on a 225 kb and a 160 kb intermediate chromosome (Guyaux et al., 1985; Shah et al.,
1987)12. In addition, in the case of T. rhodesiense, perhaps as many as 27 MES are present
(Turner et al., 1988).
1.3.1.1 Promoter
The minimal BES promoter is about 70 bp long (de Lange and Borst, 1982) and seems not
to be influenced by specific surrounding upstream and downstream sequences, although
deletion of all upstream sequences up to the 50 bp repeats (see Figure 1.5) was not
possible, suggesting that a minimal distance between promoter and upstream repeats had to
be maintained in order to have efficient transcription (Borst and DIbert, 2001). All BES
promoters are similar in sequence (around 90%) and share no similarity with MES
promoters; they can be replaced by rRNA promoters, with which they do not have
sequence homology, and still participate in VSG switching (Rudenko et al., 1995). This
suggests a lack of specific upstream control elements acting at the level of transcription
initiation (see section 1.3.1.5). A difference was noticed, though, in promoter repression in
the procyclic stage: rRNA promoters were not subject to the same level of repression as
BES promoters, when inserted either at the expression site or within VSG arrays (Horn and
Cross, 1997).
1.3.1.2 Associated genes
As mentioned above, BESs include 8-11 ESA Gs (expression site associated genes)
(Johnson et al., 1987; Kooter et al., 1987), their most studied products being the transferrin
receptor (ESAG6 and ESAG7 heterodimer), responsible for iron binding and uptake, and
an adenylate cyclase family (ESAG4), proposed to be responsible for cAMP-dependent
12In two different T. bruce; strains, 427 and ILTAR respectively.
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signal transduction. Some of the ESAGs (1, 4, 9, 11) have also been found upstream of the
MES promoter (Barry et al., 1998) and at other loci in the genome (Berriman et al., 2005)
(see Table 1.3 for a summary). Only ESAG6 and ESAG7 appear to be found in all BES
analysed so far (Berriman et al., 2002), whereas other ESAGs appear to be dispensable (at
least in monomorphic trypanosomes), possibly also due to their alternative expression
outside the expression site.
Table 1.3: Summary of ESAG product features.
Column (1) indicates whether the protein is predicted to be membrane-associated (YIN).
Column (2) gives the incidence of ESAG genes at non-ES locations for strain 927 (number of
pseudogenesltotal number of non-ES associated genes).
ESAG FUNCTION (predicted or demonstrated) (I) (2)13 REFERENCES
14
ESAGI Surface glycoprotein of unknown function; y 8/22 (Cullyet al., 1986;
expressed (at low levels) only in Carrutherset al.,
bloodstream.
1996)
ESAG2 Putative surface protein Y 3/17
ESAG3 Potentially secreted or membrane-spanning y 88/97 (Vanhammeet al.,
protein; decreased expression in procyclic 1999)
stage
ESAG4 Adenylate cyclase Y 14171
ESAG5 Putative intracellular soluble protein N 0/5
ESAG6 Transferrin receptor Y 2/3
ESAG7 Transferrin receptor Y 112
ESAG8 DNA binding protein N 0/2 (Hoeket al., 2002)
ESAG9 Surface protein of unknown function, possibly y 7/12
GPI anchored; can be transcribed from a non-
ES location
ESAGIO Transmembrane protein of unknown function; y 0/3
often absent from ES; transcribed from other
loci
ESAGll Putative surface gene (signal peptide, possibly y 6/12 (Redpathet al.,
GPI anchor); N-glycosylation sites present 2000)
SRA Present in ES of some T. rhodesiense strains y - (Xonget al., 1998)
An extreme example of post-transcriptional regulation, mRNA for ESAGs can be 100-700
fold less abundant than that of VSG mRNA (Cully et al., 1985), despite being co-
transcribed. Such low expression level makes analysis of these genes problematic.
Another problem associated with studying ESAG function is their presence in multiple
copies, expressed within and outside expression sites: an ESAGl knockout did not yield
any phenotype, as other ESAGl transcripts were found to "complement" the knockout gene
13 Data from supplementary material published online, accompanying Berriman et al. (2005).
14Information on ESAG genes with no specific reference was taken from introduction of Carruthers et al.,
(1996).
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(Carruthers et al., 1996). Current evidence, summarised in Table 1.3, suggests that most
ESAG products are surface-associated, although in most cases their specific function in
bloodstream stage trypanosomes remains unknown. ESAG8, one of the few non-secreted
ESAG products, has been shown to be a putative DNA binding protein (Hoek et al., 2002),
and has therefore been suggested possibly to have a role in BES transcription regulation.
Interestingly, sequence variation within the ESAGI family has been shown to be greater
than within other ESAGs, suggesting a comparison with the high divergence within the
VSG family (Morgan et al., 1996), although the significance of this comparison is currently
unknown.
1.3.1.3 70-bp repeats
Both MES and BES contain (A+T)-rich 70-bp repeats upstream of the resident VSG. The
repeats are thought to be important in VSG duplication and gene conversion into the active
expression site, copying silent VSGswith similar 5' flanking repeats to the expression site
(see section 1.3.4 for more details). There is a limited number (normally zero to two) of
70-bp repeats in MES, perhaps allowing limited chance for recombination, and this could
explain the small size and relative stability of the MVSG repertoire (Matthews et al., 1990).
On the other hand, switching was shown to occur readily with a single 70-bp repeat
(Matthews et al., 1990), and a more recently described MES was found to harbour 13
repeats (LaCount et al., 2001), arguing for a less genetically isolated status for MVSGs. In
contrast, BESs harbour long arrays of repeats, between one and 20 kb long (Shah et al.,
1987) (see Figure 1.5 and Figure 1.6).
1.3.1.4 Switch from MES to BES
Metacyclic trypanosomes express a set of MVSGs (metacyclic VSGs) allowing
establishment of infection in the mammalian host, a preadaptation developed in the
salivary glands of the fly (Gray, 1965; Hajduk et al., 1981). The metacyclic "archive"
comprises a conserved set of up to 27 different VSGs (with 14 MVATs, metacyclic
variable antigen types, representing 95% of population), but there is a gradual turnover in
the content of this archive that is thought to prevent herd immunity in the wild: current
evidence suggests that gene conversion introducing novel variants into a MES from the
wider silent VSG archive occurs at a rate of 0.03 of the metacyclic "archive" per fly per
transmission (Barry, 2006). The switch from MES to BES following transmission from fly
to mammal is not understood, as it does not occur simultaneously with the differentiation
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from metacyclic to bloodstream stage. Whereas the differentiation occurs within one day,
bloodstream VATs start appearing 4-6 days after infection (Barry and McCulloch, 2001).
1.3.1.5 Single BES expression
It appears that BES (and procyclin) promoters are never completely inactive in any
examined life cycle stage, instead being partially up or down regulated (Roditi, 1996),
whereas MES are subjected to a tight transcriptional control (Barry et al., 1998). While the
mechanism by which only a BES is transcriptionally active is unknown, the regulation
appears to be stringent, as stable maximal activation of two separate BESs by insertion of
two drug resistance markers has not been possible (Borst and Ulbert, 2001), and previous
examples of stable double expressors have been questioned (Cross et al., 1998).
Interestingly, transcription is only partially repressed in silent BESs, as ESAG6 and ESAG7
transcripts (the first genes in the polycistronic unit) have been found to be transcribed in
different amounts from a number of silent BESs (Ansorge et al., 1999). These different
activity states appear to be stably inherited and have been considered epigenetic.
Furthermore, the different activity levels seem not to correlate with the transcriptional
"switching avidity" of silent BESs (Navarro et al., 1999; Borst and Ulbert, 2001). In
addition, it appears that primary transcription in the active expression site is not
upregulated compared with that of inactive BESs, transcription regulation occurring at the
elongation, rather than initiation, stage (Vanhamme et al., 2000).
A positive lead to uncovering the mechanism allowing allelic exclusion to the advantage of
a single expression site was the finding that transcription appears to occur in a non-
nucleolar "expression site body" (ESB), from which silent BESs are excluded, so it is
likely that this circumscribed region contains the factors that enable full processivity of
RNA polymerase, by overcoming default silencing factors and/or allowing the opening of
chromatin (Navarro and Gull, 2001). These results fit very well with the location of
telomeres in the nucleus: it appears that in the procyclic form they are all sequestered to the
nuclear periphery, whereas dividing bloodstream forms give also a telomere signal from a
non-peripheral nuclear location, which might correspond to the ESB (Perez-Morga et al.,
2001).
An additional factor allowing silencing to occur has been considered to be the telomeric
location of expression sites: a telomere position effect silencing mechanism has been
proposed by analogy with yeast, where chromatin structure at telomeres influences their
transcriptional status. The problem with the analogy is that silencing in yeast spreads
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merely some 5 kb upstream of the telomere, whereas in trypanosomes it would have to
spread over 40-60kb, in the case ofBES (on the other hand, the MES promoter would be
close enough to the telomere to envisage this silencing mechanism as a possibility) (Barry
and McCulloch, 2001). The presence of a histone H3 variant that is enriched at
subtelomeres argues that subtelomeres can have a chromatin context different from that of
core chromosomal regions (Lowell and Cross, 2004), and that this context could be related
to default repression in all but the ESB-associated active expression site telomere (Hom
and Barry, 2005). In addition, a modified thymine base, J (Beta-D-glucosyl (hydroxy-
methyl) uracil), has been found associated with repetitive regions in the genome of
bloodstream stage trypanosomes, and in particular with telomeres. It is present in inactive
expression sites and is not in the transcribed BES, its formation being associated with a
chromatin remodelling protein, JBP2 (J-binding protein 2), which is thought to enable the
two step enzymatic reaction leading to J biosynthesis from thymine residues (DiPaolo et
al., 2005). In the same study, JBP2 has been shown to have a punctate nuclear
localisation, suggestive of an ability to associate with repetitive sequences, and it is
currently thought to be essential in bloodstream form trypanosomes. Whether base J
biosynthesis is an active player in BES repression remains to be elucidated.
In summary, current evidence tentatively suggests that inactive telomeric expression sites
are sequestered at the nuclear periphery and associate with specific chromatin remodelling
factors; both BES nucleosomes and DNA might be altered compared with the active
expression site. For activation of a silent BES to occur, at least some of the telomeric
factors would have to be displaced and epigenetic modifications would have to be
,
removed, as the tethering to the nuclear periphery is disrupted, allowing access to the ESB.
Although different BESs can be activated, there seems normally to be a dominant BES that
is used most of the time. As to why more than one BES is present, two non-mutually
exclusive theories have been put forth. The first states that expression of a given BES
might be selected in a host to maximise the affinity with the transferrin of that host (Bitter
et al., 1998), although this has recently been questioned, suggesting that the correlation
between BES switching and host transferrin might not be direct, other stress inducing
changes in the trypanosome medium contributing also to BES switching (Salmon et al.,
2005). Alternatively, silent BES can be considered to have originated as sites for mosaic
VSG production, so that the process of splicing variants together could occur in the absence
of transcription, preventing the lethal expression of a non-functional, imperfect mosaic
VSG (Barry and McCulloch, 2001). Support for this theory comes from the detection of
two silent telomeric pseudogene donors contributing respectively to mosaic genes VSG20
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(Thon et al., 1989) and VSG78 (Roth et al., 1989), detected in a rabbit infection with T.
equiperdum (this is further discussed in section 1.3.7.).
1.3.2 VSG activation (switching)
It has been show that switching between two VSGs is spontaneous and independent of the
immune system, and occurs at a rate of 10-2-10-3 switches/cell/population in pleomorphic
trypanosomes, while in laboratory-adapted monomorphic trypanosomes the rate is much
lower (10-6-10-\ The high switching trait is apparently dependent upon transmission
through the fly, as a low-switching line obtained by syringe passaging could partially
revert to high switching by completing the life cycle (Turner, 1997). One possible
explanation is that loss of a labile epigenetic state might be responsible for the reduced rate
of switching in monomorphic lines.
Several mechanisms of VSG activation have been described. These include transcriptional
(in situ) switching between BES, telomere reciprocal exchange between BESs downstream
of the activated promoter (Pays et al., 1983a; Rudenko et al., 1996) and various forms of
duplicative transposition, which involve the copying of a silent VSG (basic copy, BC, or
donor gene) into an expression site (creating an expression-linked copy, ELC) and the
deletion of the previously expressed VSG15 (see Figure 1.6 for main mechanisms).
Transcriptional switching appears to be rapid: no transient state in which two BESs are
active has been detected (Chaves et al., 1999; Ulbert et al., 2002). Although switching is
very rapid at the gene expression level, it can be regarded as the trigger for a longer
process at the organismallevel: VSG mRNA has a half life of 4.5 hours and VSGs have a
half life of 30 hours (Cross et al., 1998), so it is possible that the complete replacement of a
VSG coat with another non-cross reactive one might take around two days in vivo, unless
there exists an as yet unidentified mechanism that speeds up the process of coat exchange
upon switching. The switching from MYAT to BVAT, monitored by detection of dual
expressors with monoclonal antibodies, would suggest two days as the upper estimate for
coat replacement, as dual expressors were first detected at day four of infection and by day
six only 6% of the population had MYATs on their surface (Esser and Schoenbechler,
1985).
IS Hence the name clonal phenotypic variation to indicate the process of antigenic variation, as genotypic
information is retained in the silent archive.
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Transcriptional switching between BESs
Duplicative switching from silent archive
A 1$.0. _00. _Urq »»
1) From BESs
~"'1"'" •• ', n. "T"
2) From minichromosomes
3) From VSGarrays
Figure 1.6: VSGswitching mechanisms, transcriptional and recombinational.
"A" refers to the original active BES, "B" to the result of transcriptional switching,
activating a second BES; "C1 ", "C2" and "C3" refer to the result of duplicative transposition
from three genomic loci (BES, minichromosomes, VSG arrays). BES promoters are
indicated as red flags in the active state, as black flags in the inactive state. The depiction
of the two BESs is derived and adapted from (Berriman et al., 2002), see also Figure 1.5.
VSG genes are indicated as coloured blocs with direction of the gene highlighted. Asterisks
indicate 70-bp repeats upstream of VSGs (see section 1.3.4 on gene conversion boundaries
for a discussion of their role). The horizontal bracket underlying donor VSGs highlights the
VSG cassette of array VSGs (see section 1.3.4). The bracket is left open in the case of
telomeric conversions C1 and C2, as the conversion might include the whole downstream
region and telomere (indicated with "empty" arrows). The sequence surrounding donor and
recipient VSGsequences is given the same colour as that of the coding sequence, to
highlight the extent of sequence that is duplicated.
1.3.2.1 VSG switching and hierarchy of expression
Order in the sequential expression of different variants has been associated with distinct
switching reaction types occurring at different frequencies, leading to variants having a
range of activation probabilities, depending on their locus. Telomeric VSGs are more
easily activated than array VSGs, and this has been formally demonstrated by the
observation that a late gene was expressed early when it was transferred to a telomeric
position (Laurent et al., 1984). This is possibly because the sequence environment of a
telomeric VSG is more similar to that of the BES (allowing more sequence homology to
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trigger recombination reactions) and because of the general capability oftelomeres to
recombine ectopically with each other (Hom and Barry, 2005). Early in infection, when
telomeric genes are activated, in monomorphic strains around two thirds of switching is
transcriptional (Liu et al., 1985), while in pleomorphic trypanosomes more than 90% of
switching is duplicative" (Robinson et al., 1999); this implies that the lower switching rate
of monomorphic trypanosomes is associated with a reduced level of duplicative
transposition. Later in infection, on the other hand, duplicative transposition involving
array VSGs is common to both pleomorphic (Morrison et al., 2005) and monomorphic
strains (Timmers et al., 1987; Lee and Van der Ploeg, 1987).
1.3.3 Duplicative transposition
The process of recombination of a silent VSG into an expression site can occur in a variety
of ways, as the boundaries of transposition depend on the homology between the active
VSG and the incoming VSG. The VSG-encoding region may be replaced in its entirety
from the upstream 70-bp repeats down to the C-terminal domain-encoding sequence (or to
the telomere if the donor VSG is telomeric), or only parts of it can be replaced (segmental
duplication leading to mosaic gene formation, discussed in section 1.3.7).
1.3.4 Gene conversion boundaries, sequence homology and
hierarchy
A VSG recombination unit (also termed VSG cassette) is composed of70-bp repeats, a 5'
CTR (cotransposed region), the VSG itself and a 3' region of variable length (Liu et al.,
1983), with potential to extend to the telomere in the case oftelomeric donor VSGs (see
Figure 1.6). Unless related VSGs recombine with each other, habitually the regions of
homology between VSG cassettes would be restricted to the 70-bp repeats at one end and,
at the other end, to the final portion (encoding the GPI signal) of the VSG coding sequence
and to downstream sequences. The intervening region, comprising the 5' cotransposed
region and most of the VSG coding sequence, has been shown to be largely devoid of any
conserved or repetitive element (Van der Ploeg et al., 1982a). Both 5' and 3' flanks will
now be described in some detail, before the molecular mechanisms and players that are
thought to be associated with the use of these sequences are introduced.
16 Data from Liu (1985) are derived from single relapse studies, in which the original variant is grown in a
rodent, blood is taken from the first peak and treated with antibodies against the initial variant, then a small
number oftrypanosomes (4-5) are injected into a second rodent, amplifying switchers from the initial peak.
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The 70-bp repeat sequence was first obtained by sequencing the 5' region of transposition
in the activation of array gene 118 in strain 427 (Liu et al., 1983). Although the precise
point of transposition was not determined, itmapped to the region spanning a set of five
70-bp repeats. By southern blotting, the repeats were shown to be present in many copies
across the genome, associated with all known VSG genes CVan der Ploeg et al., 1982b),
giving a first indirect estimate of the size of the VSG archive. A more extensive analysis
was provided by the sequencing of a 4 kb array of 53 repeats present within a BES in the
EATRO 795 (ILTAR) pleomorphic strain: comparison showed that repeats are imperfect
and vary in size between 60 and 110 bp (Shah et al., 1987), although longer repeat units
(~400 bp) have also been isolated (Campbell et al., 1984). The repeat unit is a tripartite
element comprising a variable number of triplet TAA repeats, followed by a -20 bp long
GT-rich region and a -20 bp long AT-rich region. All three components of70-bp repeats
have been advocated as potential contributors to recombination initiation: the triplet repeat
has been shown to predispose the DNA helix to melting in vitro (Ohshima et al., 1996); the
GT-rich tract has been suggested to be a binding site for RAD51 and even to be recognised
and cut by a restriction endonuclease (Michiels et al., 1983; Matthews et al., 1990), due to
the possibility of it adopting a Z DNA conformation (Aline et al., 1985); the final AT rich
tract has been proposed to form a stem loop (Liu et al., 1983) and act as a recognition
signal for DNA binding proteins. As yet, no conclusive evidence has been produced for
any of these putative events to operate in switching. The association of the 70-bp repeat
with the upstream limit of recombination in VSG gene duplication reactions has been
reported extensively (Shah et al., 1987), and it appears that multiple initiation-termination
points within the repeat are chosen "at random" (Florent et al., 1987), the conversion
therefore acting possibly by homologous, rather than site-specific, recombination.
Conversions have also been found to occur in the absence of70-bp repeats in
monomorphic trypanosomes with an expression site engineered to be devoid of them
(McCulloch et al., 1997). This parallels the high numbers of duplications detected in
monomorphic trypanosomes that do not use 70-bp repeats, and contrasts with the
seemingly exclusive use of these sequences in pleomorphic trypanosomes (Barry, 1997),
suggesting that switching rate and use of 70-bp repeats in gene conversion are related
processes, both downregulated in monomorphic trypanosomes.
Although a significant number of indels are present (Field and Boothroyd, 1996), the 3'
region downstream of the VSG coding sequence has been shown to be relatively well
Data from Robinson (1999) are derived from the natural first relapse peak (the second peak) of a chronic
infection, so the two experiments might not be fully comparable.
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conserved in outline (Liu et al., 1983), providing the 3' end homology in the VSG cassette,
together with the sequence encoding the conserved C-terminal end of the VSG itself (Rice-
Ficht et al., 1981). Telomeric VSG copies are also associated with several conserved
repeats, providing more extensive blocks of homology between cassettes, in many cases
extending to the telomere itself (Kooter et al., 1988). A conserved 16-mer is present very
close to the VSG end, and further downstream TTAGGG telomeric repeats are found,
together with motifs termed Trpt and srpt2 (H. Renauld, pers. comm.). The 16-mer is
present in the 3' UTR of all T. brucei VSGmRNA (Rice-Ficht et al., 1981; Matthyssens et
al., 1981; Majumder et al., 1981)17:it has been shown to contribute to the regulation of
stage-specific abundance of VSGmRNA, apparently stabilising the mRNA transcript
(Berberof et al., 1995). The 16-mer has been found downstream of many silent VSG
copies (see this study, Chapter 5, section 5.2.5) and, in addition, other telomeric repeats
have been found 3' of some array VSGs (H. Renauld, pers. comm.), suggesting the
possibility oflow-frequency recombination from telomere to array, a possibility that has
never been demonstrated experimentally.
1.3.5 A molecular model for duplicative transposition
Several mechanisms for duplicative transposition have been proposed, within the
framework of a general model envisaging a double strand break at 70-bp repeats in the
active BES, followed by repair of the break using a silent VSG cassette as a template,
resulting in deletion of the BES-resident VSG and replacement with the silent donor VSG
(Barry, 1997; Barry and McCulloch, 2001). The favoured mechanism is that of synthesis-
dependent strand annealing (SDSA): after a double strand break in the 70-bp repeats is
produced, either by a specific endonuclease or because of the intrinsic instability of the
repeats, a 3' single strand would be revealed by the action of an exonuclease. This single
strand would then conduct strand invasion at silent VSG cassettes, seeking homology.
Once annealing with a homologous stretch of DNA has taken place, gene conversion
would then proceed by branch migration and termination of conversion would occur when
a short stretch of homology is found, usually at the 3' end of the VSG coding sequence.
The problem associated with this mechanism is that it relies on analogy with a pathway
discovered in yeast, involving the recombination enzyme RAD52, which does not seem to
be present in trypanosomes. It nevertheless has advantages over other mechanisms such as
double strand break repair (DSBR) and break induced replication (BIR): DSBR involves
17This is absent in T. congolense VSGs, which have very short (7-24 bp) or even absent untranslated regions
before the poly[A] tail (Urakawa et al., 1997). .
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formation of Holliday junctions and therefore the risk of lethal translocations occurring,
BIR converts the double strand break into a replication fork, so it could be implicated only
in telomeric conversion, where replication is allowed to run to the telomere, and
conversion preserves BES architecture. IfBIR involved array VSGs, other VSGs
downstream could be copied, effectively resulting in translocation of a VSG array
downstream of a BES, which is unlikely to be a viable conversion outcome. The presence
of these (and other) pathways might not be mutually exclusive: as described in the next
section, homologous recombination in trypanosomes relies on more than one strategy.
1.3.6 Homologous recombination pathways
A key player in homologous recombination is the RAD51 enzyme: it binds single- or
double-stranded DNA in the presence of ATP and forms nucleoprotein filaments in which
the DNA is extended and underwound relative to its normal structure, allowing strand
invasion and homology searching to take place. In order to observe whether VSG gene
conversion reactions relied on homologous recombination, the T. brucei rad51 -1-mutant
was analysed for its ability to switch between VSGs. The reduced switching rate (2-130-
fold) showed that RAD51 contributes to VSG switching and, indirectly, also uncovered a
RAD51-independent recombination pathway that is able to catalyse switching (McCulloch
and Barry, 1999). The substrate requirements for this pathway were tested by
transformation of T. brucei rad51 -1-mutants with linear constructs and by observing the
pattern of integration. A 10-30- fold reduction in transformation efficiency was observed,
but this second pathway could nevertheless perform faithful homologous recombination,
requiring as little as 24 bp of perfect sequence homology (Conway et al., 2002). On the
other hand, the minimal efficient processing sequence for RAD51 in T. brucei is 142 bp
(Bell et al., 2004), suggesting that the alternative pathway described above might provide
scope for interaction between sequences with only localised homology, such as in
intragenic recombination between VSG genes. Current evidence (R. Barnes, pers. comm.)
suggests that recombination between substrates that are shorter than 50 bp is highly
impaired and mismatches (5% divergence) are poorly tolerated. The imperfect nature of
70-bp repeats and the above-described limitations that recombination faces in allowing
short sequences with mismatches to engage in gene conversion reactions lends strength to
the argument that there must be sequence-specific features of these repeats (and/or factors
that associate with them) enabling these limitations to be overcome, enhancing
recombination at these loci.
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Additional findings were reached by analysis of the rad5] -1-mutants. A construct that
could recombine either at the BES or internally at the tubulin array gave corresponding
levels of recombination into the two locus types in the wildtype background (RAD51-
dependent pathway), whereas the radi l -1-mutants (RAD51-independent pathway)
appeared to prefer integrating at the BES. This suggests a preferential association of
putative RAD51-independent recombination factors with subtelomeres and further
implicates alternative recombination pathways with VSG switching (Conway et al., 2002).
1.3.7 Mosaic genes and hierarchy
There have been two main in vivo studies in which variants were detected that could be
ascribed to the presence of multiple donors, contributing together to form a mosaic gene.
Both involved chronic rabbit infections, one using the T. rhodesiense WaTat strain (Barbet
et al., 1982), and the other using the T. equiperdum BoTat strain (Capbern et al., 1977).
The aim of the first study was to isolate variants that were similar (partially cross-reactive)
to the initial variant WaTat1.1. Three separate expressed genes were found, WaTat 1.12,
1.13 and 1.14. Itwas possible to explain all four expressed copies by a combination of
gene conversion reactions utilising four silent genes, at least two of which were
pseudogenes (Kamper and Barbet, 1992). A limitation of this study is that expressed
variants cannot be clearly related to the rabbit infection: clone WaTat 1.12 was obtained
from passaging rabbit blood from day 14 into a rat and was then passaged in mice, where it
was grown for seven weeks before being cloned into a second rat. Similar procedures
(exact timing of gene isolation not described) were followed to isolate the other two
variants. The importance of this study lies chiefly in the attempt to assess the degree of
divergence amongst mosaic genes leading to the production of novel non-cross-reactive
variants. It appears that closely related mosaics derived from silent copies that are around
90% identical at the DNA level produce mosaics that are largely cross-reactive.
Of more interest from the perspective of understanding the in vivo significance of mosaics
is the T. equiperdum study. The study isolated 101 variants from 11 rabbit infections.
Two variants, VSG20 (Thon et al., 1989) and VSG78 (Roth et al., 1986), were explainable
as mosaic genes, derived from silent basic copies, at least some of which were
pseudo genes. Mosaics that were identical or sufficiently similar to these two VSGs to be
detected by specific antisera were observed in separate infections: VSG20 was detected in
8 rabbits between day 21 and 30, whereas VSG78 appeared between day 33 and 45 in four
rabbits (60% of the rabbits remaining in the study by those times) (Capbern et al., 1977).
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This shows that mosaic gene formation is, at least in these cases, a reproducible and
predictable event.
It has been suggested, following analysis of two mosaics related to VSG20, that the gene
ends of VSGs are responsible for ordered appearance of variants. Itwas concluded that
genes with similar 3' end could be found to be expressed at the same time, and that the
level of homology in the rest of the gene would enable prediction of the probability for
transition from one gene to another (Thon et al., 1990). On the other hand, it had been
shown previously that VSGs with the same end were expressed at different times during
two rabbit infections with strain 42718 (Michels et al., 1983), so the notion of order
imposed by 3' donor sequences needs to be tested further.
1.3.8 Modelling VSG switching and hierarchy
A hierarchy of expression of different VATs has been shown experimentally, VATs being
grouped as early, middle and late, based on their mean timing of appearance (Capbem et
al., 1977); (Gray, 1965). Recent reanalysis of data published by Capbem (J.D. Barry, pers.
comm.), suggests that VATs appear more as a continuum, in keeping with previous
experimental work conducted in T. vivax (Barry, 1986). The order is semi-predictable, as
the exact timing of appearance can vary between different infections of the same host
species. Order is retained also when infections in different host species are compared,
although progression through the VSG archive has been shown to be faster in large
animals, such as cows, than in smaller animals, such as rodents, as a larger number of
parasites can be accommodated in animals with a larger volume of blood, leading to a
higher number of switching events (Barry, 1986). The faster VAT progression in larger
animals might be the underlying cause for the reported cases of self-cure in cattle (Barry,
1986) and in pigs (Penchenier et al., 2005), an event much less common in rodents (Barry,
1986). In this scenario, natural termination of the infection might be due to exhaustion of
the entire VSG archive. At the population level, the hierarchy of expression of different
VSGs is not a linear process, as switching is also divergent and one VAT gives rise to
several VATs. On the other hand, "convergent" events represented by multiple duplicative
activations of the same silent gene within an infecting trypanosome population" (Timmers
et al., 1987) and by a similar timing of appearance of the same VAT in different infections
18 The three VSGs with related C-terminal domains are VSG 121a, 117a and MITat 1.196; in rabbit I, VSG
12la and 117a appeared at day 20 and 28 respectively; in rabbit 5, VSG 121a was used to start the infection
and MiTat 1.196 was isolated at day 45 (rabbit numbers refer to those used in the cited study).
19 Also possibly due to a single switching event followed by repeated gene conversion between donor and
expressed copies.
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(Morrison et al., 2005) have uncovered the probabilistic nature of VSG switching. The
hierarchy is therefore the result of interplay between "fixed" different VSG activation
probabilities and the pressure of the immune system against the re-emergence of VATs for
which antibodies are already present: transferring trypanosome by syringe to a new host
resets the order of expression to early VSGs (Gray, 1965), which are those with high
activation probabilities. Recent models have therefore factored in that early variants are
always activated throughout an infection, but are cleared by antibodies as the infection
proceeds (Frank, 1999; Lythgoe et al., 2006). This type of model has outlived that
proposed by Seed in 1978 (Seed, 1978), according to which hierarchy derived from growth
differences amongst VATs, such that the first VATs expressed are those that grow better.
The latter model has not received significant experimental support and there is evidence
against it from growth rates of different VATs (Seed, 1978; Miller and Turner, 1981).
Recent modelling is considering ways of constructing likely "transition pathways" between
variants to expand from the simpler idea of loose time groupings detected in the course of
infection, using published data on Borrelia antigenic variation (Frank and Barbour, 2006).
In T. brucei, statistical analysis and modelling of 30 chronic infections in mice and two in
cattle following the onset of seven single copy genes suggests that locus type is associated
with hierarchical expression early in infection, whereas possible ''transition pathways"
relying on coding sequence homology might occur at later stages of infection, when
mosaic genes are produced (Morrison et al., 2005).
1.4 Antigenic variation: VSG gene family divergence and
evolution
1.4. 1 VSG divergence
Overall, although some VSG families with more than 70% protein sequence identity have
been detected (Pays et al., 1985; Field and Boothroyd, 1996), on average two aligned VSGs
would be only 20% identical, and less than that if aligned on the basis of tertiary structure
(Carrington and Boothroyd, 1996), so the abundance and breadth of VSG families remain
elusive. As mentioned in section 1.3.7, it appears that cross-reactivity has been detected
between variants having -90% identity (Thon et al., 1990), whereas two related VSGs
sharing 75% sequence identity (AnTat 1.1 and AnTat 1.10) were non cross-reactive
(Carrington et al., 1991); it therefore seems that minimal divergence for non-
crossreactivity might lie between 75 and 90% sequence identity, although a much larger
sample size would be needed to confirm this hypothesis. Variation is continuous along the
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N-terminal domain and the reason for this non-specific divergence is unknown: it was
suggested to minimise activation of T helper cells by processed peptides derived from
VSGs that might otherwise occur during a persistent infection (Blum et al., 1993), but no
evidence confirming this has been gathered since. In addition, the extent of divergence
amongst VSGs (protein sequence identity as low as 20%) suggests that the mechanism that
generates VSG diversity might be producing more divergence than required, its only
constraint at the level of selection being conservation of tertiary structure (Blum et al.,
1993).
1.4.2 VSG epitopes
Two studies have addressed the issue of VSG divergence by selecting with monoclonal
antibodies for the emergence or detection of VSGs closely related to the initial expressed
VSG. In the first, analysis of six related variants originating from VSG78 of T.
equiperdum (cross-reactive using polyclonal antisera), experimentally selected for loss of
reactivity to monoclonal antibodies (Baltz et al., 1991), has revealed that a small number
of point mutations (1-3) might be sufficient to generate different epitopes. Analogously, a
second experiment selecting for VATs reacting to a monoclonal antibody against MYAT5
(WRATat strain) upon prolonged in vivo passaging (3-4 months) yielded three VATs,
expressing VSGs closely related to MYAT5, with 35, 11 and 28 point mutations
respectively (Lu et al., 1994). Both experiments were questioned because of the artificial
procedures utilised to select point mutated variants, far removed from the normal course of
an infection: only one point mutation in three MYSG clones was detected from the first
peak of a "standard" infection (Graham and Barry, 1996). What remains to be established
is whether point mutations accumulate in vivo in the course of an infection for the
'purpose' of immune evasion, as the above study considered only the first peak of
parasitaemia. Exposed epitopes were studied on the MITat 1.6 VSG with nine monoclonal
antibodies grouped into five classes recognising different "regions" of the protein. All
putative epitopes mapped to the N-terminal domain, but with no precise link to primary
sequence; only one of the five antibody classes was found to bind to the surface oflive
trypanosomes (Miller et al., 1984a; Miller et al., 1984b). Further work to pinpoint
epitopes on MITat 1.2 VSG, for which the crystal structure was available, did not yield a
much more precise understanding of epitope location (Masterson et al., 1988).
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1.5 Antigenic variation in other systems
Antigenic variation is a common theme of both eukaryotic and prokaryotic parasites that
develop chronic infections in their hosts. T brucei represents one of the best studied
systems, but other protozoa display this immune evasion strategy, including Plasmodium
(Kraemer and Smith, 2006), Pneumocystis (Keely et al., 2005) and Giardia (Nash, 2002).
Amongst eubacteria, the antigenic variation system of the spirochetes Borrelia hermsii
(Dai et al., 2006), and B. burgdorferi (Zhang et al., 1997) has been well characterised, as is
that of Anaplasma marginale (Futse et aI., 2005) and Neisseria gonorrhoeae (Zhang et al.,
1992; Sechman et al., 2005). Recombination between antigen alleles is a common theme
amongst all species quoted above, and seems to function as the primary diversification and
immune evasion method. Variations between species concern the size of the antigen
archive, the mode of antigen activation (transcriptional or by duplication into an expression
site) and the locus occupied by the archive (see Table 1.4). It is now also apparent that
certain antigenic variation systems include the simultaneous variation of different surface
protein gene families (see Table 1.4). In protozoan pathogens, a common theme emerging
is the use of subtelomeres to house the surface antigen archives, and again (see section
1.3.2.1) this is likely to be due to the plasticity of chromosome ends and their proneness to
ectopic recombination, involving homologous sequences on non-homologous
chromosomes (Barry et al., 2003).
Table 1.4: Antigenic variation in eukaryotic parasites (adapted and expanded from Borst and
Ulbert (2001), see text for additional references).
Organism Surface Number of Mechanism of antigen Archive location
antigen genes activation (in protozoa)
(approximate.)
Protozoa
T. brucei VSG 1000 Transcriptional and Subtelomeric
recombinational and telomeric
P. Jalciparum PfEMPl (var) 59 Transcriptional Subtelomeric
and interstitial
Rifm 200 Subtelomeric
P. carinii MSG 100 Recombinational Subtelomeric
and telomeric
G.lamblia VSP 150 Transcriptional Interstitial
Bacteria
Borrelia hermsii VMP(Vlp+ 40 Recombinational
Vsp)
Borrelia VLS 15 Recombinational
burgdorferi
Anaplasma MSP2 7-9 Recombinational
marginale MSP3 7-9
Neisseria PilE + PilS 20 Recombinational
gonorrheae
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1.6 Specific aims of project
This project fits into the efforts of Prof. Dave Barry's group to provide a model that
combines trypanosome growth with antigenic variation rate and sequential VSG expression
and then to test the hypothesis that these parameters are driven by the DNA recombination
mechanisms responsible for individual VSG switches.
The specific aims are to analyse the T. brucei strain 92714 silent VSG archive in order to
make predictions of its mode of use, exploring in detail the internal composition of the
archive, looking for patterns of relatedness amongst variants and building a model of how
these sequences are likely to contribute to antigenic variation (Chapter 3). The model was
tested in vivo by conducting a chronic mouse infection with strain 927/4 (Chapter 4),
providing further insights into the kinetics and features of antigenic variation, with the
ability to trace expressed VSGs back to the genome sequence. Bioinformatic findings
provided the scope for undertaking a bioinformatics and preliminary experimental analysis
of a novel VSG-related gene family (Chapter 5).
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2 Materials and Methods
2.1 Culturing trypanosomes
Two different trypanosome strains were handled, TREU 927 both in vivo and in vitro,
Lister 427 only in vitro. gDNA for the other two strains (EATRO 795 and STIB 247) used
in PCR experiments in Chapter 5 (see Figure 5.9), was kindly provided by Rebecca
Barnes.
In vitro growth of strain Lister 427 was performed solely for the PCR experiment in
Chapter 5 (see Figure 5.11). Itwas achieved by using HMI-9 medium (Hirumi and
Hirumi, 1989), supplemented with hygromycin (10 ug/ml), at 37°C in a humidified 5%
C02 incubator.
The bloodstream GUTat 10.1 derivative of strain TREU 927 was used for setting up a
chronic infection. This trypanosome strain is pleomorphic and cannot be grown easily in
culture. Bloodstream stage trypanosomes from the infection were differentiated to the
procyclic form, by the protocol given below. The procyclic GUTat 10.1 line was grown at
27°C to obtain RNA, for the PCR experiment shown in Figure 5.10, using SDM79
medium (Brun and Schonenberger, 1979).
2.1.1 Stabilate preparation
Bloodstream form trypanosome culture stabilates were prepared by addition of 10% sterile
glycerol to 900 J..l1of culture at a density of -2 x 106 trypanosomes/ml, in cryotubes
(Nunc). In the case of procyclic trypanosomes, the culture (at a density of 6 x 106
trypanosomes/ml) was concentrated five-fold by spinning at 360 g for 10 mins in a falcon
tube, removing four fifths of the supernatant, then gently resuspending the cells prior to
glycerol addition. Stabilate tubes were left overnight at ·80°C in a cotton-padded box to
allow the freezing process to occur gradually. They were then transported in dry ice and
transferred to liquid nitrogen.
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2.1.2 Differentiation from bloodstream to procyclic stage
In differentiating bloodstream forms to procyclic forms, 50-100 J..lIof blood with
trypanosome density at around 107 were added to 3 mls SDM79, in the presence or absence
of 6 mM cis aconitate (Sigma), and trypanosomes were left to differentiate at 27°C.
2.2 Procedures related to growing trypanosomes in vivo
2.2.1 Host immunosuppression
Immunosuppression of ICR or BALB/c mice to allow trypanosome growth from stabilate
was performed by cyclophosphamide treatment (250 mglkg body weight, Sigma), 24 hr
prior to trypanosome injection.
2.2.2 Trypanosome growth and col/ection
For the chronic mouse infection, 11 mice were each injected with -106 trypanosomes (80
J..lIblood volume with parasitaemia of 1.3 x 107 trypanosomes/ml), derived from an
immunosuppressed mouse infected four days previously with a TREU 927/4 GUTat 10.1
stabilate, kindly provided by Prof. M. Turner. Mouse blood was harvested by cardiac
puncture into CBSS (Carter's Balanced Salt Solution (1 x): 0.023 M HEPES, 0.12 M
NaCI, 5,41 mM KCI, 0,4 mM MgS04, 5.6 mM Na2HP04, 0.035 M glucose, 0.05 mM
phenol red, pH 7,4), containing 5% sodium citrate anticoagulant (0.15 ml CBSS per 0.85
ml blood).
2.2.3 Stabilate preparation
Stabilates were prepared by mixing blood 2:1 with 22.5% v/v DMSO (Dimethyl
sulphoxide) in CBSS. Blood was injected into fine bore polythene tubing (Portex), which
was then cut into "straws" and fitted into cryotubes, perforated to provide contact between
straws and liquid nitrogen. The freezing of the stabilate then followed the procedure
outlined in section 2.2.1.
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2.3 Basic laboratory procedures
2.3.1 Parasite isolation and lysis
2.3.1.1 gONA isolation
Trypanosomes were isolated from mouse blood (normally a volume of ~ Irnl, with a
trypanosome density of -1 07 cells/ml) by centrifugation at 1000 g for 10 mins, resulting in
trypanosomes forming a white layer ("buffy coat" on top of lysed blood cells). The buffy
coat was transferred to a clean eppendorftube and trypanosomes were lysed by addition of
500 ul lysis buffer (50mM Tris pH 8, 1mM EDTA, 100mM NaCI). 50 J..lII0% SDS
(Sodium dodecyl sulphate) and 2.5 J..lIproteinase K (at 20 mg/ml) were also added in order
to denature the proteins present in the sample, which was incubated overnight at 37°C. In
the case oftrypanosomes in culture, cultures were spun at 1000 g for 10 mins, resulting in
formation of a trypanosome pellet, which was resuspended into lysis buffer after removal
of most of the supernatant. A maximum number of 108 cells were used for each individual
lysis reaction.
2.3.1.2 Phenol/chloroform extraction of gONA
In order to separate gDNA from other lysed cellular components (see section 2.4.1.1), the
trypanosome lysate was mixed with an equal volume (normally -600 J..lI)of 1:1
phenollchlorophorm (Sigma). Mixing was followed by centrifugation at maximum speed
for 10 mins resulting in separation of the acqueous and organic phases. The acqueous (top)
phase was transferred to a clean eppendorftube and two volumes of absolute ethanol
(100%) were added to result in gDNA precipitation, aided by incubation of the sample at-
20°C for at least one hour. The precipitate was then pelleted by centrifugation at
maximum speed for 10 mins. The pellet was washed by addition of 1ml 70% ethanol
accompanied by a 1min centrifugation; it was then allowed to air-dry and resuspended in
50-200 J..lIwater. gDNA was then stored at -20°C.
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2.3.2 RNA and eDNA preparation
2.3.2.1 RNA isolation
In the case of RNA isolation from mouse blood, 1 ml erythrocyte lysis buffer (ELB,
Qiagen) was added to 200 J.lIof blood and the sample was then incubated on ice for 5 mins
and then vortexed. The incubation and vortexing steps were repeated twice more, before
centrifugation for 10 mins at 360 g. The supernatant was discarded and the pellet
resuspended in 400 J.lIELB, after which the centrifugation step was repeated. The pellet
obtained was then resuspended in 350 J.lIRLT buffer (Qiagen RNeasy kit) plus 1% ~-
mercaptoethanol and RNA was isolated using the Qiagen RNeasy mini kit, following the
protocol provided by the manufacturer. In the case of RNA isolation from culture, -107
cells were centrifuged at 360 g for 10 mins and then resuspended in RLT buffer as above.
2.3.2.2 Reverse transcription (RT -peR)
RNA (maximum 1 ug) was first treated with 1 J.lIDNaseI (Invitrogen), in a 10 J.lIreaction
containing 1 J.lII0 x DNase I reaction buffer and made up with water. The reaction was
performed at room temperature for 15 mins, and stopped by addition of 1 J.lI25 mM EDTA
and incubation at 65°C for 10 mins. cDNA was prepared by reverse transcription using the
Superscript II First-Strand Synthesis System for RT-PCR kit (Invitrogen). An
RNA/primer mix was then prepared by addition of2J.l1 oligo[dT] primer, 2 J.lIlO mM
dNTPs and 5 J.lIDEPC (Diethyl pyrocarbonate) water, and incubation at 65°C for 5 mins.
The 20 J.lIsamples were then transferred on ice and split in two 10 J.lIaliquots, one used for
reverse transcription and one as a control for gDNA contamination (no reverse
transcriptase added). To each aliquot were added 9 J.lIof a reaction mixture containing 2
J.lII0 RT buffer, 4J.lI25mM MgCh, 2 J.lI0.1 M DTT and 1 J.lIRNaseOUT Recombinant
Ribonuclease inhibitor. The reactions were left at room temperature for 2 mins and then 1
J.lIof reverse transcriptase (SuperScript II RT) was added to the samples (with exclusion of
the negative controls). The samples were then incubated at 25°C for 10 mins, 42°C for 50
mins and 70°C for 15 mins, then chilled on ice. Prior to PCR, 1 J.lIRNase H was added to
each sample in order to remove RNA, with incubation at 37°C for 20 mins.
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2.3.3 Gel electrophoresis
Separation of DNA by electrophoresis was achieved by loading on 1% agarose gels
(Seakem LE, BMA) run at 100V in 1 x TAE buffer (40 mM Tris, 19 mM acetic acid, ImM
EDTA). Gels contained 0.2 ug/ml ethidium bromide (EtBr) to allow DNA visualisation
under UV light. DNA size was estimated using a 1 kb ladder (Invitrogen) as a size
standard.
2.3.4 Polymerase Chain Reaction (PCR)
In order to amplify VSG sequences from cDNA for cloning and sequencing, PCR products
were generated by Herculase proofreading polymerase (Stratagene) to maximise sequence
accuracy, using a forward primer annealing to the spliced leader sequence and a reverse
primer recognising a conserved 16-mer (see Appendix, Tables 7.4 and 7.10, for primer
sequences). Reactions were composed of 1-3 III cDNA, 2 III of each primer (5mM), 1 III
of 10mM dNTPs, 1 III Herculase, 5 III lOX Herculase buffer (Stratagene) and made up to
50 IIIwith water. Reaction conditions were: 5 mins at 95°C, followed by 30 cycles of
95°C for 1 min., 38°C for 2 mins, 72°C for 2 mins and a final extension of 5 mins at 72°C,
using a Robocycler machine (Stratagene).
In the case of the other PCRs performed in Chapters 4 and 5, the polymerase used was Taq
(Thermus aquaticus) DNA polymerase (ABGene). Reactions were composed of 1-3 III
cDNAlgDNA, 2 III of each primer (1 IlM final concentration), 0.2 III Taq, 2 III custom
buffer mix (provided by Annette MacLeod, resulting in a PCRs containing 45 mM Tris-
HCI pH 8.8, 11 mM (N14)2S04, 4.5 mM MgCh, 6.7 mM 2-mercaptoethanol, 4.4 IlM
EDTA pH 8.0, 113 ug/ml BSA, 1 mM each of the four dNTPs) and made up to 20 IIIwith
water. Reaction conditions were 30 cycles of 95°C for 50 s, 55-63°C for 50 s, and 65°C
for 1min per kb of expected product.
2.3.5 Cloning of PCR products and recombinant plasmid isolation
2.3.5.1 Cloning of PCR products using TOPO vector (Invitrogen)
Prior to cloning, PCR products generated by Herculase were subjected to a 20 minute Taq
polymerase extension at 72°C, to add A residues to the ends, in order to provide cohesive
ends for the T overhangs present in the vector. PCR products were TOPO-cloned directly
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without any prior purification step (TOPO TA vector and cloning procedure developed by
Invitrogen). 1-4 JlI of PCR reaction was incubated with 1JlI TOPO vector and 1 Jll of salt
solution (1.2 M NaCI, 0.06 M MgCh), and the reaction was made up to 6 JlIwith water.
The length of incubation was of 10-15 minutes, following the manufacturer's advice for
cloning a PCR product containing a mixture of different sequence, in order to maximise
the diversity of cloned PCR products. 5 JlI of the reaction were added to 50 JlI of TOP 10
F' competent cells (Invitrogen), and these were then kept on ice for 10-25 minutes, prior to
a 40 s heat shock at 42° C. After the heat shock, cells were again placed on ice and plated
after 2 mins on pre-warmed L-agar plates containing 0.27 M ampicillin (Sigma), and
incubated overnight at 37°C. Single colonies were then picked and used to inoculate 3 mls
ofL-broth (with added ampicillin at 10 mg/ml) and grown overnight at 37°C, for plasmid
isolation.
2.3.5.2 Single colony lysis for screening colonies for recombinant plasm ids
In order to screen for colonies containing plasmids with the correct insert size, 100 JlI of
each overnight culture were added to 35 JlI of single colony lysis buffer (SCL; 1% SDS,
1.5% Ficoll, I x TAE, 1 x loading buffer, in water). This reaction was left to incubate at
room temperature for 20 mins and then centrifuged at 14000 rpm at 4°C, using a benchtop
centrifuge. 15 JlI of supernatant were loaded directly onto a 1% agarose gel, allowing
detection of clones containing a TOPO plasmid with a shift in size due to presence of
insert. 1.5 ml of the overnight cultures testing positive by the procedure described above
were then used to isolate recombinant plasmids, using a small-scale plasmid DNA
purification kit ("miniprep", Qiagen).
2.3.5.3 Plasmid DNA digestion
Restriction enzyme digestion of recombinant TOPO vector to test for PCR product
presence was conducted by using the EcoRI enzyme, present on either side of the site of
insert integration. 1 JlIminiprep plasmid DNA was routinely used, with 1 JlI enzyme and 5
JlI lOx EcoRI reaction buffer, and the reaction was made up with water in a total volume
of 50 ul, This was incubated at 37°C for 1-2 hrs.
44
2.4 Bioinformatics
2.4.1 VSG annotation
VSG arrays were identified by GeneDB automated blast searches. Further annotation was
conducted using the Artemis software (Rutherford et al., 2000). The software allowed
identification of70-bp repeats (low GC content) and then to run blastX (NCB I,
www.ncbLnlm.nih.gov/BLAST, low complexity filter disabled, Trypanosoma entrez query
limit) of DNA sequences between 70-bp repeats (3kb average). This procedure allowed
capturing the full VSG reading frame within the VSG cassette. The reading frames of VSG
pseudogenes were established by analysing blast hits and then manually assemblying the
full degenerate gene. The start and end of the putative VSG genes were checked for
presence of signal peptide (SignalP 3.0, http://www.cbs.dtu.dklservices/SignaIPD and GPI
anchor (by similarity with conserved VSG GPI signal sequences, then by big-PI predictor,
http://mendeLimp.univie.ac.atlsatlgpi/gpi server.html and DGPI
http://129.l94.l85.l65/dgpiIDGPI demo en.html). The protein sequence was then
analysed for its N- and C- terminal domain types by looking at cysteine residue presence
and spacing and performing further alignments against VSGs of known domain types
where necessary. Where applicable, the dividing line between the two domains was set at
50 amino acids upstream of the first conserved cysteine in the C terminal domain. VSGs
were classed as functional if they had a recognisable cysteine pattern and potentially
functional signal peptide and GPI anchor, as atypical if any of the above requirements
were not met, but the gene was not interrupted by frame shifts or stop codons, or as
pseudogene if the sequence was either incomplete or degenerate.
2.4.2 Phylogenetic analysis
MUltiple sequence alignments were conducted using ClustalX, or ClustalW at EBI
(http://www.ebLac.uklclustalw/) or at the Pasteur Institute
(http://bioweb.pasteur.fr/seQanal/interfaces/clustalw.html), the alignment was then edited
with Bioedit ( http://www.mbio.ncsu.edulBioEditlbioedit.html) and then a second
alignment with the edited sequences was performed. The tree produced by ClustalX was
then visualised and coloured using the HyperTree software (Bingham and Sudarsanam,
2000).
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3 A Bioinformatic Analysis of the VSG Archive
3.1 Introduction
The Variant Surface Glycoprotein (VSG) constitutes the major surface antigen of African
trypanosomes, forming a dense coat on their surface. It is encoded in the genome as a very
large gene family (-1000 copies), of which only one allele is expressed at any given time
in bloodstream stage trypanosomes, the others remaining silent. VSG N-terminal domains
are hypervariable (they normally share 20-25% identity) and part of their sequence forms
the outer exposed coat surface, while the C-terminal domain is more conserved (40-50%
identity) and forms the innermost part of the coat, adjacent to the plasma membrane. An
N-terminal signal peptide and a C-terminal GPI anchor signal allow respectively targeting
and attachment to the cell surface. Given the generally low homology, cysteine pattern
conservation is the most useful criterion for identifying and classifying VSGs; based on it,
three types ofN-terminal domain (A-C) and four types ofC-terminal domain (1-4) have
been described (See Chapter 1, sections 1.2 and 1.3 for further details).
A bioinformatic analysis of the silent VSG copies in the genome of Trypanosoma brucei
strain TREU 92714 GUTatl 0.1 was conducted, covering all megabase chromosomes.
Firstly, an overview will be given of the basic findings regarding the VSG archive in terms
of its size and coding potential. In this context, the database created for the purpose of
storing and retrieving the archive (VSGdb) will briefly be described, as it formed the basis
for subsequent analyses. Secondly, a detailed analysis of VSG N-terminal and C-terminal
domain types will be presented. This will then converge to provide a general picture of
how domains relate to each other as encoded in full-length genes. Thirdly, the sequence
environment in which VSG genes are found (subtelomeric arrays) will be described.
The results presented in this chapter have been achieved owing to the availability of the
genome sequence for Trypanosoma brucei strain TREU 927/4 GUTat10.1, due to the joint
sequencing initiative of The Institute for Genomic Research (TIGR) and The Wellcome
Trust Sanger Institute. All data were merged and analysed through the Trypanosoma
brucei GeneDB (http://www.genedb.org/genedb/tryp/index.jsp), a database created by the
Sanger Institute Pathogen Sequencing Unit (PSU) with the aim to provide reliable access
to the latest sequence data and their annotation and curation. Basic VSG annotation and
curation were undertaken using Artemis, a software package developed at the Sanger
Institute that enables visualisation and characterisation of large (chromosome-size) DNA
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molecules (Rutherford et al., 2000). Initial guidelines in VSG annotation were given by Dr.
Mark Carrington (University of Cambridge), who had constructed a small, independent
VSG database. Further developments were discussed and validated with him and with Drs
Hubert Renauld and Christiane Hertz-Fowler, genome curators at the Sanger Institute.
Some of the basic findings derived from work presented in this chapter were included in
the antigenic variation section of the trypanosome genome paper (Berriman et al., 2005).
3.2 Analysis of the T. bruce; strain 927 VSG archive -
overview
3.2.1 Estimation ofVSG archive size
VSGs present in the larger assemblies of megabase chromosomes 1-11 as found in the
GeneDB v4 release (July 2005) were analysed, and additional VSGswere annotated from
the putative chr 8 homologue array and unordered contigs of chr 9, 10, 11, yielding a total
of940 genes. A contig (short for contiguation) represents the outcome of using
bioinformatics to join sequencing reads, based on overlap between them. The ordering of
contigs with respect to one another can be achieved either through sequence overlap,
providing a physical map, or positioning of contigs in a genetic map by the use of specific
markers, to provide a scaffold or assembly. Both approaches are problematic for VSG
arrays, due to the repetitive nature of the arrays and the lack of genetic markers.
Therefore, there is still considerable work left in order to complete sequencing and
annotating VSG arrays and to distinguish between genes present on the two homologues of
each chromosome.
In order to put the current analysis into perspective and be able to draw meaningful
conclusions, an estimate of the total size of the VSG archive will first be attempted.
Knowledge of chromosome sizes from pulsed field gels (Melville, 1997; Melville et al.,
1998) and of the extent of the core region of each chromosome from genome sequencing
(C. Hertz-Fowler, pers. comm.) allows estimation of the core haploid genome size at 22
Mb; this leaves the value of the combined subtelomeric region for each chromosome and
its homologue at around 9.5 Mb (Table 3.1).
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Table 3.1: Estimate of subtelomeric chromosome size for Trypanosoma bruce; strain TREU
927/4 (data analysis by Prof. J.D. Barry, pers. comm.).
PFG stands for Pulsed Field Gel (see text).
927
core Mb 927Chromosome chromosome (genome subtelomerenumber size (PFG)
(Mb) sequencing) size (Mb)
lA 1.10 0.80 0.30
1B 1.20 0.80 0,40
2A 1.30 0.90 0,40
2B 1.34 0.90 0,44
3A 1.63 1.46 0.18
3B 1.76 1.46 0.30
4A 1.65 1.39 0.26
4B 1.78 1.39 0,40
5A 1.70 1.29 0,41
5B 1.72 1.29 0,43
6A 1.75 1.22 0.53
6B 2.00 1.22 0.78
7A 2.17 2.15 0.02
7B 2.17 2.15 0.02
8A 2.10 2.35 -0.25
8B 2.17 2.35 -0.18
9A 3.33 2.16 1.18
9B 3,49 2.16 1.33
lOA 4.39 3.85 0.54
lOB 4,41 3.85 0.56
llA 5.22 4.47 0.75
llB 5.22 4.47 0.75
diploid - 44.05 9.54
haploid - 22.00 -
total 53.59 - -
Around 2 Mb are likely to be taken up by 15-20 bloodstream expression sites (average
length 50 kb) with a barren region upstream of up to 80 kb" (LaCount et al., 2001), and
allowing 0.5 Mb oftelomeres (~10 kb at each end), 7.5 Mb of subtelomeres are left, likely
to be occupied almost exclusively by VSG arrays. Assuming that all arrays are haploid
(which appears to be the case, as discussed towards the end of the chapter), and given an
average gene density of one VSG every 5 kb (observed in the current study), yields a value
of around 1500 genes. Taking a less conservative approach and assuming that telomere
tracts and expression sites combined contribute 1 Mb of subtelomeres, a value of 1700 is
obtained (8.5 Mb of arrays). All these computations are subject to error, but it can be said
it is highly unlikely that the silent archive would exceed 2000 genes. GeneDB currently
contains around 4 Mb of subtelomeres in the main chromosome molecules and another 2.8
20 Assuming that all BES are located on megabase chromosomes, which possibly is not the case. lOOkb is the
"arbitrary" average value taken for each BES plus barren region upstream, in making the 2Mb estimate.
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Mb of VSG-containing unordered contigs (C. Hertz-Fowler, pers. comm.), giving around 7
Mb ofsubtelomeres. If the above estimate is correct, GeneDB houses currently most of
the VSG arrays (with -1250 VSGs annotated and more VSGs likely to be as yet
unannotated). Taking a value of 1600 as a likely estimate, it therefore emerges that VSGs
analysed in this study (940) represent between half and two thirds of the total VSG archive.
The 927 genome strain appears to have the shortest chromosomes amongst T. brucei
strains, and this is thought to be due to changes in VSG array length: if this is correct, the
427 strain has 2.5 times the array length of 927, corresponding to around 3000 VSG genes.
Whether an "optimal" archive size is selected for in the wild or whether archive size
fluctuations are very common, this is currently not known.
3.2.2 Annotation
Inmost cases annotation of VSGs has been reliant on a first pass automated gene
"detection" conducted by the sequencing centres. This was then refined to encompass the
full extent of genes or fragments thereof. Specific features were used to capture the
characteristics of each encoded protein, in terms of signal peptide, N-terminal and C-
terminal domain and GPI signal. Whereas the signal peptide was always based on
prediction by algorithm (SignalP 3.0, http://www.cbs.dtu.dklservices/SignaIPD. the other
three features were curated manually on the basis of sequence homology by using blastX
and blastP at NCBI. Inthe case of putative functional GPI signal anchors, the prediction
"by homology" was additionally verified by specific prediction programs (big-PI,
http://mendel.imp.ac.atlsatlgpi/gpi server.html, and DGPI,
http://129.194.185.165/dgpiIDGPI demo en.html). N-glycosylationprediction was not
performed routinely, being conducted only on putative functional VSGs: whereas the
amino acid motif allowing N-glycosylation is conserved, there is less of a consensus with
regards to the stringency ofN-glycosylation requirements, which seem to be based on
more complex structural observations, implying knowledge of tertiary structure (see
Section 1.2.2 ofIntroduction). There will therefore be no further mention of this aspect of
VSG modification: suffice it to say that VSGs classed as functional in this study seem to
have the same range of variation inN-glycosylation as that found in expressed VSGs
characterised to date (data not shown). Study of detailed tertiary structure of proteins
encoded by candidate functional genes could enable predictions to be made in terms of the
likelihood of them being expressed and could possibly question the "intactness" of some
sequences, but such analysis is beyond the scope of the work presented here.
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A total of 940 VSGs were analysed and they can be divided into four categories: functional,
atypical, pseudogene and incomplete. Whereas "functional" VSGs meet all parameters for
the features described above and are likely to be expressed, what have been termed
"atypical" VSGs encode a complete open reading frame that has potential problems
associated with folding (cysteine pattern incomplete) and targeting or anchoring
(alterations in GP! signal or N-terminal signal peptide sequence); this makes the prediction
that these VSGs could be expressed uncertain. As for the final two categories,
"pseudogenes" have been defined as full-length coding sequences interrupted by
frameshifts and/or stop codons and "fragments" are shorter than a complete VSG coding
sequence.
The striking observation made upon completing the analysis of the VSG archive was that
the great majority of the 940 silent VSG copies analysed are pseudo genes (611, 65%) or
fragments (197, 21%), only a small percentage being functional (43, 4.5%) or atypical (89,
9.5%) (see Figure 3.1). This raises questions as to how this "defective" archive contributes
to antigenic variation, an issue that will be discussed once other important aspects of the
data have been presented.
43
(4.5%)
~ functional
oatypical
full-length
pseudogene
Dfragment
Figure 3.1. Basic features of the T. bruce; strain TREU 927 VSG archive (940 genes).
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The dividing line between "functional" and "atypical" VSGs is very fine, especially as in
most cases (67 "atypicals" out of 89, 75%) it comes down to minute differences in GPI
anchor signal sequence (Table 7.3 of the Appendix gives all atypical VSGs and their
associated features). These differences can be broken down into changes at the cleavage
site (38 instances), presence of polar residues in the hydrophobic extension (22), or the
hydrophobic extension being longer or shorter than the consensus sequence (28). The
latter can often be explained by the presence of a frameshift within the GPI signal
sequence, extending the hydrophobic region or making it unusually short. Whereas the
predictions for longer anchor sequences or sequences with alterations at the cleavage site
seem to be unfavourable, there are borderline cases in which there are only a few
substitutions from the GPI signal consensus obtained from expressed VSGs, making a neat
classification into either functional or atypical very difficult. It is expected that an
increased knowledge of GPI signal sequence requirements and a larger sample of
expressed VSGs will shed light on this currently grey area. This will mean that some of the
currently functional VSGs might be classed as atypical or vice versa, depending on how
stringent are the requirements for stable in vivo expression. Other VSGs (9) were classed
as atypical due solely to missing cysteines in the C-terminal domain", and another 9
because they encode a novel C-terminal domain (type 5, described later in this chapter).
Lack of experimental evidence for processing of this domain type within a mature
polypeptide makes it difficult to define with confidence whether or not the anchor signal
sequences of these silent copies are functional or not (see Figure 7.1 of the Appendix for
an alignment of type 5 C-terminal domains). Only four VSGs have been classed as atypical
due to lack of conserved cysteines in the N-terminal domain or because of weak N-
terminal signal peptide prediction.
Just as there is a grey area between functional and atypical VSGs, it could be argued that
many atypical VSGs are "not fit for expression" and therefore could follow under a broader
definition of pseudogene, namely as a gene that is not able to form a functional expressed
protein. VSG fragments will be discussed inmore detail towards the end of this chapter, as
the architecture of VSG arrays is described.
21 A total 000 atypical VSGs have a non-conserved cysteine pattern in the C-terminal domain.
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3.2.3 VSGdb: a tool for VSG domain analysis
The overview results presented above were obtained in the first-pass analysis of the data:
as chromosomes were scanned for VSG arrays and VSGs were analysed using Artemis, a
table was compiled giving details of each VSG in terms of coding sequence features
(sequence intactness, domain types), gene location, associated non-VSG genes and repeats
(see section 3.7 for further details on VSG arrays). From this initial "catalogue" (presented
in Table 7.2 of the Appendix) the analysis was greatly aided by the development of VSGdb
(available online at www.VSGdb.org).This flat-file based database was developed using
BioPerl in collaboration with bioinformaticians Pauline Ward and Suraj Menon and is
currently maintained by Jon Wilkes, Well come Centre bioinformatician. At the core of the
database are EMBL files containing the sequence and VSG annotation for each individual
chromosome or contig; it is likely that VSGdb would need to be converted to a relational
(MySQL) database ifmore data are to be added, as the current setup, while handling the
data effectively, has limitations in terms of speed and complexity of queries.
The database allows access to all annotated VSG sequences and retrieval of sequences for
particular groups of VSGs (by domain, domain combination, chromosome, etc.), blast-
searching a VSG sequence against known VSGs, separate retrieval ofN-terminal and C-
terminal domains. Each VSG also has its own page with details of all associated features,
and all VSGs have GeneDB identifiers, allowing cross-talk with GeneDB.
Apart from providing open access to the community, making the database a useful tool for
researchers wanting to explore the VSG family with a specifically designed and flexible
tool, VSGdb allowed cross-checking the data, amending the annotation and also analysing
more closely each N-terminal and C-terminal domain type and how they relate to each
other. In short, domain types were retrieved separately, and the assignment to functional,
atypical and pseudo gene categories and to specific domain types was verified. This was
followed by several rounds of multiple sequence alignment (ClustalX), together with
alignment editing (Bioedit, http://www.mbio.ncsu.edulBioEditJbioedit.html) in order to
remove indels (large insertions and deletions) and sequences that were too diverged (as
judged from tree branch lengths and cysteine conservation). The data could then be
compared at different levels using domain type subgroups or different domain
combinations.
The following paragraphs present the results obtained, starting from N-terminal domains,
moving then to C-terminal domains, then to integrate the data and look at full length
coding sequences: as each component was dissected, a clearer appreciation of the
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sequences available for antigenic variation was gained. VSG sequence diversity,
divergence and evolution could be closely assessed, based on intradomain type
diversification and interdomain type interaction.
3.3 N-terminal domains
In the 771 full-length N-terminal domains, types A and B are the most abundant, each
amounting to about half the total number, with type C forming a small cluster within type
A (see global N-terminal domain alignment below, Figure 3.2). No novel N-terminal
domain types were found. For each N-terminal domain type, about one in three domains
are functional (see Figure 3.3) suggesting, as will become more apparent in section 3.4,
that most of the degeneracy of the VSG archive is due to defective C-terminal domains.
gr4
gr2
II
II
Figure 3.2: Tree derived from amino acid alignment of 725 VSG N-terminal domains.
The tree and multiple sequence alignment were both generated by ClustalX (Thompson et
al.,1997). The tree was visualised and the branches coloured using HyperTree (Bingham
and Sudarsanam, 2000). The three N-terminal domain types (A, B and C) were coloured in
dark blue, red and light blue, respectively. Gr1 to gr4 in both type A and type B domains
represent groups 1 to 4, the significance of which is explained in Figures 3.4 and 3.5.
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Figure 3.3: Abundance and basic characteristics of the different VSG N-terminal domain
types (A-C).
The y axis indicates number of domains; NA, NB, NC indicate N-terminal domains A, Band
C, respectively; the three columns indicate functional (f), atypical (a) and pseudogene (p)
domains. The number of domains in each category is given above the columns.
3.3.1 Types A and C
A more detailed analysis ofN-terminal domain types A and C involved analysis of 338
type A and 29 type C, totalling 377 sequences. Alignment of these N-terminal domains
indicated several distinct clusters (see Figure 3.2, giving a summary tree for all N-terminal
domains and their subgroups), so the data were analysed further and broken down into
smaller subsets, which were then edited to reduce uninformative indels and optimise the
alignment. The editing allowed a closer look at potential differences between groups, to
explain their distinctness, and this appears to be due to significant variations in the cysteine
pattern. Four main groups (corresponding to four main cysteine patterns) can be identified
(see Figure 3.4): group 1 represents the most common pattern type (44%), the one for
which tertiary structure has been solved experimentally (Freymann et al., 1990). Groups 2,
3 and 4 reveal the "hidden" diversity of type A domains, of which type C can be
considered part, its cysteine pattern being closely related to that oftype A domain group 4.
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Figure 3.4: Cysteine pattern of type A N-terminal domain groups and subgroups.
The number to the right Indicates the number of domains in each group. Gr strands for
group and subgr for subgroup.
It was of interest to look at secondary structure prediction for these four groups, to
appreciate whether they were marked also by variation in alpha helical arrangement.
While it was noted that the length of helices A and B (at the beginning of the domain, see
Chapter 1, Figures 1.2 and 1.3) was greater ingroups 2-4 than in group 1, possibly
correlating with the wider spacing of cysteines, there did not appear to be any other
significant group-specific difference (data not shown).
3.3.2 Type B
As for N-terminal domain type B, 335 sequences were analysed and groups could be
identified from the tree and multiple sequence alignment (see Figure 3.2); however, unlike
in the type A analysis, the differences between the groupings are not striking in terms of
cysteine pattern. The main difference between groups appears to be the slight variation in
distance between conserved cysteines, although all groups have the same cysteine pattern
(see Figure 3.5).
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Figure 3.5: Cysteine pattern of type B N-terminal domain groups and subgroups.
The number to the right indicates the number of domains in each group. Gr strands for
group and subgr for subgroup. cysteine pattern of N-terminal domain type B subgroups.
When producing a tree with either the first or last 100 amino acids of all N-terminal
domains (these regions were chosen because of smaller differences in cysteine pattern
between types A and B), clear separation between sequences encoding the two domain
types was maintained, suggesting a lack of interdomain short-range recombination, likely
to be due to excessive sequence divergence (data not shown).
3.4 C-terminal domains
In the analysis of VSG C-terminal domains, more diversity and complexity was .
encountered than for the N-terminal domains. A C-terminal domain can be described by a
combination of features: the presence of one or two 4-cysteine subdomains, the spacing of
cysteines within the subdomains, and the type of GPI signal. The table below proposes a
classification of C-terminal domains based upon these features. In addition to domain
types 1 to 4, two other domain types were found to be encoded in the VSG archive, and
were named 5 and 6.
Table 3.2: C-terminal domain type proposed classification.
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domain type 1 cysteine subdomain (4-cys) 2 cysteine subdomains (8-cys)
based on last four Domain type Number of Domain type Number of
cysteines and domains domains
GPI signal
1 - 0 Cl 235
2 C2 186 - 0
3 - 0 C3 152
4 C4 10 C6 38
5 C5a 28 C5b 2
C-tenninal domain type 1 is the most abundant (235), followed by type 2 (186) then type 3
(152). Types 4,5 and 6 are less common (10,30 and 38 respectively). In contrast to the N-
terminal domain, there are only 13% (85/651) functional domains. A somewhat less
degenerate domain is type 2, with 23% (43/186) being functional, whereas only 7% of type
1 are predicted to be functional, the values for the others lying somewhere between (see
Fig 3.6 for details). The difference between the level of degeneracy of type 1 and type 2
could be due to the fact that type 2 is shorter (only four cysteines) and therefore less likely
to accumulate deleterious mutations. An additional explanation would be that the
abundance of type 1 domains makes them statistically more prone to recombination than
other domains, leading to the spreading and amplification of errors due to inaccuracies in
the recombination reactions.
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Figure 3.6: Abundance and basic characteristics of the different VSG C-terminal domain
types (1-6).
The y axis indicates number of domains. C1 through to C6 indicate C-terminal domains 1 to
6. The three columns indicate functional (f), atypical (a) and pseudogene (p) domains. The
number of domains in each category is given above the columns.
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Analysis of internal variability of cysteine pattern in each individual domain failed to
reveal discrete subgroups, in contrast to the case ofN-terminal domains. The subgroups
presented in Figure 3.7 are a small subset of similar sequences taken from a very
heterogenous pool rather than representing neat and comprehensive subdivisions, as found
in N-terminal domain subgroups. Itwas of interest to note that some of the first 4-cysteine
subdomains were shared amongst different domain types (subdomains underlined in blue
in Figure 3.7), whereas the last 4-cysteine subdomain tended to be the unique signature for
the domain type (apart from C4 and C6, which share one, as underlined in red in Figure
3.7).
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Figure 3.7: Cysteine pattern of C-terminal domains, types 1-6.
Cysteine subdomains that are shared between different domain types are highlighted in the
same colour. Two to three examples of domain type subgroups are given for the main
domain types, with the number of domains within each subgroup given on the left. The half
height bar towards the end of the domain indicates the start of the GPI anchor signal (not
determined for type 5).
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It then became of interest to investigate the relationship between the 4- and 8-cysteine
domain types and how different 4-cysteine subdomains relate to each other. This was done
by producing and analysing C-terminal domain trees. Of the 651 domains that were
initially used for the trees (many others were omitted because their excessive degeneracy
rendered them unassignable to a domain type), only 541 were used in the analysis
presented below (Figure 3-8). The trees include only domains in which allocation to a type
was unambiguous and the cysteine subdomain pattern was either intact or, if degenerate, at
least similar to that of other intact ones. Two additional trees were produced, in which the
first and second 4-cysteine subdomain of 8-cysteine domains (types 1, 3, 6) were taken
separately and each compared with the core cysteine-containing part of 4-cysteine domains
(types 2, 4 and 5).
01.2
03
04
541 C-terminal domains:
1st 4-cys subdomain
541 C-terminal domains:
2nd 4-cys subdomain
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Figure 3.8: Trees derived from amino acid alignment of 541 VSG C-terminal domains.
The tree and multiple sequence alignment were both generated by ClustalX (Thompson et
al.,1997). The tree was visualised and the branches coloured using HyperTree (Bingham
and Sudarsanam, 2000). Above: global tree comparing full-length sequence of all domains.
Below to the left: tree comparing the first 4-cysteine subdomain of types 1, 3, 6 to the 4-
cysteine subdomains of type 2, 4 and 5. Below to the right: tree comparing the second 4-
cysteine subdomain of types 1, 3, 6 to the four cysteines of type 2, 4 and 5.
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Figure 3.8 suggests that there is promiscuous mixing of different C-terminal domain types
in the N-terminal domain-proximal region, corresponding to the first four cysteines of the
8-cysteine domain types. Domains seem not to mix so extensively towards the C-terminal
end of the gene, where they show more specific features (last four cysteines and GPI
signal). This confirms what was suggested from analysis of cysteine pattern of domain type
subgroups and provides the context in which the documented cases of recombination
between sequences encoding the first four cysteines of a C-terminal domain type 1 and a
type 2 C-terminal domain have been shown to occur (Hutchinson et al., 2003). A model of
recombination between C-terminal domain types can be proposed based on these analyses
(see Figure 3.9).
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Cl
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D high
D
D low
Recombination between domain types
Figure 3.9: Model of recombination between C-terminal domain types.
The height of the green area below the domain depictions is proportional to the proposed
level of interdomain recombination, increasing as it approaches the first set of four
cysteines, and decreasing in the second part of the domain. Groups of four cysteines
underlined in blue or red indicate identical spacing of cysteines.
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3.5 Full-length VSGs
Now that both N- and C-terminal domains have been described and analysed, it is of
interest to observe how they relate to each other. In order to do this, all domain
combinations in full-length VSG genes were considered and the expected and observed
values of these combinations were calculated. These are presented in Table 3.3; they
match an older set of data (produced in July 2005), but are nevertheless informative, as the
set of data was similar in size and composition to the final one presented at the beginning
of the chapter, so essentially the same results would be obtained by repeating the analysis.
Table 3.3: VSG N- and C- terminal domain combinations: expected and observed values.
Underlined in green are the main preferential domain combinations (more than 10%
difference between observed and expected valued).
N domain
A B C
obs' Ex~2 Obs Ex~ Obs Exp
C 1 101 (28) 130 149 (49) 112 3 (12) 9.5
domain 2 143 {40} 91 19 (6.2) 78 11 (42) 6.6
3 43 (12) 76 101 (33) 65 3 (12) 5.5
4 8 (2.3) 5.1 1 (0.3) 4.4 1 (3.8) 0.4
5 27 (7.6) 16 0(0) 14 4 (15) 1.2
6 9 (2.5) 17 24 (7.8) 15 1 (3.8) 1.3
other 24 (6.8) 20 12 (3.9) 17 3 (12) 1.5
total 355 306 26
355 (100) 306 (100) 26 (100)
'Each cell shows: frequency and (percentage of total for that domain type)
2Expected values were calculated as: (observed frequency proportion of each
N-terminal domain type)j(observed frequency of individual C-terminal domain type)
There appears to be a bias in domain combination, with A2, 81, B3 and 86 being the most
common. This could suggest that a single surface molecule diverged into separate families
(A and 8), possibly acquiring different functions, and that later the formation of a large
repertoire of protective coat proteins was achieved by expansion and mixing of these
families, which still show traces of their long separation. This mixing ofN-terminal
domains of one type with C-terminal domains associated with a different N-terminal
domain type is likely to have occurred because of the shared four-cysteine motif in the C-
terminal domain (see Figure 3.9), acting as a bridge between diverged hypervariable N-
terminal domains. How both N-terminal domain families acquired related Cvterminal
domains is as yet beyond explanation, although comparison with T. congolense might shed
some light, because of the lack of a C-terminal domain in the VSGs of this parasite. A
preliminary analysis of T. congolense VSG emerging from the T. congolense genome
project will be given in Chapter 5, section 5.4.1.
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As might be expected, a global tree for full-length VSGs (Figure 3.10, obtained from the
July 05 data, see beginning of section 3.5) discriminates primarily between N-terminal
domains, whereas, within the N-terminal domain groupings, the specific C-terminal
domain does not form a neat subgroup, again mirroring the above-mentioned overlap
between C-terminal domains.
A1
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Figure 3.10: Tree derived from amino acid alignment of 594 full-length VSGs.
The tree and multiple sequence alignment were both generated by ClustalX (Thompson et
al.,1997). The tree was visualised and the branches coloured using HyperTree (Bingham
and Sudarsanam, 2000). The July 2005 dataset was used, see text for more details. Domain
combinations are highlighted in different colours, apart from VSGs with N-terminal domain
type C, which were grouped together because of their small number.
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3.6 VSG families?
At this point it is important to address the question of whether, within the broad VSG
domain types and subgroups, there is further substructuring that could allow definition of
smaller VSG families, or whether there is a continuum of variation. Although the long
branches in the trees suggest the latter is correct, a quantitative estimate of this divergence
will be attempted, by analysing the pairwise score generated by the multiple sequence
alignment ofN-terminal domains (http://www.ebi.ac.uklclustalwD.This was done for N-
terminal domain type A22, with the scores being converted to percentage identity and the
proportion of different identity ranges being plotted (Figure 3.11). Between the 361 A type
N-terminal domains considered, 64980 pairwise comparisons were generated. Out of
these, only 90 show an amino acid sequence identity above 60%, that is to say that only
one in two of these domains would have a close orthologue". Sequence identity drops
dramatically between VSGs, with a 95% probability of any alignment between VSGs to
result in less than 25% sequence identity, down to 18% (see Figure 3.11). Below 25%
identity, errors in aligning sequences increase dramatically (at around 20% sequence
identity, misalignment has been estimated to occur with a frequency of one in two). In
turn, the presence of alignment errors increases the probability of inferring mistaken
relationships between protein sequences, with a maximum accuracy of 75% when the
identity between sequences is lower than 25% (Vogt et al., 1995). When looking at low
scores below 18 (corresponding to below 25% identity) there was not a linear decrease in
identity between domains, but rather a fluctuation in alignment values between 18 and 25%
identity. The fact that most VSG comparisons lie below the 25% ''twilight zone" (Vogt et
al., 1995) results in a very high level of noise in the data. The VSG groups defined earlier
in this chapter are held together by pairwise alignments in the 25-35% range, which help to
order the "noise" below 25%. This means that within each VSG group there will be VSGs
with as low as 18% sequence identity, which implies that groups cannot be defined simply
in terms of sequence homology, but rely on more complex relationships between multiple
pairs of VSGs. The implications of this highly diverged VSG archive will be discussed in
Chapter 6.
22 The same analysis was conducted with type B N-terminal domains, giving similar results (data not shown).
23 Assuming that each of the 90 pairwise alignments corresponds to 180 unique domains, which is reasonably
accurate, as there are very few domains sharing more than one close orthologue (data not shown).
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Figure 3.11: Pairwise scores from a multiple sequence alignment of 361 type A VSG N-
terminal domains (64980 comparisons).
Each range of % amino acid sequence identity (given on legend to the right) has been
associated with the number of pairwise alignments giving score values within this range.
The absolute number of each group of alignments is given above each bar.
3.7 VSG arrays: structure and features
A major finding arising from the genome sequencing and annotation project is that the
great majority of VSGs appears to be located in distinct subtelomeric arrays rather than
"internally" in the genome, as was previously thought (Vander Ploeg et al., 1982b) (see
Figure 3.12). The arrays appear to be the only context in which VSGs are found in the
genome, only one VSG-like gene out of 940 being located outside them (and it has unusual
features, see Chapter 5, section 5.2.7). A separate class of genes, related to type B N-
terminal domain-encoding genes but with many similarities to T congolense VSGs, which
are shorter than those of T brucei, has been found. They reside outside the arrays, and
have been termed "VSG-re1ated" genes. Chapter 5 will be devoted to the analysis of this
gene family, drawing comparisons and showing differences to T brucei and T congolense
VSGs.
66
" 26 250
XI o.....~;r-----~---'-----------L.-.-.-------+';.\7j'_".'-..J!\;,,~.- "_. JILL,_'I' ''',~,~u ~ ~IMVSG
X ~'r------------------~~_'-;;:~""'__
2MVSG
82" .,
IX ~ ~1IIIi oLio
l 1 I
" I
II I 11111 II II
IIIII IIIIII~IIII
I 111111
~ "
5
VII ~,.........._--------,___~
I • II I
5 II I
I'~IIliII'I~ "1"1 II ~~IIII
I II II II II III I
I: I· I 1 ,
VI ~ I
!III
Wi .. ···"
III 1154 I VSG (full length bar)I atypical VSG (mid-length bar)
I pseudo VSG (half-length bar)
I VSG -related
ESAG
pseudoESAG
Ingi/RIME/DIRE
• Telomere
o arrays of 76 bp repeats
10 'I 1V ~II
"
34-" II I
III ~I!'l!!"',____.....",_.........,. -,-:I ,'- IV-~---------'a..'Iji1i'-"
6 ,I 1.1 1 "35
Figure 3.12: Chromosome maps for T.bruce; 927with VSG arrays highlighted, modified
from Berriman (2005).
Roman numerals indicate the megabase chromosomes 1-11 in order not to confuse them
with arabic numerals indicating the number of VSGs present in each array (correct as of
July 2005). For up to date maps see www.genedb.org (arabic numerals normally indicate
chromosome numbers in this context).
The basic unit in a VSG array has been termed the VSG cassette: it is delimited upstream
by 70-bp repeats and downstream by the 3' end ofthe VSG, extending from within the end
of the coding sequence to conserved elements immediately downstream, and is around 3-4
kb long (see Chapter 1 section 1.3.4 for more details and references, and Figure 3.13).
Some 92% of full-length VSGs (6871743) are associated with at least one 70-bp repeat
upstream. By analysing variation in 70-bp repeat numbers upstream of 5 array VSG genes
it was suggested that differences amongs 70-bp might impose an order of expression
amongst array VSGs (Aline et al., 1985). The present bioinformatic analysis reveals a less
extensive diversity amongst 70-bp repeats: 80% of array genes with 70-bp repeats have
only one copy of the repeat, 15% have two copies and only 5% have between 3 and 15
copies, with no association between large number of repeats and putative functional VSGs.
In addition, it appears that the level of degeneracy amongst 70-bp repeats is greater than
what has been shown so far, with frequent departures from the consensus sequence,
especially in the case of section 3 of the repeat (see Introduction, section 1.3.4), which
sometimes is absent or incomplete (data not shown).
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A novel feature found to be associated to VSG cassettes is the presence of one or two genes
between the 70-bp repeat and the VSG sequence: the most commonly found is a
pseudogene copy of ESAG3 (11% of VSG cassettes). The second, annotated as an UDP-
Gal or UDP-GlcNAc-dependent glycosyltransferase by Prof. M. Ferguson, was found to be
present in 4% of VSG cassettes, mostly as a pseudogene. Whether there was any
significance in coexpression of these genes with VSGs at some time in the past, or even at
present, following cassette duplication into VSG expression sites, it is likely that currently
the array copies of these genes act primarily, if not exclusively, as blocks of sequence
homology facilitating recombination between silent VSGs.
* *rc:n» t:::
* 70-bp repeats
VSG ESAG3 ~
wrn~ ~?~ DD5-"~
. - cassette
C domain fragment
Figure 3.13: Example of VSG array with cassette structure highlighted.
Cassette boundaries (indicated with alternating blue and black brackets) are approximate
and given only as rough guide to VSG array structure.
Most arrays contain several copies of the retrotransposon INGL which appears to cluster in
these subtelomeric regions and largely to be absent from the core region of the
chromosome (see Figure 3.12) (Kimmel et al., 1987; Bringaud et al., 2004). All VSG
arrays are directed away from the telomere", apart from some on chromosomes 9 and 11,
where there are many strand-switches associated with INGI insertion. INGI is partly
associated to truncated VSGs in the genome, as depicted in Figure 3.14, showing that one
fourth of incomplete VSGs are flanked by an INGI element. A significant proportion
(around half) of these incomplete genes are C-terminal domains, or fragments thereof,
which are found just downstream of a full-length VSG in a cassette. An example of these
short C-terminal fragments is highlighted with a red circle in Figure 3.13: it is likely that
also these sequences (as ESAG3 and UDP-Gal) are functioning as an extra homology
24 This will be discussed in Chapter 6, section 6.1.1.3.
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flanking region, as the vast majority are degenerate, containing stop codons andlor
frameshifts.
Full-length VSGs: 743
[) I[)I[)
INGI -associated truncations:
49/197: 25%VSG fragments: 197
25/130
(19%)
24/64
(37%)
Figure 3.14: VSG fragments, proportion of different truncated versions.
The four VSG features are highlighted in the full-length gene at the top of the figure (signal
peptide, N-terminal domain, C-terminal domain, GPI signal). Below are VSG fragments
grouped into N-and C-terminal domain fragments and divided into subgroups depending on
the extent of the truncation. To the right of each subgroup is the number of VSG fragments
found to exhibit the particular truncation type. This number is then represented as a yellow
bar further to the right, and below it is a blue bar indicating the proportion of truncations
associated with INGI.
Looking for patterns of VSG gene distribution and relatedness, there appears not to be any
obvious linkage ofrelated genes within arrays, as shown in the tree below (Figure 3.15),
which is the same alignment of full-length VSG given in Figure 3.10, but coloured instead
according to array location. This is in keeping with earlier research showing that a family
of related VSGs was dispersed in the genome (Beals and Boothroyd, 1992) and suggests
that, if gene duplication is acting in tandem", genes are then rapidly reshuffled amongst the
arrays. The great divergence of the archive, mentioned when discussing VSG domains and
VSG families, significantly complicates gene duplication analysis, as only a small group of
sequences can meaningfully be compared (data not shown) when tracing locations of
related genes.
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Figure 3.15: Tree derived from amino acid alignment of 594 full-length VSGs (same as
Figure 3.10, but coloured by array).
To the right are colours associated to each complete array available (July 2005). Numbers 1
to 9 correspond to chromosomes 1 to 9, Land R correspond to the left and right
subtelomeric arm of the chromosome, respectively. 8H is the 8L array homologue.
Itwas mentioned in the Introduction (section 1.1.3) that genome sequencing has brought to
the fore the finding that at least some, if not all, subtelomeric regions containing VSG
arrays are haploid. This was explored in more detail for the chr8 array and the array on the
homologous chromosome, the first pair of homologues to be unambiguously determined,
both subtelomeric contigs being linked to a common core housekeeping region. It appears
that synteny is restricted to merely three of the >30 genes (Figure 3.16), suggesting that
there might not be any preferential interaction of arrays present on homologous
chromosomes.
25 Further considerations on the issue of gene duplications will be made in Chapter 6 (Discussion), section
6.3.1.
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Figure 3.16: Comparison of the VSG array of chr 8 and the array on the homologue.
Elements in light blue correspond to INGI sequences; the telomere is to the left; numbers
below indicate bp from the beginning of the two arrays. The five highlighted VSG pairs
share at least 30% amino acid sequence identity. All VSGs that are not highlighted share
less than 30% sequence identity.
3.8 Conclusions
The bioinformatic analysis conducted in this chapter has provided many clues as to how
silent genes forming the VSG archive can contribute to antigenic variation. First and
foremost, it was shown that the VSG archive is composed largely of pseudo genes and
sequences that have diverged from the expressed consensus (~95% of silent VSGs).
Having made an estimate of archive size at around 1600 genes, it is likely that about 80
functional genes are present, a number that is significant enough to envisage an important
contribution of these genes in the course of a chronic infection. Whether during infection
functional array genes are expressed with a specific timing, then to be replaced by hybrid
genes exploiting the ~500 functional N-terminal domains (one third of total full-length
VSGs), or whether the latter appear concurrently with their most closely related functional
counterpart, remains to be elucidated.
The C-terminal domains are more degenerate than N-terminal domains, but the necessity
for a large pool of the former is probably not as strong as that for the latter, as C-terminal
domains do not contribute to antigenic variation, not containing any epitopes exposed to
the surface. The VSG cassette structure might support the idea that most C-terminal
domains have become mere flanks of homology for recombination reactions involving the
N-terminal part of the protein, as outlined in Figure 3.9.
It therefore appears that, despite its degeneracy, the silent VSG archive contains a huge
potential for creating new variants and that most of its potential would come to fruition
through the formation of hybrid genes, utilising intact N-terminal domains and allowing
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them to recombine with functional C-terminal domains resident at telomeres. Further
recombination reactions creating mosaicism within the N-terminal domain would provide
additional scope for production of distinct surface antigens.
Another important observation was made with regards to VSG divergence within the
archive. The large number of VSG analysed allowed a more precise definition of the
concept of" VSG families". It seems that such a definition is in general an overstatement,
as any VSG would not have more than four other genes sharing above 60% amino acid
sequence identity (data not shown), the average being around one close orthologue per
gene. This level of divergence within a gene family is highly unusual, even amongst
surface antigens, which normally share around 90% sequence identity (see section 6.3.2 for
further discussion on this matter).
As for the sequence context of VSGs, it appears that subtelomeres (as in the case for other
parasites, see Introduction, section 1.5) have been exploited for the expansion and
evolution of the VSG archive. Several repetitive elements within the arrays are candidates
for mediating VSG archive expansion and rearrangement (apart from VSG themselves).
These include primarily the retrotransposon INGI and 70-bp repeats, with ESAG3 and
UDP gal glucosyltransferase having a putative ancillary role. The analysis presented
suggests that arrays are haploid and are highly prone to interacting with each other, given
the current jumbling of related sequences.
The three key features mentioned above, VSG degeneracy, divergence and
organisation/evolution, formed the three main directions of research conducted in the rest
of this project. Considerations on these aspects of antigenic variation will emerge in the
following two chapters, the first exploring the use of the VSG archive during a chronic
infection (with the aim of understanding the contribution of array genes and pseudogenes
to the infection) and the second analysing VSG-related genes, highlighting the main
features of their divergence from VSGs and their distinct organisational pattern in the
genome.
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CHAPTER4
HIERARCHICAL EXPRESSION OF VSGs IN
SUBTELOMERIC ARRAYS: EXPERIMENTAL ANALYSIS
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4 Hierarchical Expression of VSGs in
Subtelomeric Arrays: Experimental Analysis
4.1 Introduction
The finding that most VSGs in arrays are pseudo genes leads to the question of how the
VSG archive contributes to antigenic variation in the course of a chronic infection. It
seems that most genes could be activated only through the prior formation of a hybrid or
mosaic gene, by one or more gene conversion events. This phenomenon has been
described qualitatively and is believed to occur with such a low probability that its switch
products are observed only late in infection (Thon et al., 1990), but its frequency has not
been measured. A new tool to investigate the dynamics of VSG switching and activation is
represented by the availability of the genome sequence for T. brucei strain TREU 927/4
GUTat 10.1. A chronic infection with this strain was expected to allow tracing, using
bioinformatics analysis, a number of archive donor sequences (see estimate of VSG archive
coverage in Chapter 3, section 3.2.1), and to distinguish simple duplicative activations of
functional silent genes from more complex events involving pseudo genes. Published
information on parasitaemia in strain 927 inmice confirmed the experimental feasibility of
this approach (van Deursen et al., 2001). The hypothesis is that the products of mosaic
gene formation might be detected earlier in the course of an infection than is currently
thought and then gradually come to represent the predominant source of novel VSG coats,
once all other intact VSGs have been expressed and the host has become immune to their
products. Mosaic genes may become more complex as infection progresses, originating
from more than 2-3 donor sequences, and possibly resulting from the interaction of more
distantly related donors.
4.2 Chronic mouse infection experiment: overview
4.2. 1 Infection details
Initially, 11 mice were each injected with 106 trypanosomes (80 J..11blood volume with
parasitaemia of 1.3 x 107 trypanomes/ml), derived from an immunosuppressed mouse
infected four days previously with a TREU 927/4 GUTat 10.1 stabilate, kindly provided by
Prof. M. Turner. Before the experiment began, the identity of the trypanosomes was
confirmed with genome markers specific to TREU 927 (data not shown).
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As repeated sampling of individual animals would yield only a small sample volume, the
protocol adopted involved batch infection and terminal sampling of groups of mice on days
3,9,14,21-24 and 28 of infection. The mice to be sacrificed were selected on the basis of
their parasitaemia, those with the highest being chosen, but the increasing effect of
anaemia on mouse health was also taken into account as infection progressed (see Figure
4.1 for infection profile). Blood was collected from each sample and RNA, gDNA and
stabilates were prepared. Infection became patent more rapidly than in chronic mouse
infections previously carried out with pleomorphic EATRO 795 trypanosomes (Morrison
et al., 2005): the initial peak was reached at day 3 (rather than day 7), whereas the first
relapse peak occurred at around day 10 (rather than day 14). Nevertheless, the distance
between the first two peaks is the same in both 795 and 927 experiments, suggesting a
similar course of infection. As noticed in the above-mentioned study, also here the onset
of a second relapse peak was much more variable between mice.
Parasitaemia: 3 9 14 21-24 28 dayexponential
value (lOY)
7, 8, 9 10, 11~trypanosomes mouse
Iml 8.5
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7.5 -.-3
--+-4
7 ""*""5
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6.5 ___ 7
-.-8
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5.5 -+-10___ 11
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Figure 4.1: Infection profile of eleven chronic mouse infections carried out with T. bruce;
TREU 927/4 GUTat 10.1.
x axis = day of infection, y axis = parasitaemia (parasitaemia given as exponential value
(10Y)trypanosomes/ml). Numbers 1 to 11 in legend and above chart represent the 11 mice
used in the experiment. The five red arrows indicate the five timepoints.
4.2.2 Amplification of VSG cDNA
Reverse transcription was performed on the RNA obtained, using as primer oligo[ dT] to
maximise the production of full-length transcripts. peR products were generated by
Herculase proofreading polymerase (Stratagene) to maximise sequence accuracy, using a
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forward primer annealing to the spliced leader sequence (found at the 5' end of all
trypanosome mRNA molecules) and a reverse primer recognising a conserved l6-mer
sequence specific to the 3' end of all VSG mRNAs (see Table 7.4 for primer sequences).
Reaction conditions were: 5 mins at 95°C, followed by 30 cycles of 95°C for 1 min., 38°C
for 2 mins, 72°e for 2 mins and a final extension of 5 mins at 72°e. Amplified products of
the expected size (1.6 kb, see Figure 4.2) were cloned using the TOPO vector (see section
2.3.5 of Materials and Methods).
1 2 3 4 5 6 7 8 9 10 11 12
Figure 4.2: Ethidium bromide stained gel with VSG peR reactions on cDNA collected from
the GUTat 10.1 clone and its derivatives from eleven separate mouse infections, used for
TOPO cloning.
Lane 1: GUTat 10.1 cDNA pre-infection; lanes 2-12: cDNA from mouse 1 to 11. Primers used
annealed to spliced leader sequence (5') and 16-mer in 3' UTR.
4.2.3 VSG cloning and sequencing
Each positive clone obtained from the TOPO cloning reaction was given a three-part name
(e.g. 03-01-01), indicating the day of harvest (3 to 28), the mouse (1 toll), and the specific
clone number. A two part name with day of harvest and mouse will be used to indicate
each separate infection (e.g. 03-01). Cloning efficiency varied between cloning attempts,
but was generally low (average of 1 positive in 10 clones, with a minimum of 1 positive in
50 clones for the peR products of 14-06); initial colony screening was conducted using the
single colony lysis method (see Materials and Methods), which allows assessment of insert
presence by alteration in plasmid size. Candidate plasmids were isolated using a small-
scale plasmid DNA purification kit ("miniprep", Qiagen) and insert length checked by
EcoRI digest (data not shown). Table 4.1 summarises the raw data, indicating the number
of positive clones analysed for each peR cloning and specifying the nature of the analysis
(sequencing or peR based on previously sequenced clones).
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Table 4.1: VSG-containing clones obtained from RNA by RT-PCR.
Day and Sequenced clones Clones analysed by Total number of
mouse PCRonly clones
03-01 2 1 3
03-02 2 1 3
09-03 4 4 8
09-04 2 (+ 1 partial) 7 10
14-05 2 '" 5.)
14-06 1 1 2
22-07 4 0 4
21-08 2 2 4
24-09 1 1 2
28-10 5 6 11
28-11 11 4 15
Total 37 30 67
The full-length VSG coding sequence was assembled by overlapping sequencing reads,
produced from M13 forward and reverse primers present at either sides of the TOPO
vector cloning site, and internal primers designed specifically to cover the central region of
the gene (see Figure 4.3 for primer design details and Table 7.4 of Appendix for a full list
of primers used in this experiment). At least two rounds of sequencing were performed to
confirm independently the sequence of the insert across its whole length, unless the first
result gave 100% sequence identity to a VSG already present in the database.
Ci_rev
For/rev Ni_for
c----------~------------------......;;:;~N
For/rev
Figure 4.3: Primer nomenclature for VSG sequencing and analysis. Nand C refer
respectively to VSG N-terminal and C-terminal domains.
In blue are the M13 forward and reverse primers used for the first round of sequencing (for
and rev amplified either the N- or the C-terminal domain depending on the orientation of the
insert in the vector). In red are the primers used to cover the central region (Ni= N internal,
Ci = C internal), designed on the basis of the M13 sequencing results.
The two Figures below (Figure 4.4 and Figure 4.5) give details of the Pf'R analysis of
unsequenced clones based on primers developed for sequenced clones; it is shown for mice
3,4,5, 10 and 11, for which different inserts were present in the clones obtained. All
unsequenced clones derived from mice 1, 2, 6, 8 and 9 corresponded to the single variant
sequenced (peR data not shown). It is worth noting that localised sequence differences
could be present between a given sequenced clone and unsequenced clones identified
solely by peR analysis. Such "positive" clones were nevertheless not considered further,
as the main purpose of the analysis was to capture the full diversity of each infection, and
77
then to sequence clones that appeared not to match any of the known characterised VSG
sequences. The number of different VSGs obtained ultimately derives from the diversity of
antigen types present in the blood at the time of harvest, which is expected to be very low
in the first peak and to increase gradually with time (Capbem et al., 1977), but the Pf'R
reaction may preferentially amplify the most abundant mRNAs, overshadowing the actual
sample composition. Four different VSGs was the maximum number obtained per
infection, and was observed at day 9, 22 and 28, so the only increase in the number of
variants isolated was observed between day 3 (one variant) and the rest of the timepoints
(four variants).
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Figure 4.4: Ethidium stained gels showing peR products using VSG-specific primers,
amplified from clones obtained from infection 09-03, 09-04 and 14-05.
The number to the upper left of each gel indicates the specificity of the Ni_for I ei_rev
primer pair used for peR analysis of the clones (e.g. 3-1 indicates mouse 3 clone 1; primers
3-3 and 4-1 are the same, as the VSG is shared in both infections). Negative reversal of the
gel image is used in gels of infection 09-03 and 09-04, whereas the gel image for 14-05 was
not reversed. To the left of each gel is the size (in kb) for the main bands of the 1 kb ladder.
For infection 09-03, lanes 1 to 8 represent clones 09-03-01 to 09-03-08, tested with three
different primers (3-1, 3-4 and 3-3). peR with 3-3 primers includes a negative control (lane 9,
clone 28-10-02), needed due to likely primer contamination. For infection 09-04, lanes 1 to
10 represent clones 09-04-01 to 09-04-10, tested with two different primers (4-1 and 4-2).
Lane 11 in both gels represents a negative control (clone 28-10-02). For infection 14-05,
lanes 1 to 3 represent clones 14-05-03 to 14-05-05, tested with two different primers (5-1 and
5-2). Lane 4 on gel 5-1 represents clone 14-05-01, lane 4 on ge15-2 represents clone 14-05-
02. The asterisk indicates clones that are not amplified by any of the primer pairs (clones
09-03-07 and 09-04-10).
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Figure 4.5: Ethidium stained gels showing PCR products using VSG-specific primers,
amplified from clones obtained from infection 28-10 and 28-11.
The number to the upper left of each gel indicates the specificity of the Ni_for I Ci_rev
primer pair used for PCR on the clones. To the left of each gel is the size (in kb) for the
main bands of the 1 kb ladder. For infection 28-10, lanes 1 to 11 in both gels represent
clones 28-10-01 to 28-10-11, tested with two different primer pairs, 10-2 and 10-3. For
infection 28-11, lanes 1 to 15 of the first two gels represent clones 28-11-01 to 28-11-15,
tested with two different primer pairs, 11-1 and 11-2. The third gel of infection 28-11 has
clones 28-11-02, 28-11-09, 28-11-12, 28-11-14 (lanes 1-4) tested with primer pair 11-9. The
red, black and green asterisks indicate clones that are not amplified by any primer pair of
sequenced VSGs (28-10-07,28-10-10 and 28-11-14, respectively). Clone 28-11-13 (faint band
in 11-2 gel) was found to have the same VSG as clone 28-11-14, see Figure 4.6. Blue
asterisks indicate clones 28-11-09 and 28-11-12, corresponding to the same VSG, as can be
seen from the third gel of infection 28-11.
4.2.4 Sequencing errors
Errors were present in the cDNA sequence of 09-03-0 1, 09-03-04, 09-04-01, 14-05-02, 22-
07-02 and 28-11-14. These were all observed as differences between independent
sequencing reads and could be accounted for by gDNA contamination (unlikely, as PCR
was performed using mRNA-specific primers), or errors in reverse transcription, PCR, or
cloning and replication in E. coli (VSG sequences have sometimes resulted in unstable
clones with poor growth). The approach taken to correct these errors was to amplify the
corresponding VSG with specific primers, from gDNA and cDNA, when a putative donor
sequence was not present to identify the error. Table 4.2 gives details of the errors
detected.
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Table 4.2: Details of errors present in sequenced clones.
The fourth and fifth column refer to the method by which the presence of the error was
detected and corrected. Column four gives details of the sequence used as comparison
with the error-containing sequence. Column five gives the details of the new clones
obtained by reamplification of the initial clone by using specific internal primers; these
clones were then sequenced and used as a comparison
Clone Error type bp Corrected by sequence Corrected by
comparison reamplification
09-03-01 Deletion 1 donorread(98~id) No
09-04-01 Deletion 1 Clone 09-03-03 gDNAclone
09-03-04 Insertion 39 No 2 cDNA and 2 gDNA
clones
14-05-02 Point mutation 1 Clone 14-06-01 No
22-07-02 Insertion 1 Donor No
28-11-14 Insertion 1 Clone 28-11-13 No
In short, five indels (of 1 bp in four cases out of five) and one mismatch were found in 36
fully sequenced clones (totalling around 53 kb). The fidelity of the RT polymerase
supplied by Invitrogen has been shown to be around 10-6 errors. The higher error rate
detected (10-4) could therefore be due to PCR amplification. This is further suggested by
the fact that, in the case of 09-03-04, the reamplified cDNA did not contain the insertion
found in the clone. The magnitude of errors detected is also above that commonly found
with the Herculase polymerase (10-6 errors) used in PCR, so inherent features of the VSG
sequence itself impeding accurate copying in the PCR reaction should not be discounted as
an explanation. The possibility of rearrangments being generated by template copy choice,
a process by which, during PCR, the polymerase would switch to another closely related
template (Zaphiropoulos, 1998) has also been considered, and deemed unlikely: there is no
evidence as yet that any of the VSGs containing errors are present in multiple copies and
the estimate of divergence of the VSG archive given in Chapter 3, section 3.6, makes the
chance that six VSGs might have ~99% identical copies in the genome very small. In
addition, Herculase polymerase is a blend of Pfu and Taq polymerase and Pfu has been
shown to be less prone to copy choice (Shafikhani, 2002).
4.3 Overview of VSGs isolated in current study
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Figure 4.6 swnmarises the basic information with regards to all VSG clones isolated in this
study, divided by day, mouse and clone number". Table 4.3 gives a more concise list of
all VSGs identified by sequencing and relates each VSG to the clones in which it was
found.
lone 15 lSp
number 14 021
13 021
12 20p
11 15p 019
10 06 017 19p
9 3p 14p 20
S 3p 3p 15p 019
7 05 3p 016 019
6 3p 3p 15p lSp
5 3p 3p Sp 14p 01S
4 o 4 3p Sp 8p 012 15 019
3 lp lp o 3 3p Sp Os 011 [315 019
2 o 1 o 1 3p 05 OS Sp OS o 10 13p D 14 019
1 o 1 o 1 o 2 03 07 08 Sp o 9 013 15p 01S
mouse 1 2 3 4 5 6 S 7 9 10 11
ay 3 3 9 9 14 14 21 22 24 2S 2S
1 1 4 4 2 1 1 4 1 4 4
SGoverlap 1 1 2 2 1 1 1 0 0 0 0
Putative VSG donors
0 functional 0 3' donor 03 Serial n given to VSG(see text)
0 atypical 0 Nomatch in database
0 pseudogene Putative mosaic
Figure 4.6. Summary of cDNA clones isolated from each of the eleven mouse infections.
Each vertical column of squares and numbers represents the clones isolated in each
mouse. Squares show the nature of each sequence, based on its source(s) in the VSG
archive, and associated numbers are the number of clones isolated for each sequence; p
=PCR analysis only. Below each column is a summary giving the mouse number, the day,
the number of VSGs isolated in each infection, and the number of VSGs isolated that were
common to different infections (VSG overlap).
26 This is present in tabulated form with additional details (identifier and location of putative donors, domain
annotation) in Table 7.5 of the Appendix.
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Table 4.3. VSGs identified, with day of appearance and prevalence amongst clones.
The presence of a donor for the 3' end of the gene is specified in the third column (see text
for details). Novel VSGs are given the clone identifier preceded by CMI (chronic mouse
infection), whereas VSGs corresponding to known archive genes are given the GeneDB
identifier of the donor.
VSG VSGid Donor type Day mouse Clones (sequenced) Clones (PCR)
n n id n Id
1 Tbl0.v4.0001 functional 03 01,02 4 03-01-01, 03-01-02, 2 03-01-03,03-02-03
03-02-01,03-02-02
2 CM! 09-03-01 ? 09 03 1 09-03-01 0
3 CM!_09-03-03 ? 09 03,04 2 09-04-01,09-03-03 11 09-04-03 to 09-04-09;
09-03-02, 09-03-05, 09-
03-06,09-03-08
4 CM! 09-03-04 ? 09 03 1 09-03-04 0
5 CMI 09-04-02 ? 09 03,04 2 09-04-02, 09-03-07 0
6 CM! 09-04-10 ? 09 04 1 09-04-10 0
7 CM! 14-05-01 ? 14 05 1 14-05-01 0
8 Tb09.v4.0077 Atypical + 14 05, 4 14-05-02, 14-06-01, 6 14-05-03, 14-05-04, 14-
3' donor 06,08 21-08-02, 21-08-03 05-05, 14-06-02, 21-08-
01,21-08-04
9 Tb09.244.1580 functional 22 07 1 22-07-01 0
10 CM! 22-07-02 Mosaic 22 07 1 22-07-02 0
11 Tb927.3.190 Functional 22 07 1 22-07-03 0
+3' donor
12 CM! 22-07-04 Mosaic 22 07 1 22-07-04 0
13 Tb09.v4.0102 Atypical + 24 09 1 24-09-01 1 24-09-02
3' donor
14 CM! 28-10-02 Mosaic 28 10 1 28-10-02 2 28-10-05,28-10-09
15 CM! _28-10-03 Mosaic 28 10 2 28-10-03,28-10-04 4 28-10-01, 28-10-06, 28-
10-08, 28-10-11
16 CM! 28-10-07 Mosaic 28 10 1 28-10-07 0
17 CM! 28-10-10 Mosaic 28 10 1 28-10-10 0
18 CM!_28-11-01 Functionall 28 11 2 28-11-01,28-11-05 2 28-11-06,28-11-15
hybrid
19 Tb927.5.5080 Functional 28 11 6 28-11-02, 28-11-03, 1 28-11-10
28-11-04, 28-11-07,
28-11-08,28-11-11
20 CM! 28-11-09 Mosaic 28 11 1 28-11-09 1 28-11-12
(Tb927.7.6530)
21 Tbl0.v4.0088 Functional 28 11 2 28-11-13,28-11-14 0
The 37 sequenced clones were found to correspond to 21 different VSGs, as some clones
encoded the same VSG. A summary of characteristics of these 21 VSGs is given in Figure
4.7: they have been divided into different groups depending on the features of the donors
identified in GeneDB. Both "functional" and "atypical" VSG donors" were found,
although activation of the two atypical donors was probably associated with separate
donation of the 3' end of the gene, at which point mismatches were present. Because of
the small extent of this hypothetical 3' donor sequence these genes have not been defined
as "hybrids", a term reserved for genes in which N-terminal and C-terminal domains are
contributed by separate genes. Seven cDNA sequences could be best explained as putative
hybrids or mosaics arising from the combination of different donor genes (which included
functional genes and pseudogenes). For other genes no donors could account for the full
extent of their sequence, and only partial matches were found. Figure 4.7 divides them
82
into two groups: one group is likely to correspond to telomeric mini chromosomal genes
(which have not been included in the sequencing project but which are known to be
activated early in infection, Robinson et al., 1999) and the other to be array VSGs (or
mosaics thereof) that have not yet been fully sequenced or assembled. If only the 14 genes
with putative array donors are considered, it appears that ten have full-length matches to
either contigs or main chromosome assemblies, whereas, for the remaining four, partial
donors were found in short reads. This confirms indirectly the prediction that the contigs
and main chromosome molecules in GeneDB include approximately three quarters of the
VSG archive, and suggests that most of the archive is captured when genome sequence
survey reads are also included.
8
7
no of VSGs
Functional atypical Multiple
(mosaic)
partial - mini partial - array
Array donors Category unassigned
Figure 4.7: 21 unique VSGs isolated from eleven chronic mouse infections, grouped by
donor features.
Putative array donors are present in yellow (functional), orange (atypical), red (mosaic) bars.
VSGs for which only partial donors were found are divided into putative minichromosomal
genes (Partial-mini) and putative array genes (partial-array).
27 See Chapter 3, section 3.2.2 for an explanation of these terms.
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4.4 Summary of basic findings
A condensed view of Figure 4.6 is given in Figure 4.8, highlighting the relative
contribution of VSGs with unknown, single or multiple donors at the different timepoints
(day 9, 14, 21-24, 28), in order to provide a dynamic view ofthe data, mirroring the course
of a single infection.
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Figure 4.8: Relative contribution of VSGswith unknown, single or multiple donors at
different timepoints (day 9, 14, 21-24, 28).
Data in bars are expressed as percentage of total number of VSGs per timepoint; above
each bar is the absolute number of VSGs in each category. Below the chart are highlighted
the number of VSGs per timepoint and the number of VSGs common to separate infections.
The most striking observation is that, although based solely on bioinformatic detection of
putative donors, the data suggest that by day 28 mosaic gene formation contributes
significantly to variants arising, giving for the first time a quantitative appreciation of the
importance of this process in vivo. Putative mosaic genes were first detectable at day 22,
although no data are available between day 14 and 22, so their first appearance might be
significantly earlier. Appearance at day 22 fits with previous studies in rabbits (Capbem et
al., 1977), in which day 23-25 saw the emergence of the first mosaic. The timing
corresponds, at least in a subset of mice, to the emergence of a second relapse peak.
Interestingly, the fact that the infection profile starts to vary significantly between mice
around this time might suggest a possible correlation with the onset of silent array genes
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and their less predictable use to generate mosaics that are potentially unique to each
infection. A more detailed analysis of mosaic genes will follow in section 4.7.
Assuming that unknown VSGs isolated on day 9 correspond to minichromosomal telomeric
genes, the individual clones examined seem to confirm the hierarchy observed in previous
experiments (telomere-proximal VSGs preceding array VSGs, Robinson et al., 1999). There
appears to be an overlap between telomere-proximal and array genes on day 14, possibly
mirroring an overlap in activation probabilities between these two loci; whether this is due
to coding sequence homology of an array gene for the expressed VSG taking precedence
over homology at telomere sequence, this remains to be established, as a clear path for
activation of these genes cannot be determined in this experiment. The appearance of
array genes seems not to correlate with the number of 70-bp repeats present upstream of
the donors, confirming more directly the hypothesis made in section 3.7 that 70-bp repeats
might not contribute greatly to the hierarchy of array genes, as most of them have only one
or two repeats, with few exceptions.
As found in previous studies (Robinson et al., 1999; Morrison et al., 2005), it appears that
at the beginning of infection a set of predominantly, if not exclusively, telomeric genes is
activated as "default" in separate hosts (see Figure 4.8, below the chart). This is more
prominent at day 9 and gradually becomes less common as infection progresses and the
large archive of silent array genes is accessed. The two infections analysed at day 28 did
not share any expressed VSGs, suggesting that by this time the infections take distinct
routes.
All but one of the genes isolated after day 9 could be identified as having either functional,
atypical or multiple donors. The only exception is VSG 28-11-01, for which an N- and a
C-terminal donor have been found, however N and C-terminal reads do not overlap,
making the gene either a putative functional or a hybrid. Although donors for VSG 28-10-
10 do not span the whole length of the open reading frame, the overlap between putative
N-terminal domain donors suggests the gene to be a mosaic.
An important link with the genome project analysis presented in Chapter 3 was the fmding
of expressed VSGs with novel C-terminal domain types (types 5 and 6), first observed
bioinformatically in the course of the VSG array annotation and never previously isolated
in vivo. In addition, mosaic 22-07-02 showed expression of a type A N- terminal domain
with only two cysteines (similar to MYAT5, (Carrington et al., 1991», and a type 1 C-
terminal domain (as judged by the GPI signal sequence) with type 6-like cysteine spacing.
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The assembling of the latter is likely to represent a rare event in the gradient of
recombination between C-terminal domain types proposed in Figure 3.9 (in which the
beginning of the domain is more prone to intertype recombination): in the present case it
involves the normally domain-specific C-terminal end of the gene. These examples add
more information on the structural constraints (cysteine pattern and GPI signal) and
complexity (domain types) of VSGs and could possibly prompt further biochemical studies,
investigating the folding ofN-terminal domains with only two cysteines and the cleavage
features of novel GPI signals.
Three aspects of the work outlined so far will be considered in the remaining part of this
chapter. Examples of expressed VSGs with 3' donor sequence (section 4.6) will be
presented, followed by a more detailed analysis of the VSG mosaics detected in this study,
through a bioinformatic comparison with and between their donors (section 4.7) and by
experimental confirmation of the mosaic nature of one of these genes (section 4.8). Before
this, the putative presence of several expressed VSGs containing "real" mismatches with
their donors will be discussed (section 4.5).
4.5 Point mutation in expressed VSGs?
After initial interest was sparked by a few clones having a significant number of
mismatches with their donors, a systematic analysis of presence of point mutation in all
fully sequenced clones was undertaken (36 clones, with 09-04-10 excluded, as it is only
partially sequenced) (see Table 7.6 of Appendix for full list of unique mutations). Itwas
possible to observe that, in the case of clones 09-03-03 and 09-04-01, both expressing the
same VSG, there were no mismatches when the two sequences were compared, whereas
three mismatches were found when a comparison was made with the putative donor read.
This, together with the identical point mutation found between the database GUTat 10.1
VSG sequence and that of four clones from day 3, and a similar comparison made between
clones 09-03-07 and 09-04-02, suggests that there might be a slight baseline divergence
between the clone used for the genome sequencing and the clone used to start the
infections. If point mutation occurs relatively rapidly this might have occurred just by
passaging. This finding gives a good "internal control" to assess the validity of point
mutations detected in other clones, in the absence of experimental confirmation.
Moreover, if point mutations were generated by artefactual amplification during RT-PCR,
the chance of detecting two independent clones originating from separate infections
sharing the same base pair change, as just described, would be very remote. Figure 4.9
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gives an overview of the number of point mutations found across the 19 VSGs for which
complete or sufficient donor sequence was present to enable the comparison, and it also
highlights the number of clones analysed per individual VSG. Only five out of 19 do not
show any point mutation differences.
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Figure 4.9. Point mutation in 19 unique expressed VSGs (1-21, except VSGs 6 and 7).
For each VSG, the number of sequenced cDNA clones is shown below the VSG id number,
and the average number of point mutations in each VSG, in comparison with the silent gene
in GeneDB, is recorded in the green bars.
The data, rearranged "chronologically" into the same groupings as in Figure 4.8, are
displayed in Fig 4.10 below, again to see whether a pattern can be found.
8
7
6
5
4
3
2
1
o
-r--
-
r--
-
n o point mutation/clone
28-10 28-11
clones clones
14 21-24 2893 Timepoint (day)
2 166 7 54 11 n of clones
Figure 4.10: Number of point mutations per clone at the different timepoints (day 3,9,14,21-
24,28).
The number of clones considered is given below the table. Day 28 has also been split into
infections 28-10 and 28-11, to allow for the fact that at this advanced stage the infection
profile might differ significantly between mice.
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The number of point mutations per clone seems to increase dramatically when "early" and
"late" timepoints are compared. Interpreting these data is problematic, as the detection of
these mutations cannot be immediately correlated with antigenic variation and the
production of a non-crossreactive coat: this will be discussed at the end of the chapter. The
rest of this section will be devoted to further validating the point mutation data.
4.5.1 Location ofpoint mutations
The location of differences between expressed and putative donor genes strongly suggests
a non-random distribution of the mutations detected, as 173/184 (94%) unique codon
changes are located in the N-terminal domain. Figure 4.11 gives the combined location of
all mutations across the 18 VSGs analysed, highlighting mutations in N-terminal domains
type A and B: it is apparent that many of the point mutations are clustered. This was
statistically validated by a Chi-squared test, in which point mutations in the N-terminal
domain (between bp I and 1000) were grouped into ten 100 bp intervals. Types A and B
were considered separately, and in both cases the Chi-squared value supported a non-
random distribution of mutations at the 0.01 significance level", with concentration of
mutations at bp 400-500 and 600-700 for type A, and at bp 600-800 for type B.
28 The expected chi square value at 0.01 significance level is 21.67 for nine degrees of freedom, and the
observed values were of29.05 and 24.06 for mutation distribution in type A and B domains respectively (see
Table 7.7 of Appendix for full data analysis).
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N-terminal domain:
173 mutations
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18
VSGsI~IIIIIIIIIIIIIIIIII~IIIIIII~II,IIIIIIIIIIIIIIII,IIIIII1II1II1I1I11I1II~II, I I ,1111 1,111 II
200 400 600 800 1000 1200 1400 1600
Type A:
11 VSGs, 122
mutations
(87, 71% non-syn)
IIII! IIIIIIIIIIIIIIIIIIIIIIII~IIII~IIIII \ IIIIIIII I IIIIIII II I
I I I I II III III I II Type B:
III If II 111111~III~illll~ I I j
7 VSGs,51
II III III mutations
i i i
0 200 400 600 600 1000 (36, 71% non-syn)
Figure 4.11: Physical location of point mutations along the length of 18 expressed VSGs.
AII181 unique point mutations have been pooled together along the length of an "ideal"
VSG. N-terminal domain point mutations are then considered separately in type A and type
B domains. Above each set of point mutations are vertical red lines indicating the location
of cysteine residues and a depiction of the putative alpha helical content of each type
(helical regions indicated in red). The exact correspondence of a point mutation with
cysteine residues is due to the fact that the average of the cysteine positions across all
VSGs analysed was taken; no mutation of cysteines was observed. The 11 type A VSGs are
1,2,3,5,9,10,11,12,16,19 and 21. The 7 type B VSGs are 4, 8,13,15,17,18, 20.ln
brackets are indicated the number and percentage of non-synonymous point mutations.
A crude prediction of secondary structure potential (using Jpred,
http://www.compbio.dundee.ac.ukI~www-jpred/) was also undertaken, to see whether a
correlation between putative surface loops (in white) and location of point mutations could
be found. Two "global" secondary structure predictions encompassing respectively all .
type A and all type B VSGs present in this study were attempted, using a multiple
sequence alignment of these two sets of protein sequences. The secondary structure
prediction suggests that the statistically significant concentration of mutations detected
occurs in non-alpha helical regions. As none of the genes are very closely related to each
other, the accuracy of the prediction is expected to be lower than if querying with a single
sequence and allowing the program to align this with its close orthologues. In order to
refine the analysis and overcome the above-mentioned limitations of "global" secondary
structure prediction, three individual VSGs in which there are many point mutations are
presented in Figure 4.12. A clearer correlation between non-helical regions and point
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mutations was found: this was again statistically validated with a Chi-squared test
(significance at the 0.05 confidence level was observed for all three VSGs29), strengthening
the hypothesis that a process of positive selection might be operating, concentrating
mutations in regions with reduced secondary structure potential, possibly corresponding or
overlapping with surface epitope regions. Further analysis considering the number of
synonymous versus non-synonymous mutations is conducted in section 4.9.1, where the
measurement and the implications of positive selection operating on VSGs are discussed in
more detail.
22-07-03
I I I
15 mutations;
75% non-synII IIIIII II I I II
28-11-(02,
03, 04, 07,
08, 11)
I~I "II II ~ I I IIII I I11111 ! 41 mutations;70% non-syn11 IIIII III IIIIIIII II
24-09-01 l!II 1 [I I II III
I II
II
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62.5% non-syn
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Figure 4.12: Correlation between point mutation and predicted helical content in a subset of
N-terminal domains.
The first two examples are type A domains, whereas the third is type B. The short vertical
lines above each graphic show positions of cysteines, and those below each graphic show
the positions of point mutations. Predicted alpha helical regions are shown in red. The
half-height line at the beginning of each cysteine pattern indicates the location of the signal
peptide cleavage site.
29 See Table 7.8 of Appendix for the full data analysis.
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4.6 3' donor analysis
The hypothesis that the very end of expressed VSGs derived from a gene conversion of a
silent array gene is commonly contributed by a 3' donor due to the degeneracy of C-
terminal domains in the archive, as brought to light by the annotation of subtelomeric
arrays (see Chapter 3, section 3.4), receives support from the common occurrence of
conversions ending within the C-terminal domain (eight instances out of 21 genes, two
atypical donors, two functional donors and four mosaics). This fits with previous studies
in which the C-terminal domain end was found to be retained in expressed VSGs with
unrelated N-terminal domains, such as VSG20, 20* and 20bis (Than et al., 1990).
Nevertheless, termination of VSG gene conversion within the coding sequence happens
also simply because it is a region of high identity between VSGs (Rice-Ficht et al., 1981).
This is the case for duplications involving VSG 117 and 118 (strain 427): both are
functional array VSGs and most clones that activated these VSGs showed end of
conversion around or within the GPI signal sequence (Bernards et al., 1981; Michels et al.,
1983). Therefore, in addition to the previously detected "spontaneous" termination of
conversion within coding sequence, there appears to be selection to retain the C-terminal
end of the previously expressed VSG, as most incoming donors would have a faulty GPI
signal. The identity of a 3' donor is difficult to ascertain, but the fact that only in one case
there was a 3' donor match to a known array gene lends strength to the possibility that
these donor C-terminal domains reside at telomeres and originated from VSGs previously
occupying the expression site. Three instances of 3' donor detection will be considered,
relating to three main donors: Tb09.v4.0077, appearing in four clones derived from three
different mice (see Table 4.4), Tb927.3.l90 (one clone) and Tb09.v4.0102 (one clone).
Table 4.4: List of clones with 3' donor.
Highlighted in red are the three cases analysed !n section 4.6
Clone Id of main VSG Main VSG Domain VSGn
donor donor features Jype
14-05-02, Tb09.v4.0077 Atypical B2 8
14-06-01,
21-08-02,
21-08-03
22-07-03 Tb927.3 .190 Functional A2 11
22-07-04 mosaic Mosaic A4 12
24-09-01 Tb09.v4.0102 Atypical B2 13
28-10-03 mosaic Mosaic B3 15
28-10-07 mosaic Mosaic A3 16
28-11-09 mosaic Mosaic B3 20
28-11-14 Tbl0.v4.0088 Functional A2 21
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VSG Tb09.v4.0077 appears to have been activated frequently between days 14 and 21, in a
way reminiscent to VSG 118 in strain 427 (Timmers et al., 1987). It seems that this partial
duplication must have occurred at least once in the parent clone, at a time prior to the start
of the infection, as three of four duplications have the same breakpoint between the two
donors (see Figure 4.13). Such a coincidence could suggest that a telomere-proximal copy
was present at the time of infection, and this in turn could explain frequent activation of
this gene in separate infections. Nevertheless, the possibility that an array gene is activated
by identical conversion reactions in different infections cannot be formally ruled out
without further experimental analysis.
Tb09.v4.0077
14-05-02
14-06-01
21-08-02
21-08-03
Tb09.v4.0077
14-05-02
14-06-01
21-08-02
21-08-03
Tb09.v4.0077
14-05-02
14-06-01
21-08-02
21-08-03
ACATTGAGTGAGGAAGGCAAACAAGCAGCAAAAGAAGCAGAAAGTCAGGCTGAAAAAGTT 1380
ACATTGAGTGAGGAAGGCAAACAACCAGCAGAAAACACAGCAGCAGGAAACCAAGCAGGG 1380
ACATTGAGTGAGGAAGGCAAACAACCAGCAGAAAACACAGCAGCAGGAAACCAAGCAGGG 1380
ACATTGAGTGAGGAAGGCAAACAACCAGCAGAAAACACAGCAGCAGGAAACCAAGCAGGG 1380
ACATTGAGTGAGGAAGGCAAACAAGCAGCAAAAGAAGCAGAAAGTCAGGCTGAAAAAGTT 1380
************************ ***** ** * *** * ** **
Figure 4.13: Nucleotide alignment of the C-terminal domain end of Tb09.v4.0077 (donor),
with related expression-linked copies (ELC).
Donor sequence is indicated in blue, as are the ELC regions with 100% identity to the donor.
All ELC regions in red are 100% identical to each other.
GAAAAAACCACAAACACCACAGGGAGCAATTCGTTTGTCATTCATAAGGCCCCTCTTTGG 1440
ACAGATGGTAAAAACACCGCAGGAAGCAATTCTTTTGTCATTAACAAGGCCCCTCTTTTG 1440
ACAGATGGTAAAAACACCGCAGGAAGCAATTCTTTTGTCATTAACAAGGCCCCTCTTTTG 1440
ACAGATGGTAAAAACACCGCAGGAAGCAATTCTTTTGTCATTAACAAGGCCCCTCTTTTG 1440
GAAAAAACCACAAACACCGCAGGAAGCAATTCTTTTGTCATTAACAAGGCCCCTCTTTTG 1440
* * * ******* **** ******** ********* * ************* *
CTTGCAGTTTTGCTTTT-TAAAAACTTTTAG 1470
CTTGCAGTTTCGCTTTTTTAA--------- 1461
CTTGCAGTTTCGCTTTTTTAA--------- 1461
CTTGCAGTTTCGCTTTTTTAA--------- 1461
CTTGCAGTTTCGCTTTTTTAA--------- 1461
********** ****** ***
Regardless of whether they occurred during or prior to the infection, there were at least two
separate activations ofthe same array gene, both using the same 3' donor. The use ofthe
3' donor sequence appears to be mandatory for the expression of this VSG, and this could
be due to the fact that its GP! signal is "atypical" and possibly non-functional (see Figure
4.14).
3' donor
Consensus
Tb09.v4.0077 GPI
GPI
GPI
NTTGS-NSFVIHKAPLWLAVLLFKNF
NTAGS-NSFVINKAPLLLAVSLF
NTTGS-NSFVINKAPLFLAFLLF
Figure 4.14: Putative GPI anchor signal of Tb09.v4.0077 (main donor), compared with that of
3' donor.
A consensus example is given for an expressed VSG, accession code AF335472. Residues
in blue indicate the non-conserved additional amino acids at the end of the GPI signal.
Residues in red indicate amino acid mismatches between Tb09.v4.0077 and 3' donor.
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This type 2 GPI signal is three amino acids longer than the consensus sequence and has
one polar lysine residue, normally not found in the hydrophobic extension. The nucleotide
alignment in Figure 4.13 gives a possible explanation for this: the donor VSG appears to
have a deletion of one T, producing a frame shift, resulting in the incorporation of an extra
three amino acids.
The second VSG, Tb927.3.190, appears not to have undergone such a prominent alteration
through gene conversion (see Figure 4.15). From this example it could be concluded that
either the gene conversion fortuitously included the very end ofthe gene (as in the case of
VSGs 117 and 118 mentioned above) or that it was a requirement for expression. Subtle
departures from the consensus sequence are present, although the GPI signal has been
classified as functional in the bioinformatic analysis, as the signal is still conserved in
length and has a hydrophobic profile very similar to the consensus sequence.
Tb927.3.190
1390 1400 1410 1420 1430 1440
GAAGAAAATGAAGGCAAAGGCACAAACAACACAGGGAGCAATTCTATTGTCATTAACAGG
............................................................................................. .
22-07-03 GAAGAAAATGAAGGCAAAGGCACAAACAACACAGGAAGCAATTCTTTTGTCATTAACAGG
1390 1400 1410 1420 1430 1440
Tb927.3.190
1450 1460 1470
GCACCTCTTTTGTTTGCATTTTTCCTTCTATAA
:: ::::::::: ::::: :::: ::: : :::
22-07-03 GCCCCTCTTTTGCTTGCAGTTTTGCTTTTTTAA
1450 1460 1470
Tb927.3.190 GPI
22-07-03 GPI
Consensus GPI
NNTGS-NSIVINRAPLLFAFFLL
NNTGS-NSFVINRAPLLLAVLLF
NTTGS-NSFVINKAPLFLAFLLF
Figure 4.15: Nucleotide and amino acid alignment of the GPI signal region of Tb927.3.190
(donor) with its matching expressed clone 22-07-03.
Mismatches are suggested to be due to the presence of a 3' donor in clone 22-07-03.
The third in this subset of VSGs, Tb09.v4.0102, is a striking example of the requirements
of a C-terminal gene conversion for the expression of intact VSGs with faulty GPI signals
(classified as atypical or pseudogene depending on the nature of the fault). The donor in
this case was classified as atypical with a type 3 C-terminal domain", and the gene
conversion has "utilised" the first four cysteines in this domain and spliced them together
with a type 2 GPI signal (See Figure 4.16).
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370 380 390 400 410 420
Tb09.v4.0102 NTQVLEALLKAATNQNQGPEAVAGKAQQEKIEEEONKQDKDTDGlTANPKOAWNEKAADPK
· .· .
24-09-01 NTQVLEALLKAATNQNQGPEAVAGKAQQEKIEEEONKQDKDTDOTANPK AWNDKAADPK
370 380 390 400 410 420
430 440 450 460 470 480
Tb09. v4. 0102 K~SLSEEAKQAVEKANQETGGKDGKPD:€:lSKLTTQTEQEAVNKDGKKYSGLRSGKDNEEE
· .· .
24-09-01 KKgSLSEEGKQPAENTAAGNQAGTDGKNTAGSNSFVINKAPLLLAVSLF
430 440 450
490 500
Tb09.v4.0102 KDKVKCRSASFLVNYKLSLSlAAGF
Figure 4.16: Amino acid alignment of the C-terminal domain of Tb09.v4.0102 (donor) with its
matching expressed clone 24-09-01.
Highlighted in yellow are the cysteine residues. Letters in red indicate the GPI anchor signal
sequence from the first position after the cleavage site.
This VSG activation, together with that mentioned at the end of section 4.4, accords with
the model suggesting a gradient of recombination between C-terminal domain types, as
proposed in Figure 3.9: it is a clear example that the beginning of the domain is more prone
to intertype recombination and that interactions between different domain types occur
predominantly at the site of the first four cysteines.
30 CURA nON = sequence has diverged from the expressed VSG consensus sequence; cysteine pattern not
conserved in C-terminal domain, one cysteine missing in the second four- cysteine subdomain; GPI
prediction uncertain.
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4.7 Mosaic analysis
Seven putative mosaics were detected in three separate infections, at day 22 and 28 (see
Fig 4.17). Only the first four (22-07-02,22-07-04,28-10-02 and 28-10-03) will be
considered here, as the other three putative mosaics identified (28-10-07, 28-10-10, 28-11-
09) are based on incomplete donor reads, rather than full-length donors, preventing as
complete an interpretation of the data.
22-07-02
22-07-04
28-10-02
28-10-03
28-10-07
28-10-10
28-11-09
•.. ,',~ " '., of.,
" ~. , _ " _ ,<" ~.. ~ M~ , , ••• _ ... _. _ ,. _ >~ ,.. _ ~." _ .,.
'. . . :
• , .... '. • • _ ~ , ~~ ., • • • ," ~ ~ ... N~
Figure 4.17: Depiction of the seven putative mosaics detected in the experiment.
The different colours indicate the different donors contributing to the mosaic. The clone
number is given to the left. The white regions in mosaic 28-10-10 lack identified donors.
Below (Figure 4.18) is an overview of putative mosaic 22-07-02, which is proposed to
have been assembled from three donors. All three donors are pseudogenes: A is a type A6
VSG with a frameshift after bp 444 and a stop codon at bp 46 and it contributed the region
spanning the C-terminal domain and a small segment of the N-terminal domain. B and C
are also type A6 VSG pseudo genes with a single stop codon at bp 46 and bp 607
respectively. In addition, B has some irregularities before the cysteine pattern in the C-
terminal domain, including CVC in the hinge region that could cause folding problems and
has never been observed in any expressed VSG.
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Mosaic
22-07-02
200 400 600 800 1000 1200 1400
donors
A
B
96%
95%
c 90%
Figure 4.18: Mosaic gene 22-07-02 and its likely donors.
Donor A is Tb11.v4.0074, B is Tb10.v4.0161, C is Tb11.14.0001; beside each donor is the
percent nucleotide sequence identity to the expressed mosaic. Each donor has indicated,
in brown, yellow and orange respectively, the extent of its contribution to the mosaic. The
overlap between donors is shown in the individual donor gene depictions, and the
breakpoint between two donors in the mosaic is the average of the overlap. Below the
mosaic are bars indicating sites of mismatch with the three donors. Above the mosaic is
the cysteine pattern and alpha helical prediction. Vertical bars in the donor gene depictions
represent frameshifts or stop codons, with the exception of those separating blocs of
different colour.
The fact that this mosaic gene appears to have been constructed entirely from pseudogenes
suggests that either a telomeric gene has acted as a "template" for the initial recruitment of
one of the pseudo genes and/or that the assembly of the mosaic might have taken place
stepwise in a silent expression site, as any direct gene conversion of these donor genes into
the active expression site would have resulted in a trypanosome with a lethally defective
coat.
Mosaic 22-07-04 is the most simple mosaic and is best described as a hybrid: two putative
donors, Tb 11.30.0005 (A) and Tb 11.v4.0021 (B), contribute respectively to the N-terminal
domain and to the C-terminal domain. In addition, a 3' donor sequence is postulated for
the very end of the gene (see Figure 4.19). A is a pseudo gene due to a single frameshift in
the GPI signal, whereas B has been annotated as atypical due to the fact that the GPI signal
is not well conserved in sequence. As noted previously in section 4.6, it appears also in
this case that irregularities in the GPI signal of donor gene B result in expression being
mediated by an additional GPI signal donor. A putative 3' donor has been identified in
Tb09.354.0090, covering the last 60 bp, but the stretch is so short that other unknown
VSGs resident at telomeres could also have acted as donors. Formation of hybrid genes
appears to accommodate donors sharing a lower level of sequence identity, as localised
identity at the C-terminal domain would be sufficient to catalyse the gene conversion
reaction. Conversely, in the case of genes with mosaicism within the N-terminal domain,
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the level of identity required between donors appears to be higher (see mosaic 22-07-02
above and mosaics 28-10-02 and 28-10-03, discussed in the next paragraph).
Mosaic
22-07-04
donors
A 93%
B 49%
c L_ ~ 1I20%
o 200 400 600 800 1000 1200 1400
Figure 4.19: Mosaic gene 22-07-04 and its likely donors.
"A" is Tb11.30.0005, "B" is Tb11.v4.0021, "e" is Tb09.354.0090. Beside each donor is the
percent protein sequence identity to the expressed mosaic. Below the mosaic is a bar
indicating sites of mismatch with the three donors. Above the mosaic is the cysteine
pattern and alpha helical prediction. Vertical bars in the donor gene depictions represent
frameshifts or stop codons, with the exception of those separating blocs of different colour.
Other general information is given in Figure 4.18.
Finally, mosaics 28-10-02 and 28-10-03, originating from the same donors, will be
considered. It is interesting to observe the relationship between mosaics 28-10-02 and 28-
10-03, as the presence of one shared gene conversion boundary (highlighted with black
arrows in Figure 4.20) suggests that these mosaics emerged from the same predecessor.
The dynamics of formation of this mosaic seem to be complex: gene A as been classed as
functional (although it has a polar amino acid, E, in the hydrophobic extension, and could
therefore have been classed as atypical: a borderline case), gene B is a pseudogene due to a
single stop codon in the N-terminal domain and of gene C only the C-terminal part is
known. The C-terminal domain is provided by either B in the case of 28-10-02 or a
combination of B and C in the case of 28-1 0-03.
Mosaic
28-10-02
Mosaic
28-10-03
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A
B
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A
B
C
200 400 600 800 1000 1200 1400
Figure 4.20: Mosaic genes 28-10-02 and 28-10-03 and their likely donors.
A is Tb11.09.0005, B is Tb11.0260, C is read AZ217061. Beside each donor is the percent
nucleotide sequence identity to the expressed mosaic (beside mosaic 28-10-03 is the
identity to 28-10-02). Below the mosaic are bars indicating sites of mismatch with the three
donors (no mismatches are present in 28-10-02). Above mosaic 28-10-02 is the cysteine
pattern and alpha helical prediction; these apply also to mosaic 28-10-03. Vertical bars in
the donor gene depictions represent frameshifts or stop codons, with the exception of
those separating blocs of different colour. Black arrows indicate the shared gene
conversion event between the two mosaics. Other general information is given in Figure
4.18.
A diagram highlighting the possible development of this mosaic is shown below (Figure
4.21).
Step 1: Expression of intact gene A
D
Step 2: Mosaic gene formation with gene 8
Step 38: 28-10-03: Telomeric gene conversion to/from
another expression site, evolution by point mutation__ 1__ '_1
I
Figure 4.21. Diagram of possible development of mosaics 28-10-02 and 28-10-03.
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Possibly at an earlier stage A was expressed and then it gave rise to a simple mosaic, as in
step 2 in Figure 4.21, with sequence coming from gene B. After this, the two mosaics
seem to have taken different routes: 28-10-03 acquired a different C-terminal end, possibly
from a telomeric site, and started evolving by point mutation (10 point mutations are
present in the N-terminal domain). 28-10-02 had further interaction with gene B and the
array copy of gene A to produce a more complex mosaic: gene B replaced gene A at the C-
terminal domain and a total of seven different transitions between the donors A and B are
present in the end product. The colocalisation of further rearrangements with putative non-
helical surface loops might suggest that these processes have altered (or be in the process
of altering) the exposed epitope. This example highlights the possible interaction between
two diversification processes, namely mosaic gene formation and point mutation. It still
leaves unanswered the question of whether this diversification is producing new non-
crossreactive antigens: this will be discussed further in section 4.9.4.
When comparing mosaics from day 21 with those from day 28 there appears not to be an
increase in mosaic complexity. If anything, the earlier mosaics appear to be more
complex, but when looking at relatedness between donors there is a marked drop in
sequence identity: from 87-95% at day 21 to 73% at day 28. A longer infection would
have to be run and more mosaics would need to be analysed in order to test whether this is
likely to be a general trend; it is nevertheless possible to envisage this as a convincing
possibility, as there are few closely related VSGs in the archive and interactions producing
viable mosaics may eventually have to rely on more fortuitous conversions, using only
limited and therefore localised sequence similarity.
4.8 Mosaic analysis: experimental confirmation by peR
In order to confirm the bioinformatic predictions made in the previous section, it was
important to determine experimentally whether putative mosaics had been assembled in the
course of an infection or were actually intact genes that had been assembled as mosaics at a
time before the infection started. In order to differentiate between these two possibilities,
the approach taken was to design a PCR-based experiment in which primer pairs would
distinguish between donors and would amplify from only the mosaics, only the donors, or
both mosaics and donors. Results of this analysis are presented only for mosaic 28-10-02,
as PCRs for the remaining mosaics were not completed due to lack of time. Figure 4.22
gives a graphical overview of the experiment, and Table 4.5 gives more details for each
PCR, including the expected result.
1 2 3 4
Mosaic
28-10-02
B
1
2
3
4
controls
711
A toA
A toA
5
6
7
8
929
353
**B to B
B to B
568
715
99
567 8
B
Figure 4.22: Experimental confirmation by peR of mosaic 28-10-02.
Blue blocks indicate forward primers, red blocks reverse primers. Vertical lines delineate
the recombined tracts to which primers anneal. Numbers above the lines connecting the
sets of primers indicate the size (bp) of each expected peR product. The first four reactions
(1-4) are specific to the mosaic, reactions 5-8 amplify either donor A or donor B. The
forward primer of reaction 7 is indicated by an asterisk, as it anneals specifically to the non-
converted N-terminal section of donor B and therefore does not relate to the mosaic
depiction given above. Numbers above the mosaic indicate the different gene conversion
tracts, for ease of discussion.
Table 4.5: Details of peRs to confirm mosaic 28-10-02, with peR result predictions.
Pr1 and pr2 give the names of the two primers used in each peR. "Don pr1" and "Don pr2"
tell which donor the primer anneals to (A or B, followed by gene conversion tract number).
"Length product" is the length of the expected peR product. "Pre" stands for preinfection
927 GUTat 10.1 gDNA, "28-11" for gDNA from the other infection at day 28; "28-10" indicates
gDNA of the infection from which the mosaic was isolated. "28-10-02" indicates the plasmid
DNA of the clone corresponding to the mosaic.
P Pr! Pr2 Don Don Length Pre/ 28-10 28- 28-10
cr pr 1 pr 2 product 28-11 gDNA 10-02 eDNA
n (bp) _g_DNA clone +
I 10-2dA 95for IO-2dB 657rev Al B2 582 n y y y
2 10-2dA 95for IO-2dB IOOIrev Al B4 926 n y j' y
'" 10-2dA 671for 10-2dB 1362rev A3 B8 711 n _L _L y_,
4 10-2dB 648for 10-2dA 1024rev B2 A5 396 n y y y
controls
5 10-2dA 95for lO-2dA I024rev Al A5 929 _y _'j_ _L y
6 10-2dA 671 for IO-2dA 1024rev A3 A5 353 y _L _L y
7 10-2 Db 89for IO-2dB 657rev B B2 568 :t_ Y n n
8 10-2dB 648for 10-2dB 1362rev B2 B8 715 Y Y Y y
3! peR reaction 2 is applicable also to mosaic 28-10-03, which is therefore validated as well.
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The peR results given in Figure 4.23 confirm the expected results and give backing to the
initial suggestion from bioinformatic analysis that 28-10-02 is a mosaic". In addition, they
validate against the phenomenon of template copy choice that might fortuitously have
yielded some "in vitro" mosaic genes (see section 4.2.4 for a discussion of template copy
choice). The variable signal given by different primers is likely to be due to difference in
efficiency between primers, as the fluctuations are visible consistently throughout the eight
set of reactions. It is of interest that amongst the gene conversion tracts validated are also
three very short regions, B2, A3 and AS (average value 38, 23 and 28 bp respectively),
suggesting that these short gene conversions are not artefacts or explainable with the
presence of unsequenced VSG genes. Short gene conversions are the most likely to
produce changes in exposed epitopes, as longer gene conversion events tend to reduce
rather than promote diversity.
101
Testing mosaic 28-10-02 Controls
1 2 345 6 7 8 123 4 5 678
3~ 3~
1 ~.~ 5 ~.~
1 - -- ....- 1 -0.5 __,- 0.5 __,-
1 2 3 4 5 6 7 8 1 2 3 4 5 678
3~ 3~
2 ~.~ 6 ~.~1 - - 1 -
0.5 .> 0.5 __,- - _,
1 2 3 4 5 6 7 8 1 234 5 6 7 8
3~ 3~
3 7 ~.~~.~
1 -
1 - ---
0.5 __,- -- 0.5 .>:
---
1 2 345 6 7 8 1 2 3 4 5 678
3~ 3~
4 ~.~ 8 i.~
1 - 1 - ---
0.5 __,- - 0.5 __,-
Figure 4.23: Ethidium stained gels showing PCRs to test whether 28-10-02 is a mosaic
sequence.
In each gel the following samples are loaded: lane 1, strain 427 gDNA (negative control);
lane 2, strain 927 gDNA pre-infection (negative control); lane 3, gDNA from infection 28-11
(negative control); lane 4, gDNA from infection 28-10 (positive control); lane 5, plasmid DNA
of clone 28-10-02; lane 6, cDNA + from infection 28-10; lane 7, cDNA - from infection 28-10;
lane 8, no DNA control. Primer pairs for the 8 reactions (numbers in red) are given in Table
4.5. To the left of each gel is the size (in kb) for the main bands of the 1 kb ladder. Below is
a smaller version of Figure 4.22, for ease of consultation of the peR results of the gels
above.
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4.9 Conclusions
Combining the in vivo mouse experiment with the in silica bioinfonnatic data from the 927
genome strain has proved to be a valid approach yielding many insights with regards to our
understanding of the gene sequences and underlying forces promoting antigenic variation
in T. brucei. It should nevertheless be considered a pilot study in which many points are
left unanswered and many others require validation.
4.9.1 Point mutation: further experiments
Whereas the point mutation data analysed thus far suggest that changes in surface epitopes
ofVSGs were observed, further experiments are required to fully validate the data. First of
all, a subset of the genes described should be reamplified from cDNA and gDNA from
before and during the infection, in order to add certainty that the phenomenon is occurring
during the infection, as the data suggest. There appears to be a difference in the percentage
of nonsynonymous substitutions when N- and C-terrninal domains are compared: 70% in
the N-terrninal domain versus 54% (6 out of 11) for C-terrninal domain mutations. Due to
the nature of codons, it is expected that random mutation at two of the three codon
positions would result in amino acid change, making the value of 70% substitution not
significant per se. Whereas the clustered location of mutations and their statistically
significant association with putative surface loop regions suggests a process of positive
selection, no evidence could be gathered, by running a dN-dS test" using a recently
developed online software for detection of positive and negative selection
(http://www.datamonkey.orgl) (Pond and Frost, 2005). A possible explanation is the low
number of point mutations per clone due to the putative recent mutation of VSG 19 (see
next paragraph) and/or the small number of clones analysed (six clones of VSG 19, with 49
mutations).
Two indirect lines of evidence suggest that mutations are accumulating in expressed VSGs:
firstly, as shown above in section 4.7, the onset of point mutations in the case of mosaic
28-10-03 can be tied to the prior expression of an earlier form of mosaic 28-10-02 (see
Figure 4.21). Secondly, multiple clones corresponding to VSG 19 were shown to have
different point mutations, suggesting a recent acquisition of mutations, subsequent to VSG
expression. The presence of only eight shared mutations out of 49 further suggests that the
32 The dN-dS test gives a statistical validation for the likelihood that nonsynonymous substitutions are
positively selected for, allowing to establish the significance of mutations found in different alleles of the
same gene.
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process of accumulation must be rapid, leading to divergence at the population level.
Further sequencing of cDNA clones might provide a clearer estimate of the extent of this
diversification process, and possibly (if more diversity is uncovered) enable application of
the dN-dS test to a statistically valid number of data, overcoming the limitations of the
currently small dataset. Further considerations on the possible significance of point
mutations will be made in the Discussion (Chapter 6).
4.9.2 VSGs with a 3' donor: further experiments
The 3' donor analysis also requires experimental validation, with a similar PCR approach
as that used for mosaic genes in section 4.7, in order to define whether the duplication
occurred during the infection. Evidence gathered so far points to the requirements of a C-
terminal end donor for most array VSGs, but further experiments generating a larger
sample size could allow more precise definition of the in vivo requirements of GPI signal
sequences, by observing whether a pattern emerges with regards to the GPI signals that are
not "allowed" into the expression site. This in turn could shed light on the grey area
constituted by "atypical" array VSGs (See Chapter 3).
4.9.3 Mosaic genes: further experiments
As for mosaic genes, support has been gained for the tested hypothesis that they contribute
significantly to antigenic variation when the "degenerate" set of array genes starts to be
utilised. Half of the 14 expressed, putative array genes were shown, at least
bioinformatically, to be mosaic genes, and for two of them this was confirmed
experimentally. As information on donor genes was insufficient in three out of seven cases
and two mosaics were derived from the same donor, the actual sample size from which to
draw meaningful conclusions was reduced to three, or two if the hybrid gene is discounted.
A rabbit infection allowing collection of daily samples would enable more accurate
definition of the onset of mosaic genes, together with their development and changes in
donor composition, expanding from the tentative dynamic framework suggested in this
current study.
CHAPTER 5
VSG-RELATED GENES:
BIOINFORMATICS AND MOLECULAR ANALYSIS
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5 VSG-Related Genes: Bioinformatics And
Molecular Analysis
5.1 Introduction
The bioinfonnatic analysis of the VSG archive, as outlined in Chapter 3, unveiled the
presence of a small gene family that shares features with VSGs but is nevertheless distinct
enough to warrant the use of the tenn VSG-related, as will be argued in this chapter. The
chapter is divided into three parts, the first presenting the bioinfonnatic evidence for VSG-
related as a separate gene family (referred to in the remainder of the chapter as the VR gene
family) and the second giving a preliminary experimental characterisation of VSG-related
expression. Due to the similarities between VR genes and T. congolense VSGs (see
Section 3.2.3), the third part will give a brief description of what is known of T. congolense
VSG arrays, looking for shared themes between T. congolense VSGs, T. brucei VSGs and
VR genes.
5.2 VSG-related genes: bioinformatic analysis
5.2.1 Full-length VRs vs VSGs
An initial distinction between VSG and VR genes is clearly made by aligning sequences of
these two gene families. Figure 5.1 shows a full-length alignment of 35 functional VSGs
with 29 VR genes. Three clusters are formed, VSGs with a type A N-tenninal domain,
VSGs with a type B N-tenninal domain and VR genes.
Figure 5.1: Tree based on amino acid alignment of 35 full-length functional VSGs with 29 VR
genes.
Numbers 1 and 2 indicate the two main VR gene clusters, further illustrated in Figure 5.2.
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After this preliminary distinction was made with VSGs, the next step taken was to identify
clusters within VR genes: the 29 VR genes analysed fall into two main clusters, 1 and 2,
with cluster 3 forming a smaller cluster and being related to cluster 1 (see Figure 5.2).
Cluster 1 contains VR genes with short N-terminal domains while cluster 2 genes have
longer N-terminal domains, very similar to those of type B VSGs. This similarity is further
investigated in the next section.
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Figure 5.2: Tree based on amino acid alignment of full-length VR genes.
Three main clusters were defined: cluster 1 (blue), 2 (red) and 3 (green). Cluster 2 was
further partitioned in three subclusters, 2.1, 2.2. and 2.3, cluster 2.1 including VR genes
encoding cysteines at their C-terminal end. The two longest branches of cluster 1 have been
termed 10 (outgroup within cluster 1), see Table 7.9 of Appendix for details.
5.2.2 VSG Type Band VSG-related N-terminal domains
Due to the close similarity of VR genes to type B VSG N-terminal domains, it was of
interest to see whether it was possible to characterise the VR N-terminal domain region and
identify potential motifs or signature sequences that could enable its differentiation from
VSGs. The first step was to align the 29 VR N-terminal domains with 332 type B N-
terminal domains (see Figure 5.3): VSG-related N-terminal domains clustered more closely
with what was defined in Chapter 3 as VSG N-terminal domain type B group 2.
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Figure 5.3: VR N-terminal domains aligned with 332 VSG type 8 N-terminal domains.
In red are VR N-terminal domains (VR), in blue type 8 group 2 N-terminal domains (8,
group2). The three other main groups (in grey), are type 8 groups 1, 3 and 4 (clockwise from
type 8 group 2).
Focusing on a more detailed comparison with group 2, and looking for differences from
VR genes, it appears that there is no localised difference in sequence that can enable
distinction between the VSG type B domains and VR N-terminal domains; the cysteine
pattern is remarkably conserved (as is generally the case across all type B N-terminal
domains, see Chapter 3) and so are other conserved residues (data not shown). The only
significant departure in terms of structure is in VR N-terminal domain cluster 1 (see Figure
5.4), which have a shorter N -terminal domain, with a deletion of ~ 100 amino acids after
the first conserved cysteine, spanning the long domain stretch with no cysteines (see Figure
3.5, Chapter 3, for cysteine spacing of type B VSG domains). So, with this sole exception,
it appears that there is a continuum of variation throughout the domain, rather than
different clusters with more or less significant structural differences. Within this
continuum there is no overlap, suggesting that VR genes are genetically isolated from the
recombination reactions that lead to shuffling of sequences in the case of VSG genes.
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Figure 5.4: Tree based on amino acid alignment of VR N-terminal domains.
Cluster 1 and 2 are the main clusters. Cluster 2 can be divided into three subclusters, 2.1,
2.2 and 2.3. Cluster 3 of full-length VR genes is here divided into clusters 3 and 4 (the latter
is further qualified in the graph by "3 FL" (= full-length cluster 3), with two additional
sequences not clustering well (labelled as "other", corresponding to the full-length cluster 1
outgroup, see Figure 5.2).
The tree for VR gene N-tenninal domains is remarkably similar to the tree for full-length
sequences, as occurs for VSGs. Domains were divided into four clusters: cluster 1 and 2
correspond to full-length clusters 1 and 2, respectively, while full-length cluster 3 is here
split into N-tenninal domain clusters 3 and 4; two VRs (the most diverged of cluster 1 full-
length, referred to 10, cluster 1 outgroup) do not group well with any of the four clusters.
5.2.3 VR C-termina/ domains
A comparison between all 85 functional VSG C-tenninal domains (and respectively two
and 13 atypical type 4 and 5 C-tenninal domains) and 29 VR C-tenninal domains was
made (see Figure 5.5). The tree shows clear separation of VR C-tenninal domains.
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Type 5
Type 2 VR
Figure 5.5: Tree based on amino acid alignment of VR C-terminal domains (indicated as VR)
with all 85 functional VSG C-terminal domain types (indicated as types 1 to 6), plus two
atypical type 4, and 13 atypical type 5 C-terminal domains.
The separate analysis of the C-tenninal domain of VRs was prompted by the presence of a
subset of genes with cysteine residues at their C-tenninal end, reminiscent of VSG C-
terminal domains. All the sequence downstream of the conserved N-tenninal cysteine
pattern was considered (90-130 amino acids). Three C-tenninal domain clusters were
identified, 1 and 3 being more related to each other and cluster 2 being composed
predominantly of cysteine-containing C-tenninal domains (See Figure 5.6). It appears that
there is a potential for a GPI anchor in clusters 1 and 2, while cluster 3 appears not to have
a hydrophobic extension (C-tenninal domain alignments are given in the Appendix, section
7.4.2). A significant presence of proline residues was detected in domains with no
cysteines, a similarity with T congolense C-tenninal ends (see Introduction, section 1.2.2).
This was further explored by comparing VR and T congolense VSG C-tenninal domains,
it appears that although both are rich in proline, the sequence motifs are distinct, and clear
separation between the two families is present (see Figure 7.5 of Appendix for a multiple
sequence alignment)
110
.---- ll".oRo_10m05
.------~_VRc_28~"
L- __ Q,"_VRc_801l1l3
I
I L-~ I!_Vflc"_462214
L- 5VRc_1374<lSI
I '-""'-""\("
L__ Q-'vR:~::~~4812
,--- 3_Vflc_037133
1
Q_'vRdc_1l044l!4
,- U/Rc_lD:2n411
.---- 2_\lRc_ *
,- 3_'vRe_153G3Oe *
L__ UN_~_gOO5Q2*
QN_\IRc_211!5G22 *
IlN_~c_2"12tl34 * 2
L.__ __ QN_WRc_21S4381 *
QN_~_2:201311 *
QN_WRc_22OO183 *
,- --lJ-\tRc-3746l2
3_VR.c_39G343
I
I
L__ 11s_'VR.dI:_IIZZ854 *
_____________ C==~3_\JRC-388094I l_vRc_3(141IlJ
.------------1] 8_VRc_20885Bi1
8_'vfl:c_2002483
L- 11_2_'VRc
11\IRd12680:.'\l3
L_ 5N_~I_12~0331
Figure 5.6: Tree based on amino acid alignment of VR C-terminal domains.
Three main clusters (1-3, colour-coded) are present. Cluster 2 is mainly composed of
domains with cysteine residues (highlighted with asterisk).
5.2.4 N- and C-terminal domain analysis
When looking at how the C-tenninal domain clusters relate to the N-tenninal domain ones
(Table 5.1), it is apparent that, unlike for VSGs, there is a tight association between the two
domains, as no domain combinations appear to be present. This suggests a different
pattern of evolution from that of VSGs, in which the C-terminal end of VR genes does not
provide a 3' region of homology to allow N-terminal domains to recombine with each
other.
Table 5.1. Relation between full-length (FL), Nand C clusters.
FL N C OCCURRENCE
CLUSTER CLUSTER CLUSTER (NUMBER OF
TYPE TYPE TYPE VR)
1 1 1 8
2.1 2.1 2.1 4
2.2 2.2 3 5
2.3 2.3 2.l 5
3 3 1 3
3 4 2 2
Other"
10 N34 2 1
10 N2 3 1
33 FL cluster 10 = 1 outgroup, more diverged.
34 Does not cluster.
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5.2.5 Flanking regions ofVR andVSG genes
Itwas of interest to compare the VSG and VR flanking regions to see whether some
common traits were found. For the downstream region, ~300 bp were used in the
comparison, corresponding to the length of sequence between the end of a VSG and the
beginning of the next set of70-bp repeats in the array (see Chapter 3, section 3.7 for VSG
array structure). In the case of the upstream region, 300 bp immediately upstream of the
start codon were used in the alignment. Figure 5.7 shows the tree generated from the
upstream and downstream regions. It can be seen that, whereas the 3' region separates
well, with short branch lengths, the 5' region, especially in the case of VSGs, is very
diverged, leading to a degree of overlap between VSG and VR regions that is probably due
to the weakness of the alignment. In addition, 3' and 5' UTRs tend to group in a similar
way to the coding sequence, when the different trees are compared (data not shown). An
observation made with regards to the VSG 3' region is that the two separate clusters
correlate with the presence or absence of the 16-mer motif present in the 3' UTR of all
expressed VSGs (see section 1.3.4 ofIntroduction). This could suggest recombination
events between expression sites and VSG arrays.
5' LJTR aln of functional VSGs and VR genes
VSG -
Figure 5.7: Alignment of 5' and 3' flanks of functional VSGs and VR genes.
Sequence in green represents Tb927.5.3990, the only gene with intermediate features
between VSG and VR genes. VSG genes with 16 mer in 3' UTR are highlighted.
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5.2.6 VR gene location
VSG-related genes were allocated a number from 1 to 29 (see Figure 5.8 and Table 7.9 of
Appendix for correspondence between this identification and the GeneDB ids) according
to their location in the genome, from chr 1 to chr 11. Twenty VR genes out of 29 are
organised in arrays composed of between two and five genes, and VR genes occupy a total
of 15 different loci. Of these, 13 are internal and two (VR 10-11 and VR 26) are
telomeric". Twelve of the 15 loci are located just upstream of a strand switch, and 9 of
them are associated with ESAG genes (ESAG1, 2, 3, 4, 5, 6,9,11, but in particular 1,2,9
and 11). A tight association between a dispersed subset of 8 VR genes and ESAG936 2-3 kb
downstream of these genes was found (all VR with this association belonged to cluster 1,
see Figure 5.8), whereas other ESAGs appear not to form a precise pattern of association
with VRs. None of the regions upstream of VRs were found to contain 70-bp repeats.
Although no particular DNA features have been ascribed to strand switch regions, they
appear to match closely with the breaks of syntheny found when comparing T brucei with
Leishmania and T cruzi (H. Renauld, pers. comm.). This suggests that these regions might
be more prone to recombination and might have been telomeric, before chromosome
fusions occurred in T brucei, as mentioned in section 1.1.3 of the Introduction (Ghedin et
al., 2004). The current association of a subset of ESAG genes with telomeres at the
Bloodstream expression site (BES) further suggests an ancestral telomeric location for all
ESAG genes and VR genes.
35 More recently, another VSG-related gene has been found upstream ofa telomeric MVSG expression site on
chromosome 10 and VR 25 has been relocated in a discontinuity within the subtelomeric VSG array in the left
arm of chromosome 9.
36 Of these eight ESAG9 genes, six are intact and two are pseudogenes.
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Figure 5.8: Chromosome location and basic features of VR genes.
To the left is the chromosome number. The VR id number is given above each VR gene,
whereas full-length VR cluster types are highlighted below. VR 25 to 29 are located in small
contigs that have been assigned to chr11. pairs of VR genes underlined with the same
colour share 100% sequence identity. VR 25 was previously located in a contig, but it now
maps to a discontinuity in the array at the left arm of chr9. VR genes circled in red were
selected for the PCR analysis presented in section 5.3.
5.2.7 Overview of features ofVSG-related genes
In summary, 31 VSG-related genes have been found to form a separate group, distinct from
70-bp associated array VSGs37• Twenty-nine VR genes were analysed and a full-length
alignment shows clear separation from 35 functional VSG sequences (Figure 5.1). Their
N-terminal domain is type B, but forms a separate group when compared with all other
type B VSG N-terminal domains. The C-terminal domain is not closely related to any of
the conserved VSG C-terminal domains and forms a separate cluster. With regards to the
"integrity" of VR sequences, there are few pseudogenes, with only seven out of 31 (22%),
compared with a minimum estimate of 86% for the VSG archive. These estimates are very
37 This study considers 29 of the 31, the other two VR genes have more recently been found: they are not
included in the analysis, but are included Table 7.9 of the Appendix.
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tentative: as no consensus for expressed VR genes is present, it is possible that the
proportion of pseudo genes might be slightly higher.
Together with these differences at the gene level, when looking at the location of these
genes, it is striking that they are not found to be interspersed amongst VSGs. They are
predominantly located internally, as single genes or in small arrays. On the contrary, VSGs
are located within 70-bp repeat-associated arrays that are almost exclusively subtelomeric
(with the exception of a short internal VSG array on chromosome 7). VR 5' and 3' UTRs
cluster separately from VSG UTRs. A common feature 5' of VSGs in subtelomeric arrays
is the presence of 70-bp repeats; these are absent from the region upstream of VR genes.
Only one VSG, Tb927.5.3990, appears to have features intermediate between these two
groups. Its 3' UTR groups with VSG-related, its 5' UTR tentatively groups with VSGs, but
does not have 70-bp repeats, the N-terminal domain is type A, and the C-terminal domain
has 7 cysteines and does not cluster well with either VSGs or VR C-terminal domains.
Because of its unusual features, it is possible that Tb927.5.3990 has also diverged from
VSGs in a way similar to that of ESAG6, ESAG7 and SRA: all these surface molecules have
a common origin with type A N-terminal domains of VSGs (see section 1.2.3 of
introduction for a discussion of these genes). Table 5.2 gives a general overview of the
comparison between VSG and VR genes.
Table 5.2: A comparison of VSGs and VSG-related proteins.
Features VSG VSG- related
Number 940 31
Pseudogenes 808 7
70-bp repeat upstream Most None
Present in arrays with 70- All but 1 (Tb927.5.3990) None
bp repeats
Length 474-540 340-490
N-terminal domain types A,B,C B type clusters 1, 2, 3
C-terminal domain types 1,2,3,4,5,6 3 clusters, cluster 2 with
cysteines
GPI signal Present Absent or not conserved;
possibly present in clusters 1
and2
3'utr Two main subtypes Cluster together, separately
clustering closely from VSGs
5'utr Diverged, slight overlap Diverged, slight overlap with
with VR VSGs
5.3 Expression of VR genes
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The discovery of VSG-related genes with distinct genomic locations and separate
clustering from array VSGs prompted investigation of whether these genes are functional
and whether their expression patterns match those of VSGs. Because of their distinct
features, the hypothesis is that VR genes encode surface molecules with a role separate
from that of VSGs. Here, a subset of 10 VR genes are subjected to preliminary
characterisation by PCR.
5.3.1 Comparison ofVSG-related archive across T. brucei strains
Genomic DNA from strains TREU 927, Lister 427, EATRO 795 and STIB 247 of T
brucei was tested by PCR for presence of 10 different VR genes. Half of these genes was
found to be ubiquitous, showing a conservation that is possibly higher than that present
amongst VSG archives of different strains (see Figure 5.9 and Appendix for
correspondence of VR numbers and GeneDB identifiers). A good way of verifying the
preceding statement regarding VSG archive conservation across strains would be to repeat
the same analysis with ~ 20 putative functional 927 array VSGs and see what proportion
give a positive signal in the three other strains.
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Figure 5.9. Ethidium stained gels showing VR presence detected by peR on gDNA in 927,
247,427,795 T. bruceistrains.
Strain numbers are indicated in red to the left of each gel. For each gel, lanes one to ten
correspond to PCRs with primers for VR 1,2,4,5,8,9,11,13,15 and 18, respectively. To
the left of each gel is the size (in kb) for the main bands of the 1 kb ladder.
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The next approach taken was to question whether the genes are expressed. This was
undertaken by reverse transcriptase peR (RT-peR). cDNA was prepared, with the primer
oligo[dT], from 927 bloodstream and procyc1ic trypanosomes and was then analysed
further with the same set of primers for the 10 genes as used above (see Figure 5.10).
Results show expression of at least eight VSG-related genes within the trypanosome
bloodstream population of strain 927, including four of the five ubiquitous genes. VSG
related genes appear to be expressed also in procyclic trypanosomes, with an identical
pattern to that seen in bloodstream forms, although in five instances (VR 2, 5, 8, 15, 18)
there appears to be a lower level of transcript abundance, when comparing the two gels for
the apparent ratio ofVR RT-peR product to tubulin. These results would need to be
confirmed by Northern blot, which was not possible due to lack of time.
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Figure 5.10: Ethidium stained gel showing VR expression, as detected by RT-PCR analysis
of cDNA from 927 bloodstream and procyclic trypanosomes.
Above the gel, + and - indicate whether RT+ or RT- cDNA from 927 was used as template for
the eleven different sets of PCR (numbers 1 to 11 above gel). Reactions one to ten
correspond in both gels to primers specific to 10 VR genes, VR 1, 2, 4, 5, 8, 9,11,13,15 and
18 respectively. Reaction 11, in both gels, corresponds to a positive control using tubulin-
specific primers.
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5.3.2 Are VR genes used as VSG coats?
Having gathered tentative evidence that VSG-related genes are expressed in bloodstream
and possibly also procyclic trypanosomes, it was important to test whether VSG-related
expression is concomitant with that of canonical VSGs or whether it occurs mutually
exclusively of that of VSGs. To distinguish between these two possibilities, expression
was analysed in the 427 strain that has been genetically modified by insertion of the HYG
gene in tight linkage with the 221 VSG, such that 221 expression correlates with
hygromycin resistance (McCulloch et al., 1997). This strain was grown under drug
selection and then RNA was prepared. RT-PCR results show expression of three VSG-
related genes (VR2, 4 and 15), so it appears that they are coexpressed with the 221 VSG,
rather than being expressed mutually exclusively, as would occur for authentic VSGs. This
has been further confirmed by showing that 221 is the only VSG expressed, as there were
no RT-PCR products for five other VSGs that are commonly expressed as variants within
the 221 strain (see Figure 5.11).
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Figure 5.11: Ethidium stained gel showing RT-PCRs to test whether VR genes are
coexpressed with VSGs in T. bruce; strain 427 expressing the 221 VSG under hygromycin
selection.
Above the gel, + and - indicate whether RT+ or RT- cDNA from 427 was used as template for
the nine different sets of PCR (numbers 1 to 9 above gel). Reactions 1 to 3 used primers
specific to VR 2, VR 5 and VR 15 respectively. Reaction 4 amplified part of the 221 VSG.
Reactions 5 to 9 correspond to other VSGs known to be expressed in 427 (VSG 118, Vo2,
121, G4 and S8 respectively), as a control for homogeneity of VSG expression in the
trypanosome population used to harvest RNA from. Primer sequences can be found in the
Appendix, in Table 7.10. To the left is the size (in kb) for the main bands of the 1 kb ladder.
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5.4 T. brucei VSGs, VSG-related genes and T. congo/ense
VSGs: a comparative analysis
The striking differences between VSG and VR gene sequences and organisation, and the
partial similarity between VR genes and T congolense VSGs, suggest that the T
congolense VSG system might shed some light onto the T. brucei system.
5.4. 1 Analysis of T. congolense VSGs
The sequence of twenty-three T. congolense VSGs is analysed here, including the ten full-
length VSG sequences that have been published (Strickler et al., 1987; Eshita et al., 1992;
Rausch et al., 1994; Urakawa et al., 1997). The 13 novel sequences were obtained by
blasting a published sequence against the T. congolense database
(http://www.genedb.org/genedb/tcongolenselblast.jsp)(seeTable7.11). These VSGs
appear to be present in arrays of tandemly duplicated genes, and one of the contigs
analysed (chr 10) suggests the array to be immediately adjacent to a telomere tract (see
Figure 5.l2). At least four out of the 13 VSGs are pseudogenes, possibly hinting to a lower
degeneracy of the VSG archive when compared to T. brucei, however the sample size is
too small to draw definite conclusions. VSGs in the arrays are not evenly spaced, do not
have any repeats associated with their flanks, and seem not to have a cassette structure (see
Figure 5.12Y8. The range of divergence between genes seems to be comparable with that
found among T. brucei VSGs (data not shown).
38 A comparison with VR gene arrays is not included as the sequence context is too different. VRs are either
present in small numbers (two-three genes), or interspersed with ESAG genes, or in arrays of closely related
tandemly duplicated genes (one instance, VRs 20 to 24).
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Figure 5.12: Comparison of T. bruce; and T. congolense array structure.
Image derived from the Artemis annotation software. In section A, T. bruce; VSGs are in
white, narrow blue boxes indicate 70bp repeats, gray boxes indicate ESAG3 pseudogenes.
In sectionB, T. congolense VSGs are highlighted in pairs of different colours. The VSG pair
underlined in red share 60% amino acid identity, the pair underlined in blue shares 50%
sequence identity. The telomere tract found at the end of the Chr 10 assembly is
highlighted as a black box. Above each gene prediction is a graph highlighting the GC
content of the DNA sequence. T. congolense VSG arrays do not share the periodical pattern
of GC content found in T. bruce; arrays.
Searching the T congo/ense GeneDB database with a type A N-tenninal domain of T
brucei (lLTat 1.24) yielded only one ORF with significant match, which when blasted in
turn against the GeneDB T brucei protein database yielded ESAG6. Blasting the
congolense ESAG6-like gene against the congolense database, more than 60 contigs appear
to contain good hits to the sequence, suggesting the presence of a multi gene family of
ESAG6-like molecules in T congolense. The relationship between this multi gene family
and T congolense VSGs needs to be further investigated bioinfonnatically. So far, a single
contig (congo502c05.plk_12) was found to display both gene types in the same array,
indicating that they could be part of the T congolense VSG archive, or at least share the
same genomic locus.
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5.5 Conclusions
Yet unanswered questions with regards to the T. congolense array system include whether
domain combinations are present (like in the case of VSGs) or whether they are not (as in
the case ofVSG related genes). Itwould be also interesting to identify patterns of gene
duplication to see whether any flanking sequences promoting archive expansion (and
possibly copying into an expression site) can be found. For both the above questions to be
answered, many more sequences would need to be analysed, and more extensive
sequencing coverage and annotation of VSG arrays would be required. So far it looks like
T. congolense VSGs might be more similar to VSG-related genes, possibly lacking domains
and having less structured sequence loci when compared to T. brucet VSGs. Nothing is
known about the mode of expression of T. congolense VSGs, whether expression sites
similar to those of T. brucei are present: the striking differences in array structure between
the two trypanosome species suggests that there might be many more divergent traits in the
mode of antigenic variation.
A more extensive coverage of T. congolense VSGs in the genome strain might reveal a T.
congolense equivalent of the VSG-related family presented here for T. brucei. With
additional experimental data characterising the role of VSG-related genes, it would then be
possible to undertake a large comparative study in which surface receptors (such as ESAG6
and possibly VSG-related genes) and their putatively derived antigens could be analysed
across species. This would allow common themes and differences to emerge in the
antigenic variation strategies of African trypanosomes and would produce a clearer picture
of the evolution of the VSG superfamily, together with a better understanding of its past
and present biological roles.
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6 Discussion
This discussion will focus on the dynamics of antigenic variation, in terms of whole VSG
archive evolution in the course of a chronic infection and its relationship to the sequential
expression of the evolving archive. A holistic approach is called for, as post-genome
studies will be most effective if thought is given to working simultaneously on
bioinfonnatics, molecular and in vivo studies, requiring new ideas to be introduced and
tested in trypanosome antigenic variation research. Key to this holistic approach is the
concept of adaptive mutation, in which interaction with the host environment establishes a
pattern of evolution on the whole antigenic variation system (and organism), allowing a
more tailored (less random) response to immune selection (adaptive mutation is reviewed
in Caporale (2003». As selection in a specific environment is maintained, the pattern of
evolution is reinforced, producing or selecting sequence loci and molecular mechanisms
that are better tailored to, and more focused in, the generation of the "required" diversity,
sometimes resulting in the evolution of a mutator phenotype. The clear aim of elucidating
antigenic variation as a mutator phenotype is crucial in overcoming, or at least
understanding, the limitations of experiments in vitro, where key pathways might not be
operational; it also furthers the scope of bioinfonnatics studies, allowing the genome to be
queried not solely for its coding, but also for its evolving, potential.
The immune system of mammals has selected for convergent evolution of antigenic
variation strategies (Deitsch et al., 1997). The common vocabulary of antigenic variation
includes the presence of at least a multi gene family of surface antigens, a mechanism for
single antigen allele expression, often mediated by a dedicated expression site, the role of
repeats in gene conversion of a silent copy to the expression site, the frequently telomeric,
or clustered, nature of loci encoding the antigens (with often unique sequence features
when compared with the housekeeping region of the genome), the use of partial gene
conversion and point mutation to further enhance antigen diversity, and the presence of
pseudogenes. Trypanosoma brucei has outstanding features, namely a huge antigen gene
archive size (at least 10-fold more than that of all other known parasites), a very high level
of divergence and a high number of pseudogenes amongst its antigen gene copies. It also
seems to rely upon several distinct strategies: transcriptional switching, full-length gene
conversion, mosaic gene conversion and possibly point mutation, as has emerged from this
study.
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6.1 VSG Sequence mutation and evolution
The aim of this first section is to explore some of the DNA features of VSGs and VSG
arrays, outlining the sequence basis upon which point mutations arise and antigenic
variation takes place. First of all the concept of strand bias will be introduced, the
importance of which will become clear in section 6.1.1.2.
6.1.1 Strand bias, leading and lagging strands
6.1.1.1 Background on strand bias and its significance
It has been shown that, in the absence of asymmetric substitution occurring between
leading and lagging strands during replication, the relative amounts of the four nucleotide
bases found in DNA are roughly equal. In contrast, the presence of asymmetric
substitution might lead to a higher incidence of a particular base over another: in the case
of many bacterial species, the leading strand was shown to be more abundant in Gover C
and T over A (Frank and Lobry, 1999). Strand bias has been studied extensively for
bacteria and has been found in archaea, mitochondria and bacteriophage (Rocha, 2004) and
recently also in eukaryotes (Niu et al., 2003; Hou et al., 2006). No mutational mechanism
has been described that satisfactorily explains this G+T bias: cytosine deamination,
resulting in a C to T transition, has been suggested to playa role, but would have to act on
the leading strand in order to generate the bias, which is in conflict with data suggesting
the lagging strand as being more prone to mutation (Frank and Lobry, 1999). Furthermore,
AID, the enzyme involved in cytosine deamination, has been implicated in mutations
occurring during transcription in somatic hypennutation of the immunoglobulin genes, but
the spectrum of mutations generated is not directly linked to the enzymatic specificities of
this protein and the observed mutations do not result in a strand bias (Samaranayake et al.,
2006). There appear therefore to be big gaps in the current understanding of strand bias and
mutational mechanisms, so what is presented below is just a brief overview of some of the
main points related to this area of study, which are of relevance for discussing VSG arrays
and VSG point mutations. In bacteria, the lagging strand is suggested to be maintained for
longer in single-stranded conformation (ssDNA), compared with the leading strand, and
cytosine deamination occurs more than one hundred-fold faster in ssDNA than in double-
stranded DNA (Rocha, 2004). Indeed, it has been shown that genes on the lagging strand
mutate more rapidly than those on the leading strand (Szczepanik et al., 200 I). This could
also be due to head-on collisions between DNA and RNA polymerases, causing stalling
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and the potential for errors being introduced during replication fork restart. It is in fact the
case in many bacteria that replication seems to affect the orientation of operons, which
tend to be located on the leading strand (Rocha, 2004).
As for eukaryotes, the okazaki fragments generated during lagging strand replication are
much shorter than those in prokaryotic DNA, suggesting that ssDNA-dependent mutation
would exert a weaker effect. Replicons also tend to be shorter in eukaryotes, and are
generally not identifiable bioinformatically; this, together with the lack of such a rigid gene
organisation as the bacterial operon, makes eukaryotic strand bias more difficult to detect
(Niu et 01.,2003). Strand biases have nevertheless been detected, although they have been
ascribed also to factors other than asymmetric substitution during replication, such as
transcription-associated mutation bias and selective codon usage bias (Niu et 01.,2003).
6.1.1.2 Strand bias in VSG point mutations and in VSG arrays
In the case of T. brucei, a single report of strand bias was made with reference to point
mutations in three VSGs (Lu et al., 1994). The type of mutations in expressed VSGs
detected in this study (see Table 6.1 below) are comparable with those published data
(comparison not shown). If both strands were mutating at random in the course of
replication, the number of G to A mutations on the leading and lagging strands should
match; those on the lagging strand would result in the leading strand mutating from C to T,
so comparing G:A (G to A) with C:T mutations on the same strand provides indirect
evidence for preferential mutation of one strand versus the other. Table 6.1 shows 171
mutations ordered in pairs corresponding to the same mutation on the two strands. While it
clearly appears that mutations are not generated on either strand at random, there being
asymmetric substitution, what remains unclear is whether, at least for this dataset, this
would correlate with a general compositional strand bias at VSG loci: although skewed,
these mutations are not predicted to generate any skew, as, overall, the number of
mutations giving rise to A is roughly the same as the number of A residues mutating to the
other three bases, and this is true also for C, G and T.
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Table 6.1: 171 point mutations in expressed VSGs isolated in current study, ordered in six
pairs, corresponding to identical mutations arising on the VSG coding strand and the
opposite strand.
VSG strand Number of VSG strand mutation Number of
mutation mutations (equivalent mutation mutations
on opposite strand)
A:C 15 T:G(A:C) 5
C:A 17 G:T(C:A) 2
A:G 38 T:C (A:G) . 11
G:A 41 C:T(G:A) 9
A:T 1 T:A (A:T) 4
C:G 16 G:C (C:G) 12
A recent publication analysing strand asymmetry in kinetoplastids (Nilsson, 2005) detected
asymmetric substitution at strand switch regions of T. brucei chromosome 1, adding to the
similarities in gene organisation between trypanosomes and bacteria (presence of
polycistrons) and possibly implicating the switch regions as origins of replication. The
scarcity of VSG sequences on this chromosome (only four VSGs) has meant that VSG
arrays were not included in the analysis. To address more specifically whether a bias is
present within the VSG archive, a comparison of DNA composition between the 154 VSGs
of the array on the right arm of chr 9 and 99 housekeeping genes on chr 8 was made, and is
presented in Table 6.2. This suggests that genes present in the polycistrons of mega base
chromosomes do not show any significant strand bias (see Table 6.2), whereas VSGs show
a marked bias in favour of A over T (35% A content), with no obvious bias in G versus C.
Interestingly, the one clear example of strand bias to be detected in eukaryotes has been
reported for yeast subtelomeres (Niu et al., 2003): whether this is a wider feature of
subtelomeric contingency loci (Barry et al., 2003) remains to be investigated.
Table 6.2: Percentage of the four DNA bases at different genomic loci in T. brucei.
Chr899 Chr9 VSG Expressed Chr9 VSG Expressed Chr9GPI
internal N-terminal VSGN- C-tenninal VSGC- signal
genes domains terminal domains terminal
domains domains
A 23.89 34.64 32.73 39.96 38.31 24.06
C 23.60 25.75 27.41 18.77 2l.69 16.12
G 28.07 24.46 25.54 22.37 23.47 16.81
T 24.44 15.15 14.32 18.89 16.54 43.00
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To summarise, VSG mutations are not generated at random between leading and lagging
strand and VSG arrays appear to have a DNA composition (and bias) different from that of
the core region of mega base chromosomes (see Table 6.2). Interestingly, the prevalence of
mutations in the VSG N-terminal domain (see Chapter 4) seems to correlate with a
localised skew in favour of A and C in this domain (see Table 6.2), which corresponds in
E. coli with the lagging strand of replication. Additionally, such localised bias fits with the
concept of adaptive mutations as enunciated by Caporale (2003): "When we observe
different rates of mutation at different positions in a gene, we should consider the
possibility this may be due to evolution of mechanisms that modulate the rate of variation,
rather than selection for and against mutations one by one". Another way mutations could
be targeted to the N-terminal domain is by repeated error-prone gene conversion reactions,
in which C-terminal domains would act as homology flanks and therefore might not be
affected, at least not in their entirety. There is evidence against such error-prone gene
conversion reactions, as a study monitoring repeated gene conversions between two genes
(AnTat 1.1 and AnTat 1.10) did not find any evidence of point mutation (Pays et al.,
1985). This was reported in a monomorphic strain, so an error-prone gene conversion
might still be part of the recombination events that are characteristic of pleomorphic
trypanosomes.
6.1.1.3 Significance of VSG array strand bias
If bacteria and trypanosomes have similar strand bias, then it could be suggested that VSGs
are, or have been, preferentially located on the lagging strand of replication. Nothing is
known about origins of replication in T. brucei and their directionality, but the above data
prompt at least a speculative comparison with bacteria. As mentioned above, in bacteria
orthologues present on the lagging strand have been shown to diverge at a faster rate than
those in the leading strand (Szczepanik et al., 2001). There might therefore be significance
in the orientation of arrays away from the telomere and in expression sites being oriented
towards the telomere: different mutation rates might be established between expression site
and donor regions, either to enhance or to reduce mutation at expression sites. It is also
possible that a replication origin is placed between the array and the expression site, and in
this case the mutation rate of these two loci might be the same. An additional reason for
this opposite orientation could be for ease of aligning telomeric and array VSGs during
gene conversion; this could occur by the telomere-proximal region folding back and
pairing with more internal sites of the same DNA molecule or ectopically with other
arrays. A similar head to head orientation of silent antigen copies and expression site is
observed in Borrelia burgdorferi linear plasmids, suggesting a common architectural
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theme (Zhang et al., 1997). Another remarkable finding with regards to mutation in
bacteria is that genes that have recently changed strand exhibit a faster mutation rate
(Szczepanik et al., 2001): this might suggest an advantage in the mixed orientation of
VSGs in the long arrays of chr 9 and chr 11. An alternative explanation for this could be
that the strand bias in VSG arrays produces some instability in DNA conformation,
requiring it to be balanced by strand switching, when the length of the array surpasses a
certain threshold. A further effect imputed to residency within the lagging strand,
deletions between direct repeats are observed frequently and preferentially on the lagging
strand inE. coli (Sinden et al., 1999), so again, to stretch parallels to their limits, the
preferential location of VSG arrays on one strand might facilitate deletions (and
rearrangements ingeneral) involving 70-bp repeats. It is difficult to conceive how this
could be tested in T. brucei in any other way apart from sequencing at least some VSG
arrays for the genome strain after prolonged growth in vivo, as a large number of events
would need to be detected for statistical evaluation of the different changes. Prior to this,
an experimental study to provide an estimate of the frequency of such events could be
conducted, involving genomic DNA digestion and probing of selected array fragments,
with the aim to observe changes in their size over time (across different clones). This
would also allow to select specific clones that have diverged sufficiently and to then use
them for array sequencing.
Inparallel to an analysis of large sequence rearrangements, a more thorough analysis of
strand (and codon) bias and a wider knowledge of mutations at VSG loci could reveal the
relative contributions to mutation rates in the VSG archive provided by DNA sequence,
sequence location, chromatin conformation and possibly transcription",
6.1.2 Understanding VSG mutations
6.1.2.1 Mutational mechanisms for VSGs
It is currently unknown whether there is a dedicated mechanism for mutation at
subtelomeres, and how it might operate. Hypermutation in the variable region of
immunoglobulin genes begins with regulated, targeted, enzymatic cytosine deamination
events on either strand at the sequence RGYW, followed by action of a mutator
polymerase (Caporale, 2003): the basic use of cytosine deamination to promote mutation in
both bacteria and humans, together with the preliminary evidence provided above of a
39 Somatic hypennutation has been shown to be strongly dependant on transcription, as mutation frequencies
correlate with transcriptional activity (Aguilera, 2002).
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mutation bias in trypanosomes, might suggest an involvement of this process in VSG
mutation. An alternative mechanism could involve base J, which replaces a fraction of
thymine at subtelomeres (van Leeuwen et al., 1997), and for which a function has not yet
been fully ascribed: its association with subtelomeres might increase mutation rate,
possibly by causing the DNA polymerase to stall. Base J, or other factors, could also result
in promotion of double strand breaks (DSBs), and lead to a phenomenon termed
recombination-dependent adaptive point mutation; in this pathway, the DSB leads to
mutations being produced in its proximity, by a process involving (in E. coli) the error
prone polymerase pollV and downregulation of mismatch repair (Rosenberg, 2001). So far
this process has been described only in E. coli, although some analogies with somatic
hypermutation in humans have been drawn" (Rosenberg, 2001). The potential for it to
operate in trypanosomes has been suggested, based on the presence in the genome of all
the required factors, such as error-prone polymerases (McKenzie and Rosenberg, 2001).
While looking for a specificmutation mechanism, it should not be forgotten that a mutation
rate is achieved through "integration of a wide range of cellular activities, including the
level of and balance between distinct repair, polymerase and proofreading activities and
their interaction with different sites in the genome" (Caporale, 2003), so further
explanations could be found by increased knowledge in processes such as DNA
replication, mismatch repair and genome architecture dynamics.
6.1.2.2 Where do gene conversion and point mutation occur?
Where mosaic formation and point mutation occur remains to be established: in the case of
mosaic genes it has been suggested that silent expression sites might be the loci at which
they are assembled (see section 1.3.1.5), then to be switched on or converted into the active
expression site. Telomeric 3' donor VSGs have been found in two instances to be
pseudogenes (Thon et al., 1989; Roth et al., 1989), lending strength to the idea that not all
telomeres harbour intact VSGs. Although there are reasons to think that point mutations
detected in the experiment originate from the VSG Expression-Linked Copy (ELC) (see
Chapter 4, section 4.9.1), an analysis of mutation across the archive as a whole during
infection would be highly informative, especially to observe whether the donor copies also
mutate and whether they would be transferring (or eliminating) mutations to the ELC by
gene conversion.
40 An error prone polymerase, polu, has been found to be involved in somatic hypermutation, see also section
6.3.2.
129
6.1.3 Is VSG gene evolution fast enough to contribute to
antigenic variation?
Both point mutation and mosaic gene data produced in this work lead to a major and yet
unanswered question, namely whether there is evolution of expressed VSG sequences
contributing to antigenic variation alongside VSG switching (be it by full-length or
segmental gene conversion).
Modelling based on current data suggests that within 5 to 6 days of appearance of a VAT
beyond a certain threshold, polyclonal antibodies would be produced by the host and the
VAT would be eliminated (Morrison et al., 1982). Within this time window, point
mutation or further mosaic formation would need to affect the initial expressed VSG to an
extent that the outcome of these diversification mechanisms renders it non-cross reactive
with the starting VAT. The time frame is further reduced by the fact that once switching to
a non-cross reactive variant has occurred, current knowledge of mechanisms suggests it
may take up to two days for the coat to be completely replaced (exact timing unknown, see
Introduction, section 1.3.2), extending the time in which the switching trypanosome is
vulnerable to existing antibodies. Point mutation is also restricted by the limitations
imposed by VSG structure and function and possibly also by the "homogenising" effect of
repeated gene conversions from the original silent donor. What therefore remains
unanswered is not so much whether point mutations occur, but whether they have
biological significance in terms of helping prolong a chronic infection. Their role could be
in further diversification of the VSG archive on a longer time scale, rather than in short
term immune evasion. Alternatively, point mutated or mosaic versions could be retained
in a silent expression site after an unrelated VSG has been switched on, allowing them
more time for divergence to occur, possibly to be reactivated later on in the infection, once
they have achieved non-cross reactivity.
If indeed point mutation and "real-time" evolution of mosaic genes are promoting
antigenic variation, this could explain the observation made when comparing the two
infections at day 28, that the point mutations per clone in infection 28-10 were lower than
in 28-11. Whereas all VSGs isolated in 28-10 are suggested to be mosaics, only one
putative mosaic is present in 28-11, perhaps hinting that in this infection the diversification
strategy (mutator phenotype) used was biased towards point mutation. This in turn could
be due to the presence or absence of closely related orthologues for a VSG that has been
duplicated into the expression site: lack of orthologues would invoke point mutations,
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whereas presence of orthologues could result in the preferential formation of more
complex mosaic genes.
6.1.3.1 Point mutation in other systems
Point mutations have been reported alongside gene conversion in both Borrelia hermsii
(Restrepo and Barbour, 1994) and Borrelia burgdorferi (Sung et al., 2001); in both cases
they are thought to occur after gene conversion, at the expression site. Interestingly, in the
case of Borrelia hermsii, increase in point mutation incidence was observed as the
infection progressed. On closer inspection, this latter example, unlike that of Borrelia
burgdoferi, does not constitute an accurate analogy, as mutations in Borrelia hermsii were
templated, actually resulting from short-range gene conversion events from very closely
related silent pseudo gene copies of the antigen.
To formally demonstrate that point mutated antigen variants contribute to the generation of
escape mutants is not trivial and is currently being addressed in the field of virology, for
example in the case of hepatitis C virus (HCV) (Guglietta et al., 2005); in this study,
previously characterised epitopes were followed in their evolution over a period of a year
in a single chronic infection, and by ex vivo analysis of synthetic peptides representing the
altered epitopes, were shown to be recognised with diminished efficiency by the wild-type
specific cytotoxic T cell response.
6.1.3.2 Do trypanosomes rely also on "escape mutants"?
A way to find out whether point mutated genes result in immune evasion would be to force
their expression (and also that of its non-mutated predecessor) into the BES of a
monomorphic trypanosome strain; this would allow us to test these variants in vitro for
reactivity with infection serum. Putative non-cross reactive variants could then be tested in
vivo by initial infection with one variant, followed by curing the host and superinfecting
with the second variant. By pursuing this line of research itwould be possible to
appreciate the upper limit of non-crossreactivity between variants and the interplay
between mosaic gene formation and point mutation.
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6.2 Modelling infection: infection evolution
6.2.1 Host parasite interactions
Another interesting aspect of antigenic variation is the relationship between infection and
mutation, which could be better characterised by comparing mutation rates for the VSG
archive in vitro and in vivo (the latter both in the absence and presence of immune
responses). If, as it does, the VSG switching rate rapidly decreases upon prolonged
passaging in the absence of immune responses (Turner, 1997), it might be that the whole
process of VSG archive diversification is affected. Different cues for the mutator
phenotype to be switched on might be present, and not all simply connected to selection by
the immune system. A good example of (indirect) second order selection is that of
segmental gene conversion of the vls antigen in Borrelia burgdorferi. Compared with the
high levels of gene conversion detected in chronic infections, parasites grown in vitro do
not exhibit any gene conversion and tend to lose plasmids and infectivity; on the other
hand, in vivo growth in the absence of immune selection results in an intermediate level of
gene conversion (Zhang and Norris, 1998), suggesting that there might be several host-
parasite interactions influencing the mutator phenotype. Drawing analogies with bacteria,
this phenotype might also be transient during infection and expressed only in a
subpopulation, allowing short term rather than long term survival (McKenzie and
Rosenberg, 2001), in a balance between survival and general organismal viability.
Drawing analogies with the process of differentiation from long slender to short stumpy
bloodstream forms, a stress-mediated response based on accumulation of unknown factors
in the bloodstream as the infection progresses might also be operating.
6.2.2 Stage 2 antigenic variation?
As pointed out in Chapter 4 (section 4.2.1), the timing of the onset of array VSGs and
mosaic genes and the putative upregulation or build up in the number of point mutations
seem to coincide, at least in mice, with a dramatic change in infection profile, in which
distinct peaks are absent. The change in infection profile suggests that point mutation of
VSGs might have an immunomodulatory role, reminiscent of the difference between
antigenic shift (large changes, exchange of RNA segments between viral strains) and drift
(point mutations) in the neuroaminidase gene of the influenza virus. While shift causes
severe pathogenesis, drift causes only a mild disease (Vossen et al., 2002).
Immunomodulation by point mutation could be due to the host needing to select
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continually B cells through the process of affinity maturation. Additionally, the divergence
in expression of different surface coats late in infection might contribute to spreading the
resources of the host to engage in a more subtle "hide and seek" game. High affinity
antibodies can be derived from low affinity ones by selection of six to eight point
mutations (Beale and Iber, 2006), a number comparable with that of mutations found in
VSGs, which therefore might be sufficient to lower the affinity of antibodies, rather than be
completely non cross reactive. The fact that a polyclonal antibody response is mounted
against each VAT, possibly limiting the efficacy of immunomodulation by point mutation,
might be countered by the observed rapid and divergent mutation pattern within the VAT
population, likely to result in a broad spectrum of altered epitopes. As an important caveat
to the above statements, the effectiveness of antibodies during infection has been shown to
be long-lasting (Morrison et al., 1982), and is a requirement for a hierarchy of expression
to be maintained: in the absence of specific antibodies, the order is immediately reset to
"early" variants. Therefore, the proposed modulation would be operating "at equilibrium"
with the immune response, rather than subverting it completely. On the other hand, it has
been suggested that the process of antibody affinity maturation is impeded late in infection
by a inhibition ofT helper cells, and this would correlate to the prevalence of the IgM
antibody subclass in response to infection (Turner, 1989). More immunological data on the
course of prolonged trypanosome infections are needed to provide a framework for more
robust models of chronic stage antigenic variation to be built.
6.2.3 Hierarchy late in infection
At the level of hierarchy of VSG expression, stage 2 antigenic variation could represent a
"genome-encoded" phenotypic shift from order to chaos, based on progressive lowering of
gene activation probabilities to levels at which new variants seem to appear at random (Le.
non reproducibly between separate infections). Reanalysis of rabbit infections originally
conducted by Capbern et al., (1977) suggests that variants appear as a continuum rather
than in distinct groups of early, middle and late (J. D. Barry, pers. comm.). This correlates
well with the lack of distinct VSG classes within the subtelomeric archive reported in this
work, likely to result in only small differences in activation probabilities between genes.
These differences appear nonetheless significant, as the study mentioned above reported a
very consistent pattern of expression across eleven rabbit infections; they are expected to
derive from the additive effect of small variations in locus (proximity to expression site),
sequence environment and sequence homology with telomeric VSGs. In this continuum,
the "dramatic" shift from telomeric to array VSGs is liable to remain the only exception to
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a less notable progression across the variant archive, complicating the prospects of
producing an accurate model of VSG hierarchical expression. As the infection progresses,
the variants arising appear to be increasingly unique, found only in single infections, and
are likely to be formed entirely by mosaic genes, through low probability "random" events.
Mosaic genes are likely to be a feature in both "ordered" and "chaotic" stages of antigenic
variation: one testable hypothesis would be that some mosaics would initially appear
alongside functional array genes, due to further recombination of the latter with related
pseudogenes, and then later in infection would manifest as the outcome of rarer
recombination events between more diverged and / or degenerate donors. This could be
tested by monitoring the onset of 10 functional genes across a statistically significant
number of infections. Doing this could define whether timing of appearance is indeed
present and reproducible, rather than stochastic. A "generic" VSG PCR could then be
performed on cDNA from the days in which these VSGs are present, to see whether related
VSGs are consistently being coexpressed in the same time window (or immediately after).
Sampling of variants appearing after 2-3 months of infection could also be carried out, to
probe into the currently unknown depths of antigenic variation.
6.3 VSG array evolution
6.3.1 VSG array structure
The present analysis, as part of the genome sequencing and annotation efforts, has unveiled
much complexity in the organisation and features of the VSG archive. It is now apparent
that VSGs are organised in subtelomeric arrays, in a unique sequence environment in which
VSG cassettes (70-bp to VSG coding sequence) are enriched with ESAG3 and UDP Gal
pseudogenes and VSG genes are interrupted and rearranged around INGI and RHS
sequences (see Chapter 3, section 3.7). A hint uncovering the plasticity of VSG arrays was
provided by early studies comparing the sequence environment of the donor copy of VSG
118 in strain 427 and related strains (Bernards et al., 1986), showing lack of gene order
conservation and breaks of syntheny, leading to a model involving deletion and duplication
of VSG cassettes. This outline has been confirmed: tracing recent duplications in the
genome and looking for putative conversion tracts shows that most gene duplications in
VSG arrays involve 70-bp repeats and the end of the C-terminal domain (data not shown).
A more up to date model of array evolution can now be suggested: shorter rearrangements
(including deletions) and conversions utilising the VSG cassette promote at the same time
.. gene duplication and divergence; these are accompanied by larger scale contractions and
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expansions due to transposition events involving INGI. A role for transposons in reshaping
genomes has been shown in other systems (Kazazian, 2004) and, in the case of
trypanosomes, it could explain large differences in archive size between strains and
between arrays and homologues; on the other hand, cassette duplication might explain the
original expansion of the arrays and the shuffling of sequences covering up larger
rearrangements caused by INGI. That the latter are rarer than 70-bp mediated gene
conversions can be inferred from the low incidence of detection of such event in the
genome (data not shown).
70-bp repeats have been suggested to be related to transposons, as the conserved TGTTG
sequence in the GT-rich tract has been found in eukaryotic transposable elements (Aline et
al., 1985). An alternative scenario would be that they originated from within the VSG
coding sequence: TAATGATGATAATAACAATAATAATGATAATGATAATATTAA41 was found within
the coding sequence of VR 4 (Tb03.IJ15.190, a VSG-related gene), and shorter runs can be
found in several VSG C-terminal domains (data not shown). Whichever might be the
explanation, the highly recombinogenic properties of 70-bp repeats are evident in the
absolute predominance of gene conversion events involving these repeats, both within
arrays (current study, data not shown) and between arrays and expression sites (Peter
Burton, PhD thesis, 2003, University of Glasgow).
Interestingly, gene duplication has recently been proposed to be a form of adaptive
mutation: "a link between gene duplication and mutation is explicit in the finding that
decreased activity of the mismatch repair proteins MLHI or MSH6 increases the rate of
gene amplification in eukaryotic cells" (Caporale, 2003).
6.3.1.1 Antigen archive architecture in other systems
The types of organisation and expansion seen for the VSG archive are not without
precedent. Ina recent study of the silent archive of the antigen (vlp / vsp) genes in
Borrelia hermsii, the spirochete responsible for relapsing fever, an organisation remarkably
similar to that of VSG genes has been found, including a cassette structure and repeats
providing one of the flanks, although downstream, rather than upstream, (Dai et al., 2006).
Most gene conversions in this system appear to use flanks rather than create mosaics, at
least in the first relapse studied (only one mosaic gene detected), and this might suggest a
41 Triplets highlighted with alternating blue and black colour.
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similar hierarchy in switching mechanisms, allowing more complex mosaics to appear later
in infection.
Another example of subtelomeric antigen archive with analogies to the VSG system is that
of Pneumocystis carinii. The -75 copies of the MSG antigen genes are arranged in tandem
arrays and, like VSGs, close relatives are jumbled in the arrays (Keely et al., 2005).
Sequence shuffling seems to be due to intergenic spacer sequences, which appear to be
more conserved than the coding sequence itself, as is the case for VSG cassette flanks.
6.3.2 VSG divergence and VSG pseudogenes
When considering that at least one half to two thirds of the 927 VSG archive has been
analysed, it appears that the level of divergence between VSGs is generally very great. A
conservative definition ofVSG family is proposed here, encompassing genes that are at
least 60% identical at the protein level: these would be defined as orthologues (See Chapter
3, section 3.6). It might be that the high level of divergence (and therefore mutation)
amongst VSGs is required for long-term survival in the field, as this might maximise the
chances of being able to spread in a host population that is already at least partially
immune against the products of a given archive. This need for high levels of mutation
could have in turn pushed for the expansion of the archive, possibly to compensate for the
number of deleterious mutations accumulating; alternatively, mutation and repertoire
expansion could have been (and possibly are) simultaneous, concerted processes, reaching
a steady state based on optimal transmission. The high number of pseudogenes (-90%)'2
might be a side effect of the high mutation rate (in the case of the N-terminal domain)
together with the inaccurate resolution of gene conversion reactions (in the case of the C-
terminal domain). The unusual DNA content (50% ofT residues) and likely instability of
the VSG GPI signal might lead to a heightened level of recombination involving this
sequence; this correlates well with what was observed with regards to cassette duplication
within arrays (see section 6.3.1), where the C-terminal domain is preferentially used as one
of the boundaries of conversion (data not shown). This heightened recombination of a
putatively unstable sequence would lead to errors accumulating, and this is indeed what is
observed in the archive (see Chapter 3, section 3.4), where most C-terminal ends are
defective, due to stop codons or frame shifts. The generation of errors through
recombination could be explained by analogy to the role of polu in somatic hypermutation:
42 Only limited numbers of pseudo genes are present inBorrelia burgdorferi (3 out of 15 silent genes) (Zhang
et al., 1997) and inPneumocystis carinii ("few" out -75) (Keely et al., 2005).
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polu is involved in processing microhomology junctions (similar junctions might be used
in VSG cassette recombination) and has been shown to generate more frameshifts than the
conventional poll3 (Tippin et al., 2004). It might be that a similar error prone polymerase
dedicated to processing microhomology junctions is involved in VSG gene conversion.
Alternatively, the DNA conformation in which VSGs are found might prevent access of
repair factors.
As mentioned above, the extent of divergence needed to produce non-cross reactive coats
is unknown. The detection of point mutations in this study and speculations made so far
on their role should not detract from the possibility that a significant amount of divergence
(e.g. 10%) is required for non cross-reactivity. On the other hand, the level of divergence
might be purely fortuitous, due to the plasticity of the alpha helical conserved regions,
which impose only limited constraint on mutation. This in tum might be the reason for the
lack, within the N-terminal domain-encoding region, of conserved sequences that might
anchor segmental gene conversion, which therefore seems to have to rely on more
extensive homology between donors (see Chapter 4, section 4.7). Again a comparison
with Borrelia burgdorferi is informative: unlike VSGs, the vls surface protein is suggested
to have retained function in infection, and displays six variable and six conserved regions,
resulting in the possibility of utilising the conserved regions as anchors for segmental
duplication, focusing divergence in restricted regions and minimising overall divergence
(Zhang et al., 1997). A comparison of the tertiary structure constraints of other antigens,
together with knowledge of level of divergence within each antigen archive, might provide
an answer as to whether the extensive VSG divergence is due to the lack of strong
restriction in sequence variation of its helical backbone.
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6.4 Perspectives: archive evolution
The high level of divergence might suggest that the whole archive is constantly mutating,
and that mutation occurs at a higher rate than gene conversion and repertoire expansion.
Using the reference genome strain, both gene duplication and mutation can now be
followed over time, allowing analysis of the speed of these events. A new, dynamic era in
trypanosome antigenic variation research has begun.
Figure 6.1: A model of archive evolution.
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7 Appendix
7.1 Supplementary material to Introduction
7.1. 1 Published VSG table
Table 7.1: Summary of all published full-length VSG sequences.
Species are T.b.b. (T. brucei brucei), T.b.r. (T. brucei rhodesiense), T.b.g. (T. brucei
gambiense), T.ev. (T. evans/), T.eq. (T. equiperdum), T.c. (T. congo/ense), T.v. (T.vivax).
Domain combinations with an asterisk beside indicate that the type 2 C-terminal domain is
devoid of cysteines; VSG sequences without a reference were submitted to the database
and are not connected to any publication (unpublished); the four VSG sequences with
"pers. comm." have not been submitted yet.
species Strain VSGname Accession Domain reference
n combination
1 T.b.b. AnTat 1.1ELC P06015 Al (Matthyssens et al. 1981J.
2 T.b.b. AnTat 1.1(B) K00398 Al lP~s et al 1983Ql
3 T.b.b. AnTat 1.10 K00397 Al lP~s et al'1_1983Ql
4 T.b.b. ILTat 1.21/VAT-E X56766 82 ((arril}9_ton et al. 19911
5 T.b.b. ILTat 1.22/VAT-J X56765 A2 (Carrlnqton et al. 19911
6 T.b.b. ILTat 1.23/VAT-G X56768 . B3 _1(arrington et al. 1991)
7 T.b.b. ILTat 1.24 X56767 Al J(arril}9_ton et al. 1991)
8 T.b.b. ILTat 1.25/VAT-A X56769 81 _[(arril}9_ton et al. 1991)
9 T.b.b. ILTat 1.1BC AF317934 C2 Urakawa T. 2000
10 T.b.b. ILTat LlB AF317935 Al Urakawa T. 2000
11 T.b.b. ILTat 1.61(MVSGl CAA09956 81 JMatthews et al. 199Ql
12 T.b.b. ILTat 1.67/VAT-B Al J.D. Bar-ry,_j)ers. comm.
13 T.b.b. ILTat 1.68/VAT-C A2* J.D. Bar-ry,..Q.ers.comm.
14 T.b.b. ILTat 1.69/VAT-D A2 J.D. Barry, pers. comm ..
15 T.b.b. ILTat 1.73 A2 J.D. Barry, pers. comm.
16 T.b.b. MITat 1.1 X56761 A2 l(arrin_g_ton et al. 1991)
17 T.b.b. MITat 1.2 (221) X56762 A2 _(_Carrin_g_tonet al. 1991)
18 T.b.b. MITat 1.4A (117) P02896 Al (Boothroyd et al., 1982)
(Allen and Gurnett, 1983)
_(_Bohmeand Cross 2002).
19 T.b.b. MITat 1.5 (118) X56763 A3 _(_(arrin_g_tonet al. 1991)
20 T.b.b. MITat 1.6 X56764 Al (Carrinqton et al. 1991)
21 T.b.b. MITat 1.11 AY935571 81 Cross G.A. 2005
22 T.b.b. MITat 1.12 AY935577 Bl Cross G.A. 2005
23 T.b.b. MITat 1.13 AY935576 Cl Cross G.A. 2005
24 T.b.b. MITat 1.21 AY935572 A2 Cross G.A. 2005
25 T.b.b. MITat 1.3 AY935575 Bl Cross G.A. 2005
26 T.b.b. MITat 1.8 AY935574 Al Cross G.A. 2005
27 T.b.b. MITat 1.9 AY935573 83 Cross G.A. 2005
28 T.b.b. 427 G4 AAG03079 A2 (Alsford et al. 20011
29 T.b.b. 222 AJ007019 B2 (Ansorge et al 19991
30 T.b.b. Buteba 1 AJ549081 B2 (Hutchinson et al. 2003)
31 T.b.b. Bugosa 1 AJ560648 A3 lHutchinson et al. 2003)
32 T.b.b. AAN78184 C2* B~ O.U'1_2002
33 T.b.b. GUTAT 10.1 AF335471 A2* (laCount et al. 20011
34 T.b.b. GUTAT 10.3 AF335472 C2* (laCount et al. 20011
35 T.b.b. MVAT5-RX2 A45175 Al (Lu et al., 1993; Lu et al.,
19911
36 T.b.b. ILTat 1.3 J01221 Al (Rice-Ficht et al. 1981)
37 T.b.b. MSA1.13 1909283C Al (Kamper and Barbet 199~
38 T.b.g. M62629 Al (Dai Do et al., 1991)
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39 T.b.g. LiTat 1.3 AJ304413 B1 (Berberof et al. 2001)
40 T.b.r. AF097332 B2 (Milner and Hajduk 1999)
41 T.b.r. AAA21275 A1 (Alarcon et al., 1994)
42 T.b.r. LouTat 1 X56643 A1 (Reinitz et al., 1992)
43 T.b.r. WRATat A M33823 B2 (Reddy et al., 1990)
44 T.b.r. WRATat B M33824 B2 (Reddy et si, 1990)
45 T.b.r. MVAT5-like M33825 A1 (Reddy et al. 1990)
46 T.b.r. MVAT4 076421 A1 (Pedram and Donelson,
1999)
47 T.b.r. MVAT7 U83435 C4 (Kim and Donelson 1997)
48 T.b.r. LouTat 1.5 M89932 B2 (Schopf and Mansfield,
1998)-
49 T.b.r. ETat 1.2RC AJ010198 A2 Pays E. 1998
50 T.b.r. ETat 1.2SC AJ010199 A2 Pays E. 1998
51 T.b.r. AnTatl MVAT5 AF259553 A1 (Brinaaud et al. 2001)
52 T.b.r. WaTat 1 M83694 A1 (Barbet et al., 1982)
53 T.b.r. WATat 1.2 M86646 A2 Clarke, M.W 1992
54 T.b.r. WATat 1.12 M83695 A1 (Barbet et sl, 1982)
55 T.b.r. WATat 1.13 M83696 A1 (Barbet et et, 1982)
56 T.b.r. WATat 1.14 M83697 A1 (Barbet et et, 1982)
57 T.b.r. A45175 A1 (Lu et al. 1993)
58 T.b.r. AAA30249 A1 (Kamper and Barret, 1992)
59 T,m. BoTat VSG78-20 M29498 B2 (Roth et al. 1989)
60 T~. BoTat VSG20bis X55534 A2 (Than et st, 1990)
61 T~. BoTat VSG78 M29497 B2 (Roth et al. 1989a)
62 T~. BoTat 1 X60228 A2 (Baltz etal. 1991)
63 r.eo. BoTat VSG20 X16723 C2 (Thon et al. 1989)
64 T.ev. AnTat 3.3 AF317915 A1 Urakawa T., 2000
65 T.ev. AF317914 A2 Urakawa T. 2000
66 T.ev. AF317916 A2 Urakawa T. 2000
67 T.ev. AF317917 A2 Urakawa T. 2000
68 T.ev. AF317918 B1 Urakawa T. 2000
69 T.ev. AF317919 B1 Urakawa T. 2000
70 T.ev. AF317920 Al Urakawa T. 2000
71 T.ev. AF317921 B2 Urakawa T. 2000
72 T.ev. AF317922 B1 Urakawa T. 2000
73 T.ev. AF317923 A2 Urakawa T. 2000
74 T.ev. AF317924 A1 Urakawa, T. 2000
75 T.ev. AF317925 A2 Urakawa T. 2000
76 T.ev. AF317926 A1 Urakawa, T. 2000
77 T.ev. AF317927 B2 Urakawa, T., 2000
78 T.ev. AF317928 A2 Urakawa T. 2000
79 T.ev. AF317929 A2 Urakawa, T. 2000
80 T.ev. AF317930 A2 Urakawa, T., 2000
81 T.ev. AF317931 A2 Urakawa T. 2000
82 T.ev. AF317932 A2 Urakawa T" 2000
83 T.ev. AF317933 B1 Urakawa T" 2000
84 T.ev. ShTat 1.3 AF418693 A1 Zhou J. 2001
85 T.ev. ShTat 1.1 AAS66653 A2 Xiana F. 2004
86 T.ev. ShTat 1.2 AAS66654 B1 XianQ F. 2004
87 T.ev. ShTat 1.5 AY216527 A2 Zhou J. 2003
88 T.c. ILNAR2 IL3000 bVSG U07140 Urakawa T.,1994
89 T.c. ILNAR2 ILNat2.1 U07141 Urakawa T., 1994
90 T.c. ILNAR2 ILNat3.2 U07142 Urakawa T., 1994
91 T.c. ILNAR2 mVSGl M74802 (Eshita et al. 1992)
92 T.c. ILNAR2 MVSG2 M74803 (Eshita et al. 1992)
93 T.c. BeNAR1 BeNatl X79399 (Rausch et al., 1994)
94 T.c. BeNAR1 BeNat1.2 X79400 (Rausch et al., 1994)
95 T.c. BeNAR1 BeNat1.3 X79401 (Rausch et al. 1994)
96 T.c. YNAR1 YNat1.1 M15112 (Strickler et al., 1987)
97 T.e. YNAR1 YNat1.3 M15113 (Strickler et al., 1987)
98 T.v. ILDat2.1 Z48228 (Gardiner et et, 1996)
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7.2 Supplementary material to Chapter 3
7.2.1 VSG table
Table 7.2: Sequence, cassette and locus features of all 940 T. brucei 927 silent array VSGs
analysed.
Locus features include three columns, chr (chromosome number, 1-11, plus 8h for the
homologue array of chr 8), array (I = left subtelomere, r = right subtelomere, n = not at
subtelomere), orient (orientation, b = backwards, t = towards, with respect to general
chromosome orientation). Sequence features include seven columns, FL (full-length, y or
n), IN (intact, no stop codons, y or n), F (putative functional, y or n), N type (N-terminal
domain type, a, b or c; d = degenerate I pseudogene; u = uncertain I atypical; d = too
degenerate to assign to type; ? = no similarity to any domain types; n = not present), C type
(C-terminal domain type, 1 to 6, with type 5 with 8 cysteines present at 5b; for additional
notation see N type), N (N-terminal domain presence, y or n; f = fragment), C (C-terminal
domain, y or n; f = fragment). Cassette features include four columns, 70 (number of 70-bp
repeats upstream of VSGs). Alternate shading of rows matches separate chromosomes I
contigs to which the VSGs belong. No information is available for array and orientation
features of short contigs in chr 9,10 and 11 (names not provided, indicated only as 9, 10
and 11).
GENEdb identifier Locus features Sequence features cassette features
Chr Array Orient FL IN F N C N C 70 ingi E3 UDP
type type GAL
Tb927.1.0S 1 n b y y y b 3 y y 31 n n n
Tb927.1.S20 1 n t n n n n 1d f Y 0 Y n n
Tb927.1.S300 1 r b y Y Y c 2 y y 1 n n n
Tb927.1.S320 1 r b y n n ad 3d v v 1 n n n
Tb927.1.S330 1 r b y y n b 3u y y 0 n n n
Tb927.2.63S0 2 r t y n n ad Sd y Y 0 n n n
Tb927.2.6372 2 r b n n n bd 3d f y 0 n n n
Tb927.2.637S 2 r b n n n bd n f n 1 n n n
Tb927.2.6380 2 r b y n n b 1d y y 1 n n n
Tb927.2.6390 2 r b v n n bd 3d y y 2 n y y
Tb927.2.6410 2 r b y y n au 2u y y 1 n n n
Tb927.2.6430 2 r b y n n b 1d Y y 1 n n n
Tb927.3.120 3 I t y n n b 3d y v ? n y n
Tb927.3.130 3 I t n n n d n f n 1 n n n
Tb927.3.140 3 I t Y n n ad 2d y y 0 n n n
Tb927.3.1S0 3 I t Y Y Y b 3 y y 2 n n n
Tb927.3.170 3 I t Y n n b 3d y y 1 n y n
Tb927.3.180 3 I t y y n a 1u y y 1 n n n
Tb927.3.190 3 t y y y a 2 y y 1 n n n
Tb927.3.200 3 t n n n n d n f 0 y n n
Tb927.3.210 3 t y y n b 3u y y 1 y n n
Tb927.3.220 3 t n n n d 1d f Y 1 n n n
Tb927.3.230 3 t y n n ad 2u y y 2 n n n
Tb927.3.240 3 t Y n n b 1d Y Y 1 n n n
Tb927.3.260 3 t n n n n 1d n y 1 n n n
Tb927.3.270 3 t y n n ad 2 y y 1 n n n
Tb927.3.280 3 t y n n a 1d y Y 1 n n n
Tb927.3.300 3 t y n n b ld y y 1 n n n
Tb927.3.310 3 t y n n ad 3d y y 1 n n n
Tb927.3.320 3 t y n n ad 2 y Y 1 n n n
Tb927.3.330 3 t Y n n d 2d y y 1 n n n
Tb927.3.340 3 t y y y b 6 y v 1 n n n
Tb927.3.350 3 I t y n n ad 4d y y 3 n n n
Tb927.3.360 3 I t y n n bd 1d y y 1 n n n
Tb927.3.370 3 I t y y n au lu y y 1 n n n
Tb927.3.380 3 I t n n n n 3d n y 0 n n n
Tb927.3.390 3 I t Y n n ad 1d y Y 1 n n n
Tb927.3.400 3 I t y n n bd 3d y y 1 n n n
Tb927.3.410 3 I t y n n b 3d y y 5 n n n
Tb927.3.420 3 I t y n n ad 1d y y 1 n n n
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Tb927.3.440 3 I t y y y b 6 v va 2 n n n
Tb927.3,450 3 I t n n n n 3d n v 0 n n n
Tb927.3,470 3 I t y n n b ld y y 1 n v n
Tb927.3,480 3 I t y n n ad ld v v 1 n n n
Tb927.3,490 3 I t y y n a 2u y y 1 n n n
Tb927.3.500 3 I t y n n bd 3d v v 1 n n n
Tb927.3.S8S0 3 r b y n n ad 2d y y 1 v n n
Tb927.3.5860 3 r b y n n a 1d v v 1 n n n
Tb927.3.5870 3 r b n n n n 3d n y 0 n n n
Tb927.3.S880 3 r b y n n a 2d v v 1 n n n
Tb927.3.5890 3 r b y n n au Id v v 1 n n n
Tb927,4.5400 4 r t y y n a 5u y y 0 n n n
Tb927.4.S410 4 r t y y n a 5u y y 1 n n n
Tb927.4.S420 4 r t v v n a 5u v v 1 n n n
Tb927.4.5430 4 r t y y n a 5u y y 1 n n n
Tb927.4.5450 4 r b v n n ad ?d v v 1 3' n n
Tb927.4.S460 4 r b y y y a 2 y v 1 n n n
Tb927.4.5470 4 r b y n n bd 3d v v 1 n y n
Tb927.4.5490 4 r b n n n n 3d n f 0 n n n
Tb927.4.S500 4 r b y n n au 3d v v 1 n n n
Tb927.4.5510 4 r b y n n bd 3d v y 1 n n y
Tb927.4.5530 4 r b y y y a 2 y y 1 n n n
Tb927.4.5540 4 r b v n n ad d v y 1 n n n
Tb927.4.5550 4 r b n n n n 2d n y 0 n n n
Tb927,4.5560 4 r b y y y b 3 y y 2 n n n
Tb927.4.5570 4 r b y n n ad 2 v y 1 n n n
Tb927,4.5580 4 r b y y n a 2u v y 1 n n n
Tb927,4.5590 4 r b y n n ad d v v 1 n n n
Tb927.4.5600 4 r b y n n ad 2d y y 1 n n n
Tb927.4.5610 4 r b y n n bd 1d v y 1 n n n
Tb927,4.5620 4 r b y n n ad d y y 1 n n n
Tb927.4.5630 4 r b n n n n 3d n y 0 n n n
Tb927.4.5640 4 r b y n n bd 1 v v I n n n
Tb927,4.5650 4 r b y n n bd 3d y y 0 n v n
Tb92704.5670 4 r b n n n n 1d n y 1 v n n
Tb92704.5680 4 r b y n n bd 3d y y 1 n n n
Tb92704.5690 4 r b y n n b 6d y v 1 n n n
Tb92704.5700 4 r b y y n a 2u v y 1 n n n
Tb92704.5710 4 r b y n n bd 3d v y 1 n n n
Tb92704.5720 4 r b y n n ad 2d y y 1 n n n
Tb92704.5730 4 r b v n n a 3d v v 1 n n n
Tb92704.5740 4 r b y n n ad 1d v y 1 n n n
Tb927,4.5750 4 r b n n n n d n y 0 n n n
Tb92704.5760 4 r b y n n bd 3d y v 1 n v n
Tb927,4.5780 4 r b y n n bd 3d y v 1 n n y
Tb92704.5800 4 r b n n n n d n f 0 n n n
Tb927.S.180 5 I t v n n ad 1d v v 1 n n n
Tb927.S.190 5 I t y n n a 2d v v 1 n n n
Tb927.5.200 5 I t y n n ad 2d y y 1 n n n
Tb927.S.220 5 I t y n n bd 3d y y 1 n y n
Tb927.5.230 5 I t y Y n a 1u y y 2 n n n
Tb927.S.240 5 I t Y n n bd 1 y v 1 n n n
Tb927.S.2S0 5 I t n n n n 4d n f 0 n n n
Tb927.5.270 5 I t n n n b n f n 2 v n n
Tb927.5.3990 5 n t y y n a ?u v y 0 n n n
Tb927.S,4650 5 r b y n n bd 3d y y 0 n y n
Tb927.S,4670 5 r b v v n a 5u v y 1 n n n
Tb927.S,4680 5 r b y n n ad 2d y y 1 n n n
Tb927.S.4690 5 r b y 'i n a Su v v 15 n n n
Tb927.S,4700 5 r b y n n b 2d y y 3 n n n
Tb927.S,4710 5 r b n n n bd 1d f v 1 v y n
Tb927.S,4730 5 r b y y n c u y y 1 n n n
Tb927.S,4740 5 r b y n n ad 1d v v 3 n n n
Tb927.S.47S0 5 r b y n n b 3d y y 3 n y n
Tb927.S.4770 5 r b y y n a 2u y y 1 n n n
Tb927.S.4780 5 r b v n n ad 1d y y 1 y n n
Tb927.S,4790 5 r b y n n ad 2u y y 0 n n n
Tb927.S.4800 5 r b n n n ad n f n 1 n n n
Tb927.S.4810 5 r b y y n a 4u v v 1 n n n
Tb927.S,4820 5 r b y n n ad 1d y y 1 n n n
Tb927.S.4830 5 r b y n n ad 4d y y 2 n n n
Tb927.S,4840 5 r b y y n a 2u y y 1 n n n
Tb927.S,48S0 5 r b y n n bd 1u y y 1 n v n
Tb927.S,4870 5 r b y n n bd 3d y v 1 n n n
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Tb927.5.4880 5 r b y n n ad id y y 1 n n n
Tb927.5.4890 5 r b n n n n 3d n f 0 n n n
Tb927.5.4900 5 r b y n n ad 2u y y 11 n n n
Tb927.5.49i0 5 r b v n n bd id v v 1 n n n
Tb927.5.4920 5 r b y n n ad 5u y y 1 n n n
Tb927.5.4930 5 r b v n n bd 2 v v 1 n n n
Tb927.5.4940 5 r b y n n ad 2 y v 1 n n n
Tb927.5.4950 5 r b v v n b 6u v v 1 n n n
Tb927.5.4960 5 r b y n n ad 2d y y 1 n n n
Tb927.5.4970 5 r b y n n bd ld y y 1 n n n
Tb927.5.4980 5 r b y n n a 2d y y 1 n n n
Tb927.5.4990 5 r b v n n bd ld y y 1 n n n
Tb927.5.5000 5 r b y n n ad 2d v v 1 n n n
Tb927.5.5010 5 r b v n n bd 3d y y 1 n n y
Tb927.5.5030 5 r b n n n n ld n f 0 n n n
Tb927.5.5040 5 r b y n n a 3d y y 2 n n n
Tb927.5.5050 5 r b y y n b 3u v v 0 n n n
Tb927.5.5060 5 r b n n n bd n f n 2 n n n
Tb927.5.5070 5 r b n n n n 2d n f 0 n n n
Tb927 .5 .5080 5 r b v v v a 2 v y 2 n n n
Tb927.5.5090 5 r b y n n b ld v v 1 n n n
Tb927.5.5100 5 r b y n n cd 5d y y 1 n n n
Tb927.5.5110 5 r b v n n ad id v v 2 n n n
Tb927.5.5120 5 r b y n n ad ld v v 1 n n n
Tb927.5.5130 5 r b v n n b 3d v v 1 n n y
Tb927.5.5150 5 r b y n n ad id y v 1 n n n
Tb927.5.5160 5 r b v n n ad 5d y y 1 n n n
Tb927.5.5170 5 r b y n n bd ld v v 1 n n y
Tb927.5.5190 5 r b y n n bd ld y y 0 n n n
Tb927.5.5200 5 r b n n n bd n f n 1 n n n
Tb927.5.5210 5 r b y v n b 2u v v 2 n n n
Tb927.5.5220 5 r b y n n bd ld y y 1 n v n
Tb927.5.5240 5 r b v n n b d y y 4 n n n
Tb927.5.5250 5 r b n n n n 3d n f 0 n n n
Tb927.5.526O 5 r b v n n b 6d y y 1 n n n
Tb927.5.5270 5 r b y n n cd 2 y v 3 n n n
Tb927.5.5280 5 r b v n n b 3d y y 9 n n n
Tb927.5.5290 5 r b y n n bd 3d y v 1 n n n
Tb927.5.5300 5 r b v n n a 1d y y 6 n n n
Tb927.5.5310 5 r b y n n b 1d v v 2 n n n
Tb927.5.5320 5 r b y n n ad ld y v 2 n n n
Tb927.S.5330 5 r b v n n bd 1d v v 1 n y n
Tb927.5.5350 5 r b n n n n d n y 2 v n n
Tb927.6.5210 6 r b y n n ad 3d v v 1 n n n
Tb927.6.5220 6 r b n n n n 2d n f 0 n n n
Tb927.6.5230 6 r b y n n bd ld v v 1 n n n
Tb927.6.5240 6 r b y y n a 2u v v 2 n n n
Tb927.6.5250 6 r b n n n n 2d n f 0 n n n
Tb927.6.5260 6 r b y y y b 2 y y 1 n y n
Tb927.6.5280 6 r b y n n ad 3d v v 1 n n n
Tb927.6.5290 6 r b y n n ad 2d y y 0 n n n
Tb927.6.5300 6 r b v n n bd 3d y y 2 n n y
Tb927.6.5320 6 r b n n n ad d v f 1 n n n
Tb927.6.5330 6 r b y n n bd 1d y y 1 n n y
Tb927.6.5350 6 r b y n n ad 2 y v 1 n n n
Tb927.6.5360 6 r b y n n ad 2d y y 1 n n n
Tb927.6.5370 6 r b v y v a 2 y y 0 y n n
Tb927.6.5380 6 r b n n n d 2d f f 1 n n n
Tb927.6.5390 6 r b v n n bd 1d y y 1 n y n
Tb927.6.5410 6 r b y n n ad ld v v 1 n n n
Tb927.6.5420 6 r b y n n ad 4d y y 1 n n n
Tb927.6.5430 6 r b n n n ad 2d y f 1 n n n
Tb927.6.5440 6 r b y n n ad 2u v v 2 n n n
Tb927.6.5450 6 r b y y n au 2 y y 0 n n n
Tb927.6.5460 6 r b n n n bd n v n 1 n n n
Tb927.6.5470 6 r b v n n bd 3d y v 0 y n n
Tb927.6.5480 6 r b y n n bd d y v 1 n v n
Tb927.6.5500 6 r b y n n bd ld y y 1 n y n
Tb927.6.5520 6 r b v n n ad 2d v v 1 n n n
Tb927.6.5530 6 r b y n n bd id v v 1 n n n
Tb927.6.5540 6 r b y n n ad 3d v y 1 n n n
Tb927.6.5550 6 r b y y n a 3u y y 1 n n n
Tb927.6.5560 6 r b y n n ad 2 v y 1 n n n
Tb927.6.5570 6 r b n n n n 2d n y 1 v n n
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Tb927.6.5S90 6 r b y n n bd 3d y y 1 n n n
Tb927.6.S600 6 r b y n n b id y y 2 n n n
Tb927.6.S61O 6 r b y n n ad id y y 1 n n n
Tb927.6.5620 6 r b y n n bd id v v 1 n n n
Tb927.6.5630 6 r b y n n au id y y 1 n n n
Tb927.6.S640 6 r b y n n b 2d v v 1 n n n
Tb927.6.56S0 6 r b y n n bu 3d y y 1 n n n
Tb927.6.S660 6 r b y n n ad ld v y 1 n n n
Tb927.6.S670 6 r b y n n ad d y y 0 n n n
Tb927.6.S680 6 r b n n n bd n f n 0 n n n
Tb927.6.S690 6 r b n n n d n f n 1 n n n
Tb927.6.S700 6 r b n n n n 3d n f 0 n n n
Tb927.6.5710 6 r b y n n bd 3d y y 2 n y n
Tb927.6.S730 6 r b y n n ad 2d y y 1 n n n
Tb927.6.S740 6 r b y y n b iu y y 0 n n n
Tb927.6.S7S0 6 r b n n n bd n f n 2 n n n
Tb927.6.S760 6 r b y n n bd 3d y y 1 n y n
Tb927.6.57S0 6 r b y n n cd 3u y y 1 n n n
Tb927.6.S790 6 r b y n n au 2d v v 1 n n n
Tb927.6.SS00 6 r b n n n n 3d n f 0 n n n
Tb927.6.SS20 6 r b n n n ad n y n 1 n n n
Tb927.6.5S30 6 r b y n n ad 2d v v 0 y n n
Tb927.7.110 7 I t v n n bd id v y 1 n n n
Tb927.7.120 7 I t y n n ad 3d y y 1 n n n
Tb927.7.i40 7 I t v n n bd id y y 0 n y n
Tb927.7.iS0 7 I t y n n bd 6 y y 1 n n n
Tb927.7.6S00 7 n t y y y c 1 v y 2 y n n
Tb927.7.6S10 7 n t y n n bd 6d y y 1 n n n
Tb927.7 .6S20 7 n t v n n a 6d v y 1 n n n
Tb927.7.6S30 7 n t y n n b 3d v v 1 n n n
Tb927.7.6S40 7 n t y y n a 3u v v 2 n n n
Tb927.S.i00 S I t n n n ad 2 f y 0 n n n
Tb927.S.110 S I t y n n ad 2d v v 2 n n n
Tb927.S.130 S I t y Y n b 3u y y 1 n y n
Tb927.S.140 S I t n n n d n f n 1 y n n
Tb927.S.iS0 S I t y n n a 3d y v 0 y n n
Tb927.S.160 S I t n n n n 3d n y 0 n n n
Tb927.S.170 S I t y y n c lu y y 1 n n y
Tb927.S.1S0 S I t n n n n 3d n y 0 n n n
Tb927.S.i90 S I t y n n bd 6d y y 1 n n n
Tb927.S.2i0 S I t y n n bd id y y 2 n n y
Tb927.S.220 S I t y n n bd ld v v 1 n n n
Tb927.S.240 S t y n n bd id y y 2 n y n
Tb927.S.2S0 S t y n n bd id v v 1 n n n
Tb927.S.260 S t v n n a 2d y y 2 n n n
Tb927.S.270 S t y n n ad 1 y v 1 n n n
Tb927.S.2S0 S t v v n c 2u y y 3 n n n
Tb927.S.290 S t y n n bd ld v v 1 n n n
lb927.S.300 S t y n n ad 2d y y 1 n n n
Tb927.S.3i0 S t y n n bd ld y y 1 n n n
Tb927.S.320 S t v n n ad 2d y y 0 y n n
lb927.S.330 S t y n n ad 2 v v 2 n n n
Tb927.S.340 S t y n n ?d d y y 3 n n n
Tb927.S.3S0 S t y n n bd 6 y y 1 n n n
Tb927.S.360 S t y n n ad 2d v v 3 n n n
Tb927.S.3S0 S t Y n n bd id y y 2 n y n
Tb927.S.400 S I t y n n b 3d v v 1 n y n
Tb927.S.4i0 S I t y n n ad 3d y y 1 n n n
Tb927.S.420 S I t y n n au id y Y 1 n n n
Tb927.S.430 S I t y n n ad d y v 1 n n n
Tb927.S.440 S I t y n n b d y y 2 n n n
Tb927.S.460 S I t y y n b 3u y v 0 n y n
Tb927.S.470 S I t n n n bd 3d f y y y n n
lbOS.27P2.120 Sh b n n n bd 3d f y 0 y n n
TbOS.27P2.140 Sh b y y n b 6u y y 1 n n n
lbOS.27P2.1S0 Sh b y n n bd ld v v 1 n y n
lbOS.27P2.165 Sh b y n n ?d 3d y y 1 n n n
lbOS.27P2.190 Sh b n n n ad d y f 1 n n n
lb08.27P2.2i0 8h b y n n ad 2 v v 1 n n n
lb08.27P2.220 8h b v y n au 3 y y 1 n n n
lb08.27P2.230 8h b y n n bd id v y 9 n n n
Tb08.27P2.240 Sh b y y y b 3' y y 1 n y n
lbOS.27P2.260 8h b y y n a iu y y 1 n n n
Tb08.27P2.270 8h b v n n a 2d y y 1 n 'n n
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Tb08.27P2.290 8h b y y n b lu y y 0 n n n
Tb08.27P2.3l0 8h b y n n bd d y y 1 n y n
Tb08.27P2.340 8h b y n n ad 3d y y 1 n n n
Tb08.27P2.370 8h b y n n a 2d y y 1 n n n
Tb08.27P2.380 8h b y n n a 3d y y 1 n n n
Tb08.27P2.390 8h b y n n b ld y y 1 n y n
Tb08.27P2.4l0 8h b n n n n d n f 1 .s. n n
Tb08.27P2.435 8h b n n n n 3d n f 1 n n n
Tb08.27P2.460 8h b y y y a 2 y y 1 n n n
Tb08.27P2.480 8h b y n n bu 3d y y 1 n n n
Tb08.27P2.490 8h b y n n au ld y y 2 n n n
Tb08.27P2.5l0 8h b y n n ad 2 y y 2 n y n
Tb08.27P2.530 8h b y n n ad 5d y y 1 n n n
Tb08.27P2.550 8h b y n n ad 3d y y 1 n n n
Tb08.27P2.565 8h b n n n n 6d n f 0 n n n
Tb08.27P2.580 8h b y n n bd 3 y y 1 n n n
Tb08.27P2.6l0 8h b y n n ad 1d y y 1 n n n
Tb08.27P2.620 8h b y n n ad 3d y y 1 n n n
Tb08.27P2.630 8h b y n n bd ld y y 1 n n n
Tb08.27P2.640 8h b y n n bd 1d Y Y 1 n n y
Tb08.27P2.650 8h b y n n a ld y y 1 n n n
Tb08.27P2.660 8h b y n n bd 6d y y 1 n n n
Tb08.27P2.670 8h b y y n b 1u y y 1 n n n
Tb08.27P2.680 8h b y n n bd 3 y y 1 n n n
Tb08.27P2.690 8h b n n n bd ld f y 1 n n n
Tb08.27P2.710 8h b y n n bd ld Y y 1 n n n
Tb08.27P2.720 8h b y n n a 2d y y ? ? ? ?
Tb09.354.00l0 9 b y n n ad 2d y y 2 n n n
Tb09.354.0030 9 b y n n ad 2d y y 1 n n n
Tb09.354.0040 9 b y n n ad 2d y y 0 n n n
Tb09.354.0055 9 b n n n d n f n 1 n n n
Tb09.354.0060 9 b y y n a 2u y y 0 y n n
Tb09.354.0070 9 t n n n ad ld f y 0 y n n
Tb09.354.0090 9 t y y y b 6 y y 1 n y n
Tb09.354.0l00 9 t n n n n 6 n y 0 n n n
Tb09.354.0l20 9 t y n n b ld y y 2 n y n
Tb09.354.0130 9 t y n n bd 3d y y 4 n n n
Tb09.354.0l40 9 t y n n ad 3d y y 1 n n n
Tb09.354.0150 9 t n n n n 2d n y 1 n n n
Tb09.354.0160 9 t y n n b 3d y Y 1 n n n
Tb09.354.0l80 9 t y y n b 3u y y 1 Y Y n
Tb09.354.0200 9 t y n n cd 2 y y 0 n n n
Tb09.354.02l0 9 t y n n ad ld y Y 1 n n n
Tb09.354.0220 9 t y n n b 1d Y Y 1 n n n
Tb09.354.0230 9 t y n n ad 2d y y 1 n n n
Tb09.354.0240 9 t y n n bd 3d Y Y I n n n
Tb09.354.0250 9 t y n n bd ld Y y 1 n n n
Tb09.354.0260 9 t y n n ad 3d y y 1 n n n
Tb09.142.0010 9 t y n n a Id y y 0 n n n
Tb09.142.0020 9 t n n n ad d y f I n n n
Tb09.142.0040 9 t y n n bd 1d Y Y 1 n y n
Tb09.142.0050 9 t y n n ad 3d y y I n n n
Tb09.142.0060 9 t y n n ad 2d y y I n n n
Tb09.142.0070 9 t y n n ad 3d y y 1 n n n
Tb09.142.0090 9 t y n n ad 2d y Y I n n n
Tb09.142.0100 9 t y y n a 5u y y I n n n
Tb09.142.0l20 9 t Y n n bd 3d y y 1 n y n
Tb09.l42.0l30 9 t n n n bd Id y f I n n n
Tb09.142.0140 9 t n n n n ? n y 0 n y n
Tb09.142.0160 9 t y n n ad 1d y y 1 n n n
Tb09.142.0170 9 t y n n bd 3d y y I n n n
Tb09.142.0180 9 t y n n a d y y 2 n n n
Tb09.142.0200 9 t y n n cd d y y 1 n n n
Tb09.142.0210 9 t n n n n 6d n y 0 n n n
Tb09.142.0230 9 t y y n b lu y y I n y n
Tb09.142.0240 9 t y y y b 6 y y 2 n n n
Tb09.142.0245 9 t n n n n 4d n f 0 n n n
Tb09.142.0250 9 t y n n ad Id y y I n n n
Tb09.142.0280 9 t y n n bd 3d y y 1 n y y
Tb09.142.0290 9 t y n n bd 3d y y 1 n n n
Tb09.142.0460 9 t y n n bd 3d Y Y I n n y
Tb09.142.0470 9 t y n n b 3d y y I n n n
Tb09.142.0480 9 t y n n bd 3d Y y 1 n n n
Tb09.142.0490 9 t y n n ad 2d y Y I n n n
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Tb09.I42.0500 9 t y n n ad 5d y y I n n n
Tb09.v4.000I 9 t y n n au 2d s. s. 0 x. n n
Tb09.v4.0002 9 t y n n bd 3 y y I n s. n
No id 9 t n n n n 3d n f 0 n n n
Tb09.v4.0003 9 t y n n bd 3d y y I n n n
Tb09.v4.0004 9 t y n n au Id y 'i 2 n n n
Tb09.v4.0005 9 t Y Y n a 2u y y 2 n n n
No id 9 t y n n ad d y s. n n n
Tb09.I60.0010 9 t y n n a 2d s. s. I n n n
Tb09.I60.0030 9 t y n n ad Iu y y I n n n
Tb09.I60.0040 9 t n n n a n f n I y n n
Tb09.I60.0045 9 t n n n n 4d n f 0 y . n n
Tb09.I60.0060 9 t y n n ad 2d s. s. I n n n
Tb09.I60.0070 9 t y n n bd Id y y 3 n n n
Tb09.160.0080 9 t y n n c 2d y_ s. I n n n
Tb09.160.0100 9 t y n n bd Id y y I n n n
Tb09.v2.0100 9 t n n n n 3d n f 0 n n n·
Tb09.I60.0110 9 t y Y y a 2 y y 2 n n n
Tb09.160.0120 9 t y n n b Id y Y 2 n n n
Tb09.160.0150 9 t y n n ad 2u y y I n _y_ n
Tb09.v2.0110 9 t n n n n 3d n y 0 n n n
Tb09.I60.0I60 9 t y y n a 5u y _y_ 2 n n n
Tb09.160.0170 9 t n n n b d y f I n n y
Tb09.I60.0180 9 t y n n ad d y y I n n n
Tb09.160.0I85 9 t n n n n d n f 0 n n n
Tb09.v2.0120 9 t n n n n Id n f 0 n n n
Tb09.I60.0200 9 t y n n bd Id .s. .s. I n n n
Tb09.I60.0220 9 t n n n ad d y f I _y_ n n
Tb09.v2.0130 9 t n n n n 2d n f 0 y n n
Tb09.I60.0230 9 t y n n ad Id y Y I n n n
Tb09. v2.0I40 9 t t n n n n 3d .s. f 0 n n n
Tb09.I60.0250 9 t t y n n b 6d y _y_ 4 n s. n
Tb09.v2.0I50 9 t t n n n n Id n y 0 n n n
Tb09.160.0260 9 t t y y n au 3 .s. .s. 2 n n n
Tb09.I60.0280 9 t b y y n a 5b u y y 0 y n n
Tb09.244.1940 9 r b n n n n 6d n x 0 n n n
Tb09.244.I930 9 r b y n n ad 3d y f I n n n
Tb09.244.I920 9 r t y n n a 2d y_ _"/_ I n n n
Tb09.v2.0I60 9 r t n n n n Id n f 0 n n n
Tb09.v2.0I70 9 r t y n n ad 2d y Y I n n n
Tb09.244.I890 9 r t n n n n 3d n y 0 n n n
Tb09.244.I880 9 r t y n n ad 4d .s. .x. I n n n
Tb09.244.I870 9 r t y n n a 5u y _"/_ I n n n
Tb09.244.I860 9 r t y n n b Id .s. .s. I n n n
Tb09.244.I8S0 9 r t y n n ad 3d y y I n n n
Tb09.244.I830 9 r t y y n b Iu _"/_ .s. I n n y
Tb09.v2.0200 9 r t y n n bd 3d y y I n s. n
Tb09.244.I800 9 r t n n n ad Id f s. I y n n
Tb09.244.I790 9 r t y y n au Su y y_ I n n n
Tb09.244.I780 9 r t . y n n b Id s. s. 3 n y n
Tb09.v2.0220 9 r t y n n ad 2d y y 1 n n n
Tb09.v2.0230 9 r t n n n d n f n I y n n
Tb09.244.I7S0 9 r t y n n c 5d s. s. I n n n
Tb09.244.1740 9 r t y s. y b I y y 3 n n n
Tb09.244.I730 9 r t n n n n Id n 'f 0 n n n
Tb09.244.I720 9 r t y n n a 6d x. _y_ I n n n
Tb09.244.I710 9 r t y n n a Id y y I n n n
Tb09.244.I700 9 r t y n n a 2 y s. I n n n
Tb09.244.I690 9 r t y n n bd I y y 0 n n n
Tb09.244.I680 9 r t n n n ad 2d y f I y n n
Tb09.v2.0240 9 r b y n n bd Id y y I n n n
Tb09.244.I620 9 r b y n n ad 2d y y I y n n
Tb09.244.I600 9 r b y 'f n b Iu y "/_ 1 n n n
Tb09.244.I590 9 r b y n n bd 3d s. s. 1 n n '1-
Tb09.v2.0250 9 r b n n n n Id n s. 0 n n n
Tb09.244.1580 9 r b y y y a 3 y s. 1 n n n
Tb09.244.1570 9 r b y y n a lu y y 1 n n n
Tb09.244.IS60 9 r b y n n bd 2d y y 1 n n n
Tb09.244.I550 9 r b y n n ad 2 y s. 1 n n n
Tb09.244.1540 9 r b y n n ad 2d y s. 1 n n n
Tb09.244.1530 9 r b s. n n ad Id y _y_ I n n n
Tb09.244.I510 9 r b y n n bd Id y y I n n n
Tb09.244.I490 9 r b y_ n n ad 3d y y 3 n n n
Tb09.244.I480 9 r b s. n n bd 3d y y I n y n
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Tb09.244.l450 9 r b v n n cd 2d V s 1 n n n
Tb09.244.l440 9 r b V n n c 2d y V 2 n n n
Tb09.v2.0260 9 r b n n n n ld n f 0 s. n n
Tb09.v2.0270 9 r t n n n n ld n f 0 V n n
Tb09.244.l4l0 9 r t V Y V b 3 s. s. 1 n n n
Tb09.v2.02S0 9 r t n n n n 3d n f 0 n n n
Tb09.244.I390 9 r t V n n a Id s. s. 2 n n n
Tb09.244.1380 9 r t s. n n ad 3d V V I n n n
Tb09.244.1360 9 r t n n n ad d y n I n n n
Tb09.244.I350 9 r t V n n cd 6d s. s. I n n n
Tb09.244.I330 9 r t n n n d Id f V I n x. n
Tb09.244.1310 9 r t '1- n n ad 2d y y 1 n n n
Tb09.244.I300 9 r t V n n ad d y s. I Y n n
Tb09.244.I280 9 r b s. n n ad Id y V I s. n n
Tb09.244.l260 9 r b V n n ad 5d y y 1 n n n
Tb09.v2.0290 9 r b n n n n 3d n f 0 n n n
Tb09.244.I250 9 r b V n n bd 3d s. x. I n n x.
Tb09.244.l230 9 r b y n n ad 2d V s. 1 n n n
Tb09.v2.0300 9 r b n n n n 3d n f 0 n n n
Tb09.244.I220 9 r b y n n bd d y V 0 n s. n
Tb09.244.l200 9 r b n n n bd n f n 2 n n n
Tb09.244.1190 9 r b V n n bd ld x. s. 1 n n n
Tb09.244.1180 9 r b V n n bd Id V V 1 n V n
Tb09.v2.03l0 9 r b V n n ad ld .s. .s. 1 n n n
Tb09.244.ll40 9 r b V n n ad 2d V V 3 n n n
Tb09.v2.0320 9 r b n n n n ld n f 0 n n n
Tb09.244.1130 9 r b x. n n ad 2 y V 1 n n n
Tb09.244.11l0 9 r b V n n bd ld .s. .s. 1 n n n
Tb09.244.l090 9 r t y n n bd 2d V .t 0 n v n
Tb09.244.l070 9 r t s. n n b 2d V V 3 n n n
Tb09.244.l050 9 r t n n n bd n f n 1 y n v.
Tb09.v2.0330 9 r b n n n n d n f 0 n n n
Tb09.244.l020 9 r b V n n bd 3d y y 0 V n n
Tb09.v2.0340 9 r b n n n d n f n 1 n .s. n
Tb09.244.1000 9 r b V V n a lu V y I n n n
Tb09.244.0990 9 r b x. n n bd 3d y y 2 n n n
Tb09.244.0980 9 r b y n n a 2d y y 1 n n n
Tb09.244.0970 9 r b y n n ad ld .s. .s. I n n n
Tb09.244.0960 9 r b x. n n bd Id y y I n y n
Tb09.v2.0350 9 r b n n n n ld n f 0 n n n
Tb09.244.0930 9 r b y n n a 3d y V 1 n n n
Tb09.244.0920 9 r b V n n ad ld .x s. 1 n n n
Tb09.244.09l0 9 r b y y y a 2 y _y_ 1 n n n
Tb09.244.0900 9 r b y n n bd 3d y '1 1 n n n
Tb09.244.0S80 9 r b n n n bd ld f y I n n n
Tb09.244.0S70 9 r b y n n b ld y y 1 n n n
Tb09.244.0S60 9 r b y n n ad ld y y 0 n n n
Tb09.244.0Sl5 9 r b n n n n 2d n f 0 y n n
Tb09.v2.0360 9 r t n n n n ld n y 0 n n n
Tb09.244.0S00 9 r t y n n ad lu y s. 1 n n n
Tb09.244.0790 9 r t s. n n ad Id y y 1 n n n
Tb09.244.07S0 9 r t y n n a ld s. Y 1 n n n
Tb09.244.0770 9 r t y_ n n bd ld y y 2 n n n
Tb09.244.0750 9 r t y n n ad 5d s. Y 2 n n n
Tb09.v2.0370 9 r b y n n ad 2d s. s. 0 n n n
Tb09.v2.03S0 9 r b n n n ad n f n 1 n n n
Tb09.244.0710 9 r b y n n bd 3d v s. 1 n y s.
Tb09.244.0690 9 r b s. n n ad 2d y V 1 n n n
Tb09.244.0680 9 r b n n n bd d _y_ f 1 n n n
Tb09.244.0670 9 r b y n n ad Id y x. 1 n n n
Tb09.244.0660 9 r b y n n a ld s. V 1 n n n
Tb09.244.0650 9 r b y n n ad 2d _y_ s. 1 n n n
Tb09.v2.0390 9 r b n n n n Id n f 0 n n n
Tb09.244.0640 9 r b y y n a u s. s. 1 n n n
Tb09.244.0630 9 r b y_ n n ad 2d y y 1 n n n
Tb927.2.6480 9 r b y n n ad d .s. Y 1 n n n
Tb927.2.6490 9 r b s. n n ad ld y V 1 n n n
Tb09.v2.0400 9 r b n n n ad d .s. f 1 n n n
Tb927.2.6520 9 r b y n n ad 1d .x. x. 1 n n n
Tb927.2.6530 9 r b y n n bd 1d y V 1 n n n
Tb927.2.6550 9 r b y n n ad 3d y y 2 n n n
Tb927.2.6560 9 r b y n n bd 2d s. s. 1 n y n
Tb09.v1.0950 9 r b y n n cd 2d y y 1 n n n
Tb927.2.6590 9 r b s. n n c 2d y y 2 n n n
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Tb09.v2.0410 9 r b n n n n 1d n f 0 y n n
Tb09.v2.0420 9 r t n n n n 6d n f 0 y n n
Tb927.2.6620 9 r t y n n bd 1d y y 1 n n n
Tb927.2.6630 9 r t n n n d 2 f y 1 n n n
Tb927.2.6640 9 r t n n n ad d y f 1 n n n
Tb927.2.6650 9 r t y y y b 3 y y 1 n n n
Tb09.244.0475 9 r t n n n n 2d n f 0 n n n
Tb09.v2.0430 9 r t y n n ad 6d y y 1 n n n
Tb09.v2.0440 9 r t n n n n 3d n f 0 y n n
Tb927.2.6690 9 r b n n n bd n f n 1 y n y
Tb927.2.6710 9 r b y n n bd 2d y y 2 n n n
Tb927.2.6730 9 r b y n n b 6d y y 1 n n n
Tb09.244.0375 9 r b y n n ad d y y 1 n n n
Tb927.2.6760 9 r b y n n ad ld y Y 1 n n n
Tb927.2.6770 9 r b y n n ad d y y 3 n n n
Tb927.2.6790 9 r b y n n b Id y y 1 n n n
Tb927.2.6800 9 r b n n n d 2 f y 0 y n n
Tb927.2.6830 9 r t y n n bd 1d y y 1 n n n
Tb927.2.6850 9 r t y n n b ld Y Y 1 n y n
Tb09.244.0250 9 r t y Y n u 2u y y 1 n n n
Tb927.2.6880 9 r t n n n d n f n 0 y n n
Tb927.2.6890 9 r t y n n cd 3d y Y 1 n n n
Tb927.2.6910 9 r t y n n ad ld y Y 1 n n n
Tb09.244.0200 9 r t y y n b 3u y y 1 n y n
Tb927.2.6970 9 r t n n n bd n y n 1 n n n
Tb09.244.0l50 9 r b y n n b 3d y y 1 n n n
Tb09.244.0140 9 r b y n n ad 3d y y 1 n n n
Tb09.244.0130 9 r b y n n b 1d y y 1 n n n
Tb09.244.0l20 9 r b y n n ad 5d y y 1 n n n
Tb09.244.0110 9 r b y n n ad 1d y Y 1 n n n
Tb09.244.0090 9 r b y n n b 1d y y 2 n n n
Tb09.244.0080 9 r b n n n ad 1d f y 1 y n n
Tb09.244.0060 9 r b y n n ad 2 y Y 1 n n n
Tb09.244.00S0 9 r b y y n a 2u y y 1 n n n
Tb09.244.0030 9 r b y n n bd Id y Y 1 n n n
Tb09.244.0020 9 r b y n n bd d y y 0 n n n
Tb09.v2.0060 9 r b n n n ad n f n 1 y n n
Tb09.v2.0070 9 r b y n n bd Id y y 1 n n n
Tb09.v2.0080 9 r b y n n ad 2d y y 1 n n n
Tb09.v2.0090 9 r b y n n b 6d y y 2 n n n
Tb09.244.0005 9 r b n n n n d n f 0 y n n
Tb09.2I8.0010 9 t n n n d 1d f y 0 n n n
Tb09.218.0020 9 t Y Y Y c ? y y 2 n n n
Tb09.2l8.0030 9 t Y n n bd 6d y y 0 n n n
Tb09.2l8.0040 9 t y n n cd 5d y Y 0 n n n
Tb09.218.00S0 9 t Y n n bd 1d Y Y 1 n n n
Tb09.218.0060 9 t y n n bd 3d y y 2 n n n
Tb09.218.0070 9 t n n n n 3d n y 0 n n n
Tb09.218.0071 9 t n n n d n f n 1 n n n
Tb09.218.0073 9 t y n n ad 2d y y 0 n n n
Tb09.218.0090 9 t n n n bd n f n 1 y n y
Tb09.218.0110 9 b n n n bd Id Y f 1 n n n
Tb09.v4.0102 9 t y y n b 3u y y 1 n n s
Tb09.2I8.0150 9 t y n n ad Iu y y 2 n n n
Tb09.218.0260 9 t n n n a 1d y f 1 y n n
Tb09.218.0270 9 t y n n a 2d y y 1 n n n
Tb09.2l8.0280 9 t Y Y n b lu y Y 14 n n n
Tb09.218.0290 9 t y_ Y n a u y y 1 n n n
Tb09.218.0310 9 t n n n b d y f 1 n y n
Noid 9 t n n n d 1 f y 0 n n n
Tb09.218.0330 9 t n n n bd d y f 0 n n n
Tb09.218.0340 9 t Y n n b 3d y y 1 n n n
Tb09.2I8.03S0 9 t y n n b Id Y Y 1 Y n n
Tb09.2I8.0360 9 b y n n bd 3d y y 2 n y n
Tb09.218.0370 9 b y n n b 1d y y 1 n n n
Tb09.218.0390 9 b y n n bd Id y y 1 Y n n
Tb09.218.0400 9 b y n n ad 1d y y 1 n n n
Tb09.218.0410 9 b y n n b 6d y y 1 n n n
Tb09.2I8.0420 9 b n n n n d n f 0 n n n
Tb09.2I8.0430 9 b y n n bd 4 y y 2 n y n
Tb09.218.04S0 9 b y n n bd 1d y y 1 n y n
Tb09.218.0470 9 b y n n a 1d y Y 1 n n n
Tb09.v4.0134 9 b y n n ad 2 y y 1 n n n
Tb09.2I8.048S 9 b n n n n d n f 0 n n n
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Tb09.2I8.0490 9 b y y n a Iu y y 1 n n n
Tb09.2I8.0500 9 b v n n bd Id y y 0 y n n
Tb09.v4.0073 9 t y n n b Id y Y 1 n n n
Tb09.v4.0077 9 t Y Y Y b 2 y y 1 n n n
Tb09.354.0270 9 t n n n n 5d n y 1 y n n
Tb09.354.0290 9 t y n n bd Id y y 1 n n y
Tb09.354.0300 9 t y n n a d y y 1 n n n
Tb09.354.0320 9 t y n n bd Id y v 1 n y n
Tb09.354.0330 9 t v n n ad 3d y y 1 n n n
Tb09.354.0350 9 t y n n bd Id Y Y 1 n n n
No id 9 t n n n ad n f n 1 y y n
Tb09.354.0370 9 t y n n ad ?u y y 1 n n n
Tb09.354.0390 9 t y n n bd Id Y y 1 n -"L n
Tb09.3S4.0400 9 t v n n b 3d y v 1 n n n
Tb09.3S4.04l0 9 t y n n ad Id y y 3 n n n
Tb09.3S4.0420 9 t n n n ad ld f f 1 n n n
Tb09.3S4.0430 9 b n n n au n y n 1 y n n
Tb09.354.0440 9 b y n n ad ?u y y 4 n n n
Tb09.v4.0168 9 b y n n b ld y y 1 n n y
Tb09.v4.0l66 9 b v v n a lu y y 1 n n n
Tb09.354.0475 9 b n n n n 1 n f 0 -"L n n
Tb09.3S4.0480 9 b n n n bd d Y f 1 y n n
Tb09.3S4.0490 9 b v n n bd 3d y y 2 n n n
Tb09.354.0500 9 b n n n n ld n f 0 n n n
No id 9 n n n n 2d n f 0 n n n
Tb09.v4.0l77 9 y y y a 1 y Y 3 n n n
No id 9 n n n n 3d n f 0 n n n
Tb09.v4.0178 9 y n n ad 3d y y 1 n n n
Tb10.v4.0001 10 b y y y a 2 y y 10 n n n
TblO.v4.0004 10 b y n n ad 6d y y 1 n n n
Tb10.v4.0005 10 b v n n ad 2u y y 1 n n n
Tbl0.v4.0006 10 b y n n bd ld Y y 1 n n n
Tbl0.v4.0007 10 b v n n b Id y y 1 n n n
No id 10 t n n n n 6d n y 0 y n n
Tbl0.v4.0008 10 t v n n ad 2d y y 1 n n n
Tbl0.v4.0009 10 t y n n bd 2d v y 1 n n n
Tb10.v4.0010 10 t y n n b 3d y v 1 n n n
Tbl0.v4.0012 10 t y n n bd Id y y 1 n n y
No id 10 t n n n n 3d n y 0 n n n
Tb10.v4.0013 10 t y n n bd 6d y y 1 n n n
Tbl0.v4.0014 10 t y n n b Id v y 1 n n y
TblO.v4.001S 10 t y n n bd Id Y y 1 n n n
Tbl0.v4.0016 10 t n n n bd n y n 1 n n n
No id 10 t n n n bd Id f y 0 n n n
Tbl0.v4.0017 10 t v n n ad Id V V 1 n n n
Tb10.v4.0018 10 t V n n ad 2d y y 1 n n n
TblO.v4.0019 10 t y n n cd Id y V 1 n n n
No id 10 y n n bd 3d y v. 1 n n n
No id 10 n n n n 5u f y 1 n n n
Tbl0.v4.0020 10 y n n bd 1 y V 1 n n n
TblO.v4.002I 10 Y n n au d y y 1 n n n
No id 10 n n n n 2d n f 0 n n n
TblO.v4.0022 10 V n n ad 5u y V 1 n n n
TblO.v4.0023 10 y Y n a 5u y y 1 n n n
Tbl0.v4.0024 10 y n n a 3d y V 2 n n n
Tb10.v4.0025 10 y n n a 3d y y 2 n n n
TblO.v4.0026 10 y n n ad 1u y y 1 n n n
Tb10.v4.0027 10 V n n a d y y 1 n n n
Tb10.v4.0028 10 V n n cd 1u V y 1 n n n
Noid 10 n n n d 3d f y 1 n n n
Tb10.v4.0029 10 n n n d d f f 1 n n n
Tb10.v4.0030 10 y n n bd 2d y V 1 n n n
Tbl0.v4.0031 10 y V y b 2 y y 45 n n n
Tbl0.v4.0160 10 t v n n a 2d V V 1 n n n
Tb10.v4.0161 10 t y n n ad 6 y V 1 n n n
Tbl0.06.0030 10 t n n n n 3d n y 0 n n n
Tbl0.06.0040 10 t V V v a 1 y y 1 n n n
Tbl0.06.0050 10 t V n n d 2d Y Y 1 n n n
Tb10.06.0070 10 t n n n bd 3d f V 1 n n n
Tbl0.06.0080 10 t v n n bd 6d y y 2 n n n
Tb10.06.0090 10 t y n n ad 2u y y 1 n n n
Tbl0.06.0100 10 t V n n ad 3d y y 1 n n n
TblD.06.0105 10 t n n n n 3d n y 0 n n n
Tbl0.06.0108 10 t n n n a n y n 1 n n n
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Tb10.06.0110 10 t V n n bd 1d v v 0 n n n
Tb10.06.0120 10 t n n n bd 2d y f 1 n n n
Tb10.06.012S 10 t n n n n 3d n y 0 n n n
Tb10.06.0130 10 t Y n n bd 1d Y Y 2 n n n
Tb10.06.0140 10 t V n n ad Sd V V 1 n n n
Tb10.06.01SS 10 t n n n n 3d n y 0 n n n
Tb10.06.0160 10 t V V n b 3u v V 1 n n n
Tb10.06.0170 10 t Y n n ad Sd y y 2 n n n
Tbl0.06.0180 10 t n n n bd n v n 2 n n n
Tbl0.06.0190 10 t v n n b 1d v v 0 n V .n
Tb10.06.0200 10 t Y n n bd 3d v v 2 n n n
Tbl0.06.0220 10 t Y n n bd 1d y y 1 n n. n
Tbl0.06.0230 10 t V n n a Id y Y 2 n n n
Tb10.06.0240 10 t V n n a 1d V V 2 n n n
Tb10.06.02S0 10 t V n n b 3d y y 1 n n n
Tb10.06.0270 10 t V V n b 3u V V 4 n n V
Tb10.06.0280 10 t V n n ad 2d y y 1 n n n
Tb10.06.0290 10 t y n n ad 2d V V 1 n n n
TblO.06.0300 10 t Y n n a Id y Y 1 n n n
Tbl0.v4.0193 10 t V n n a 2d V V 2 n n n
Tb10.v4.010S 10 b n n n b d y f 1 V n V
Tb10.07.0020 10 b V V n au 2 V V 1 n n n
Tb10.07.0030 10 b y n n bd 1d Y Y 1 n n n
Tbl0.07.0040 10 b y n n bd 3d y Y 1 n n n
Tbl0.07.00S0 10 b n n n n 6d n f 0 y n n
Tb10.07.0060 10 b n n n bd n f n 1 y n n
Tbl0.07.0070 10 b V n n ad 2d y y 1 n n n
Tbl0.07.0080 10 b y n n c 2d y V 1 n n n
Tb10.07.0090 10 b y n n bd Id y y 1 n n n
Tb10.07.009S 10 b n n n n 2d n y 0 n n n
Tbl0.07.0100 10 b y n n a 3d _y Y 1 n n n
Tb10.07.0110 10 b n n n au d V f 1 n n n
Tbl0.07.0120 10 b y n n ?d 2d y y 1 y n n
Tb10.07.0130 10 b y n n ad Id y Y 1 n n n
Tb10.v4.0120 10 b y n n ad 1d y y 1 n n n
Tb10.07.01S0 10 b V n n ad Id y V 1 n n n
Tbl0.07.160 10 b y n n a Sd y y 1 n n n
Tb10.07.0170 10 b y n n bd Id Y Y 1 n n n
Tbl0.v4.0124 10 b y n n ad Id y V 5 n n n
Tbl0.v4.0144 10 b n n n n d n y 0 n n n
Tb10.08.0020 10 b y y n bu 2 y y 1 n n n
TblO.08.0030 10 b V n n bd 2d Y Y 1 n V n
TblD.OB.0040 10 b y n n ad 2d y y 1 n n n
Tb10.0B.00SO 10 b y n n bd 1d Y Y 1 n n n
Tbl0.0B.0060 10 b y n n a 1d y V 1 n n n
Tb10.0B.0070 10 b y n n bd Id Y Y 1 n n n
Tb10.0B.0080 10 b y y n bu 3u y y 1 n n n
Tbl0.08.0090 10 b Y n n b Id Y y 1 n n n
Tbl0.0B.0100 10 b Y n n a Id y Y 1 n n n
Tbl0.0B.OllO 10 b n n n n 3d n y 0 n n n
Tb1D.OB.0120 10 b n n n n 2d n V 0 n n n
Tbl1.01.88S0 11 b y n n bu d y y 1 n n n
Tbl1.0S.0001 11 t n n n ad Id f Y 0 y n n
Tb11.06.0002 11 t Y n n bd Id Y Y 2 n n n
Tbl1.06.0003 11 t y n n b Id y y 1 n n n
Tbl1.09.0001 11 b y n n ad 2d y V 1 n n n
Tbl1.09.0002 11 b y n n ad 2 y y 1 n n n
Tbl1.09.0003 11 b y y V a 2 V Y 2 n y n
Tbl1.09.000S 11 b Y Y Y b lu y y 2 n n n
Tbl1.09.0006 11 b y n n bd Id Y y 2 n n n
Tbll.09.0007 11 b y n n a Id y y 1 n n n
Tbl1.09.0008 11 b y n n ad 2d y Y 1 n n n
Tb11.09.0010 11 b y n n au 3d y y 1 n n n
Tbl1.09.0011 11 b y n n bd 3d y y 0 y n n
Tbl1.09.0012 11 b n n n n 2d n f 0 n n n
Tbl1.09.0013 11 b n n n n d n f 0 n n n
Tbl1.13.0001 11 b y n n ad 2d y V 1 y n n
Tbl1.13.0002 11 b y n n bd 6d y V 2 n n n
Tbl1.13.0003 11 t Y n n bd 3 y y 0 n n n
Tbl1.13.0004 11 b y y n b 2u y y 1 n n n
Tbl1.13.000S 11 b y n n ad 3d y y 0 n n n
Tbll.13.0006 11 b y n n bd Id y y 1 n n n
Tb11.13.0007 11 b n n n d n f n 2 n n n
Tbll.13.0008 11 b y n n bd Id Y Y 0 y n n
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lbl1.14.000l 11 b s. n n ad 6 x. y 1 n n n
lb11.l4.0002 11 b y n n ad 2d .s. s. 2 n n n
lbll.l4.0003 11 b s. n n ad ld y Y 2 n n n
lbll.l4.0004 11 b y n n cd 3u s. s. 3 n y n
lbl1.14.0006 11 b s. n n bd 3d y y 1 n n n
lbl1.14.0007 11 b y y n a 2u .s. 'L 1 n n n
lbl1.14.0008 11 b v. y n a 2u y y 2 n n n
lbl1.l4.0009 11 b y n n bd 1d s. s. 1 n n n
Tbl1.l4.0010 11 b y n n bd 3d y 'L 0 n n n
lbl1.14.0011 11 b y n n ad d y y 1 n n n
lbl1.14.0012 11 b s. n n bd 6d s. y 1 n y n
Tbl1.14.0013 11 b y n n bd 2d 'j_ s. 1 n n n
lb11.14.0014 11 b x. n n a d y y I n n n
lb11.14.001S 11 b y y y b 2 s. s. 1 n n n
lbl1.14.0016 11 b 'L n n ad 3d y s. 1 n n n
lbll.l4.0017 11 b y n n ad 2d s. s. 1 n n n
lb11.14.0018 11 b x. n n ad Id y y I n n n
lb11.14.0019 11 b y y n a 2u s. y I n n n
lb11.14.0021 11 b y n n ad 6d s. s. I n n n
lbll.14.0022 11 b y n n bd Id s. y I n n n
Tbll.14.0023 11 b y n n ad 2d s. s. 1 n n n
lbll.14.0024 11 b s. n n ad Sd y y 1 n n n
lbll.14.002S 11 b y n n ad Sd x. .s. 1 n n n
lb11.14.0026 11 b .s. n n bd 3d y -"- 1 n n nlb11.14.0027 11 b n n n bd 3d f .s. 0 y n n
lb11.14.0029 11 b n n n n 3d n f 0 n n n
Tb11.l4.0031 11 b n n n n 1d n f 0 n n n
Tb11.14.0032 11 b y n n ad 1d y y 1 n n n
lb11.14.0033 11 b n n n n 3d n f 0 n n n
Tbll.14.0034 11 b n n n n 3d n y 0 n n n
lbll.1S.0001 11 b y n n ad Sd y -"- 2 n n nlbll.1S.0002 11 b y n n bd Id _If y I y n n
Tb11.1S.0003 11 t y n n ad 1d -"- s. 1 x. n nTb11.1S.0004 11 t y n n bd 3d y y I n n .s.
lbll.IS.0006 11 t y n n bd 1d -"- .x I n n nlb11.1S.0007 11 t y n n b 3u .s. y 0 n y n
Tb11.16.0001 11 t y n n a 2d -"- s. 1 n n nlb11.16.0002 11 t .s. x. n a 2u y y 1 n n n
lb11.16.0003 11 t y y n a 2u -"- .s. 1 n n nTb11.16.0004 11 t y n n bd 1d y -"- 1 n n nTbI1.20.0001 11 t n n n n 2u n y 0 .s. n n
Tb11.20.0003 11 b y n n ad 1d y .s. 1 .s. n n
Tb11.20.0004 11 b y n n ad 2 y y 1 n n n
Tb11.21.0001 11 t y n n ad Id -"- .s. 2 n n nTb11.21.0002 11 t y n n ad 1d .s. y 1 n n n
Tb11.21.0003 11 t y n n ad 1d -"- .s. 2 n n n
Tb11.21.0004 11 t s. s. n a 2u y y I n n n
Tbl1.21.000S 11 t y n n b 3d s. s. 1 n n n
Tb11.21.0006 11 t y n n bd 1d 'j_ s. 1 n n n
Tb11.21.0007 11 t s. n n ad 2d y y 1 n n n
Tb11.21.0008 11 t n n n d n f n I n n n
Tb11.21.0009 11 t y n n bd 1d s. s. 0 n n n
Tb11.21.0011 11 t n n n bd n y n 1 s. s. n
TbI1.24.0002 11 b y n n a 2d s. s. I n n n
Tb11.24.0003 11 b s. n n bd 1u y s. 1 n y n
Tbll.24.000S 11 b y n n bd 1d s. s. 2 n y n
Tbll.24.0007 11 b s. s. n b lu y y I n n n
Tbll.24.0008 11 b y n n ad d s y 1 n n n
Tbll.24.0009 11 b n n n d 1d f .s. 1 n n n
Tbll.24.0010 11 b n n n n 3d n y 0 x. n n
Tb11.24.0011 11 b n n n b d s. f 1 y n n
Tb11.24.0012 11 b y y n bu 1 s 'L 1 n n n
lb11.24.0013 11 b y n n ad 2d y y ? n ? n
lb11.24.0014 11 b n n . n ad n y n 2 y n n
Tb11.29.0001 11 t 'j_ n n bd 1d y y ? n n n
lbl1.3D.OOOI 11 b y n n a 3d s. s. 9 n n n
Tb11.30.0003 11 b y n n bd 1d y y 1 n s. n
Tb11.30.000S 11 b y n n a 4d s. s. 2 n n n
lb11.30.0007 11 t y n n ad d y s. 0 s. y n
lbl1.30.0008 11 t y n n ad 1d y y 2 n n n
Tb11.30.0009 11 t y_ n n bd 6d y y 2 n n -"-lb11.30.0010 11 t y n n a 2d x. x. I n n n
lbll.30.0012 11 t Y n n b 1d y y 1 n 'f_ n
lb11.30.0013 11 t _'f_ n n ad 2d y y 1 n n n
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lb11.30.0014 11 t y n n bd 2d y y 1 n n n
lb11.3Q.001S 11 t y n n a 2d y y 1 n n n
lb11.30.0016 11 t v. n n ad lu y y 1 n n n
lb11.32.0001 11 t y n n ad 2u y y 1 n n n
lb11.32.0002 11 t Y n n a ld y y 1 n n n
lb11.34.0001 11 t y n n bd 3d y y 1 n n n
lb11.3S.000l 11 b y y n a lu y y 2 n n n
lb11.3S.0002 11 b y n n b 3d y y 2 n n n
lb11.3S.0003 11 b y n n bd 3d y y 2 n y n
lb11.3S.000S 11 b y n n bd 3d y y 1 n n n
lb11.3S.0006 11 b y n n a 3d y y 1 n n n
lb11.38.0001 11 b n n n b n y n 1 y n n
lb11.38.0002 11 b y n n a 1d y y 1 n n n
lb11.38.0003 11 b y y y b 1 y y 2 n n n
lb11.38.0004 11 b y n n bd 1d y y 1 n n n
lb11.38.000S 11 b y y n b 1u y y 1 n n n
lb11.38.0006 11 b y n n c 2d y y 2 n n n
lb11.38.0007 11 b y y y a 2 y y 1 n n n
lb11.38.0008 11 b n n n n d n f 0 n n n
lb11.38.0009 11 b n n n n 3d n f 0 n n n
lb11.41.0001 11 t y n n b 1d y y 1 n n n
lb11.43.0001 11 b y y n bu lu y y 1 n n n
lbl1.43.0002 11 b y n n ad 2d y y 1 n n n
lbl1.43.0003 11 b y n n bd 1d y y 1 n n n
lb11.43.0004 11 b y n n ad 2d y y 1 n n n
lb11.44.0002 11 t y n n bu ld y y 0 y y n
lb11.44.0004 11 t y n n bd 1d y y 1 n n y
lb11.44.0006 11 t y n n bd 3d y y 1 n y n
lb11.44.0007 11 t y n n ad 4d y y 2 n n n
lb11.44.0008 11 t n n n n 3u n f 0 n n n
lb11.44.0009 11 t y n n cd Su y y 1 n n n
lbll.44.0010 11 t y n n b 6d y y 2 n n n
lb11.4S.0001 11 b y n n a 1d y y 1 n n n
lb11.4S.0002 11 b y n n b 3d y y 1 n n n
lb11.4S.0003 11 b y n n b 3d y y 1 n y n
lb11.48.0002 11 t y n n bd 3d y y 2 n y n
lb11.48.0003 11 t y n n a 3d y y 1 y n n
lbll.49.0002 11 t y n n b 2d y y 1 n y n
lb11.49.0003 11 t y n n ad 2u y y 1 n y n
lb11.49.0004 11 t n n n bu d y f 2 n y n
lb11.49.000S 11 t y n n a d y y 0 n n n
lb11.49.0007 11 t y n n bd 3d y y 1 n n y
lb11.49.0008 11 t y n n cd 1d y y 1 n n n
lb11.49.0009 11 t y n n ad 1d y Y 1 n n n
lb11.49.0010 11 t y n n ad 2u y y 1 n n n
lbll.49.0012 11 t y n n bd 3d y y 1 n y n
lb11.S1.000S 11 t y y y a 2 y y 7 n n n
lb11.S4.0001 11 t y n n ad 2u y y 1 n n n
lb11.57.0011 11 t y n n cd d y y 1 n n n
lb11.S7.0012 11 t y n n b 3d y y 1 n n n
lb11.S7.0013 11 t n n n n 3d n f 0 n n n
lbll.S7.001S 11 t y n n b 6d y y 0 n y n
lb11.S7.0016 11 t n n n n d n y 0 n n n
lb11.S7.0018 11 t n n n d n f n 1 y y n
lb11.S7.0019 11 b y y n a 2u y y 1 n n n
lb11.S7.0020 11 b y n n ad 2d y Y 1 n n n
lb11.57.0021 11 b y n n bd 1d y y 1 n y n
lb11.S7.0023 11 b y n n ad 1d y y 2 n n n
lb 11.57.0024 11 b y y n b 1u y y 2 n n y
lb11.S7.0026 11 b y n n ad 3u y y 1 n n n
lb11.57.0027 11 b y n n bu 1d y y 1 n n n
lb11.57.0028 11 b y n n ad 5 y y 1 n n n
lb 11.57.0029 11 b y n n ad 4d y y 1 n n n
lb11.S7.0030 11 b y n n ad 2d y y 1 n n n
lb11.57.0031 11 b y n n ad 2d y y 1 n n n
lb11.57.0032 11 b y n n bd d y y 2 n n n
lbll.57.0033 11 b y n n bd 1d y y 0 n y n
lb11.S7.003S 11 t y y n a 2u y y 0 n n n
lb11.S7.0037 11 t y n n b 3d y y 1 n y n
lb11.57.0038 11 t y n n ad 2d y y 1 n n n
lb11.57.0039 11 t Y n n ad 2d y y 1 n n n
lbl1.57.0040 11 t y n n ad 1d y y 1 n n n
lb11.57.0041 11 b y n n bd 3d y y ? n n n
lb11.57.0043 11 t Y n n bd 2d y y 2 n n n
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Tb11.v4.00n 11 t y n n ad 2 y y 1 n n n
Tb11.57.0045 11 t v n n b ld y y 0 n n n
Tbl1.57.0049 11 b y n n bd 3d v v 1 n y n
Tb11.57.00s1 11 b v n n ad ld y y 1 n n n
Tb11.57.00s2 11 b y y n b lu v v 1 n n n
Tbl1.57.00s3 11 b v n n bd lu y y 1 n n n
Tb11.57.00s5 11 b v n n bd ld v v 1 n n n
Tb11.57.0076 11 t n n n d d f y 0 y n n
Tb11.57.0082 11 t v n n bd 2 y y 2 n y n
Tb11.57.0083 11 t v n n ad 2d v y 1 n n n
Tb11.57.0084 11 b y y v a 2 v v ? n ? ?
Tb11.57.0085 11 b n n n n d n f 0 n n n
Tb11.57.0086 11 b n n n n d n f 0 n n n
Tb11.57.0087 11 t n n n n 1d n v 1 n n n
Tb11.57.0088 11 t n n n n 4d n f 0 y n n
Tb11.v4.0010 11 t n n n a d y f 1 y n n
Tb11.v4.0015 11 t v y v a 2 v v 6 n n n
Tb11.v4.0016 11 t y n n a 1d y y 1 n n n
Tb11.v4.0021 11 y y n a 4u v y 1 n n n
Tb11.v4.0027 11 n n n a 3d y f 1 n n n
Tb11.v4.0028 11 v n n a ld y y 1 n n n
Tbl1. v4.0029 11 y y y a 5 v y 1 n n n
Tb11.v4.0030 11 v v n a 2u y y 1 n n n
Tb11.v4.0033 11 y n n b 1d v v 2 n y n
Tbl1.v4.0034 11 v v v b 3 y y 1 n n y
Tbl1.v4.0035 11 y n n b 1d y y 1 n n n
Tb11.v4.0036 11 v v' n b 5b u y y 2 n n y
Tb11. v4.0038 11 y y y b 6 v v 1 n y n
Tbll.v4.0040 11 y y n a 2u y y 1 n n n
Tbl1.v4.0050 11 y y y b 1 y y 11 n n n
Tb11.v4.0058 11 v y v b 6 v y 2 n y n
Tb11. v4.0063 11 y n n a 1d v v 1 n n n
Tb11.v4.0065 11 v v n a 2u y y 2 n n n
Tb11.v4.0067 11 y n n b 1d v v 1 n n n
Tb11.v4.0068 11 v n n b 1d y y 1 n n n
Tb11.v4.0070 11 y n n a 1d v v 1 n n n
Tb11.v4.0074 11 v n n ad 6 y y 1 n n n
Tb11.56.0001 11 v n n ad 2d y y 2 n n n
Tb11.56.0002 11 v n n b 1d y y 1 n n n
Tb11.56.0003 11 y n n ad 3d v y 1 n n n
Noid 11 n n n n 2d n f 0 n n n
Tb11.56.0004 11 v n n ad 1d y v 1 n n n
Tb11.56.0006 11 v n n bd 1d y y 1 n n n
Tb11.01.8840 11 n n n d 2d y f 3 y n n
Tb11.1085 11 y n n ad 1d y y 1 y n n
Tb11.0905 11 n n n n 3d n y 0 n n n
Tb11.0910 11 y y y a 1 y y 1 n n n
Tb11.01.8870 11 y n n a 1d y y 1 n n n
Tb11.01.8880 11 y n n ad 5d y y 3 n n n
Tb11.0935 11 n n n n 3d n y 0 n n n
Tb11.01.8890 11 v n n bd 3d y y 2 n n n
Tb11.01.8910 11 y n n bd Id y y 0 n n n
Tb11.01.8920 11 y n n a 1d y y 1 n n n
Tb11.1145 11 n n n n 6d n y 0 n n n
Tb11.01.8930 11 n n n b 2d y f 2 n y n
Tb11.0495 11 v n n ad 1d y y 0 n n n
Tb11.0500 11 y n n ad 6d y y 1 n n n
Tb11.0510 11 v n n ad 1d y y 1 n n n
Tb11.0610 11 y y n b 1u v n 2 n n n
Tb11.0620 11 y n n ad 2d y n 1 n n n
Tb11.57.0058 ? v n n ad 2d y y 1 n n n
Tb11.57.0059 ? y n n ad d y y 1 n n n
Tb11.57.0060 ? v n n bd 1u f n 1 n n n
Tb11.57.0061 ? n n n d 1u f y 1 n n n
Tb11.57.0063 ? v n n ad 3d y y 2 n n n
Tb11.57.0064 ? v n n bd 1d v v 2 n n n
Tb11.57.0065 ? v n n bd ld y y 0 y n n
Tb11.28.0001 ? v y n a 2u y y 1 n n n
Tb11.28.0002 ? n n n n 3d n y 0 n n n
Tb11.40.0001 ? y n n ad d y y 1 n n n
TbI1.40.0002 ? y n n a 2d y y I n n n
Tb11.40.0004 ? v n n ad 2d y y 1 n y n
Tb11.40.0005 ? y n n b 1d y y I y n n
TbI1.40.0006 ? y n n b Id y y I y n n
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Tbl1.40.0007 ? y y n a lu y y 1 n n n
Tbll.40.0008 ? y n n b 6d y s. 1 n n y
Tbll.57.0066 ? y n n b ld y y 1 n n n
Tbl1.57.0067 ? y n n ad 2u y s. 1 n n n
Tbll.57.0070 ? y n n bd 6d y y 1 n s. X
Tb11.57.0071 ? y n n ad d y .s. 1 n n n
Tbll.57.0072 ? y n n bd 3d y y 1 n n n
Tbll.57.0073 ? y n n bd 2d y y 1 n n n
Tb11.57.0074 ? y n n a 1d y y 1 n n n
Tb11.57.0075 ? y n n bd 1d y y 1 n n n
Tbll.31.0001 ? y n n ad 6 y .s. 1 n n n
Tb11.57.9999 ? n n n n d n f 0 n n n
7.2.2 Atypical VSG table
Table 7.3: Atypical VSGs and associated departures from expressed VSG consensus
sequence.
The first column gives the GeneDB identifier, the second and third give the N and the C-
terminal domain type, respectively. Domain types followed by u (uncertain), Indicate they
include "atypical" features. The remaining eight columns each highlight different problems
associated with these VSGs. "GPI cl" indicates mutations at the cleavage site. "GPI hyd
polar/not cons" indicates that the GPI signal hydrophobic extension contains polar or non
conserved amino acids. "GPI hyd short" indicates that the GPI signal hydrophobic
extension is shorter than the consensus, whereas "GPI hyd long" indicates that it Is longer
than the consensus. "cys C t" indicates non-conserved cysteine pattern in the C-terminal
domain. "type 5" refers to C-terminal type 5, for which no consensus or cleavage site
requirements are known. "Sig pep" indicates weak signal peptide prediction. "cys Nt"
indicates non-conserved cysteine pattern in the N-terminal domain. A description for each
individual gene is available at VSGdb.
Atypical VSGs N C GP! GP! GP! GP! Cys Type Sig Cys
d Hyd hyd hyd et 5 pep Nt
Polar/ short long
not
cons
summary 38 22 9 19 30 12 5 4
Tb927.1.S330 b 3u 1 0 0 0 0 0 0 0
Tb927.2.64l0 au 2u 0 0 0 1 0 0 0 0
Tb927.3.210 b 3u 0 1 0 0 0 0 0 0
Tb927.3.370 au lu 1 0 0 1 0 0 0 0
Tb927.3.l80 a lu 1 0 0 0 0 0 0 0
Tb927.3.490 A 2u 0 0 0 1 0 0 0 0
Tb927.4.S400 A Su 0 0 0 0 0 1 0 0
Tb927.4.S410 A Su 0 0 0 0 0 1 0 0
Tb927.4.S420 A Su 0 0 0 0 0 1 0 0
Tb927.4.S430 A Su 0 0 0 0 0 1 0 0
Tb927.4.SS80 A 2u 1 0 0 0 0 0 0 0
Tb927.4.S700 a 2u 1 1 0 0 0 0 0 0
Tb927.S.230 a lu 1 0 0 0 1 0 0 0
Tb927.S.49S0 B 6d 0 0 0 0 1 0 0 0
Tb927.S.S0S0 B 3d 0 0 0 1 0 0 0 0
Tb927.S.4670 a Su 0 0 0 0 1 1 0 0
Tb927.S.4690 a Su 0 0 0 0 0 1 0 0
Tb927.S.4730 c 4u 1 1 0 0 1 0 0 0
Tb927.S.48l0 a 4d 0 0 0 1 1 0 0 0
Tb927.S.4840 A 2u 0 0 0 1 0 0 0 0
Tb927.S.3990 a ?u 1 1 0 0 0 0 0 0
Tb927.S.S2l0 b 2u 1 0 0 1 0 0 0 0
Tb927.S.4770 A 2u 0 1 0 0 0 0 0 0
Tb927.6.S240 a 2u 0 0 0 0 1 0 0 0
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Tb927.6.5450 au 2 0 1 0 0 0 0 1 0
Tb927.6.S550 a 3d 0 1 0 0 0 0 0 0
Tb927.6.S740 b ld 0 1 1 0 0 0 0 0
Tb927.7.6540 a 3d 0 0 0 1 0 0 0 0
Tb927.S.170 C ld 1 0 0 0 0 0 0 0
Tb927.S.2S0 C 2d 0 0 0 1 0 0 0 0
Tb927.S.130 B 3u 1 1 0 0 0 0 0 0
Tb927.S.460 B 3u 1 0 0 0 0 0 0 0
TbOS.27P2.140 b 6d 1 0 0 0 0 0 0 0
TbOS.27P2.220 au 3 0 0 1 0 0 0 1 0
TbOS.27P2.260 a ld 0 0 0 0 1 0 0 0
TbOS.27P2.290 b ld 1 0 0 0 0 0 0 0
TbOS.27P2.670 b ld 0 0 0 1 1 0 0 0
Tb09.142.0100 a 5d 0 0 0 1 0 1 0 0
Tb09.142.0230 b ld 1 0 1 0 1 0 0 0
Tb09.160.0160 A 5u 0 0 0 0 0 1 0 0
Tb09.160.0260 ad 3 0 0 0 0 0 0 0 1
Tb09.160.02S0 a Su 0 0 0 0 0 1 0 0
Tb09.244.00S0 a 2u 0 1 0 0 0 0 0 0
Tb09.244.1000 a lu 0 1 0 0 0 0 0 0
Tb09.244.1570 a ld 1 0 0 1 1 0 0 0
Tb09.244.1600 b 1 0 0 1 0 0 0 0 0
Tb09.244.1790 Au Sd 0 0 0 0 0 1 0 0
Tb09.244.1830 b ld 1 0 0 1 1 0 0 0
Tb09.354.0060 a 2u 0 1 0 0 0 0 0 0
Tb09.354.01S0 b 3u 1 1 0 0 0 0 0 0
Tb09.244.0640 a d 1 0 0 0 0 0 0 1
Tb09.244.0250 a 2u 0 1 0 0 0 0 0 0
Tb09.244.0200 b 3d 1 0 0 1 1 0 0 0
Tb09.218.02S0 b lu 1 0 0 0 1 0 0 0
Tb09.21S.0290 a u 1 0 0 0 1 0 1 0
Tb09.21S.0490 a lu 0 0 0 0 1 0 0 0
Tb09.v4.0102 B 3u 1 0 0 0 1 0 0 0
Tb09.v4.0166 A lu 0 0 0 0 1 0 0 0
TblO.06.0160 b 3d 1 0 0 1 1 0 0 0
TblO.06.0270 B 3u 1 1 0 0 1 0 0 0
TblO.07.0020 Au 2 0 0 0 0 0 0 0 1
TblO.OS.OO20 Bu 2 0 0 0 0 0 0 1 0
TblO.OS.OOSO B 3u 1 0 0 0 0 0 0 0
TblO.v4.0023 A Su 1 0 0 0 0 1 0 0
Tbll.0610 B lu 0 0 1 0 1 0 0 0
Tbl1.13.0004 B 2d 1 0 0 0 1 0 0 0
Tbll.14.0007 A 2u 0 1 0 1 0 0 0 0
Tbll.14.000S a 2u 0 1 0 0 0 0 0 0
Tbl1.14.0019 a 2u 1 0 0 0 0 0 0 0
Tbll.16.0002 a 2d 0 0 1 0 0 0 0 0
Tbll.16.0003 a 2d 1 0 0 0 1 0 0 0
Tbl1.21.0004 a 2u 0 0 0 0 1 0 0 0
Tbll.24.0007 b ld 0 0 0 1 0 0 0 0
Tbll.24.0012 bu 1 0 0 0 0 0 0 0 1
Tbl1.35.0001 a ld 1 0 1 0 0 0 0 0
Tbll.3S.0005 b ld 0 0 0 0 1 0 0 0
Tbll.43.0001 bu d 1 0 1 0 1 0 1 0
Tbll.S7.0019 a 2u 1 1 0 0 0 0 0 0
Tbll.S7.0024 b lu 1 1 0 0 0 0 0 0
Tbll.S7.0035 a 2u 1 0 0 0 0 0 0 0
Tbll.S7.0052 b lu 0 1 1 0 1 0 0 0
Tb09.v4.000S a 2u 1 0 0 0 1 0 0 0
Tbll.v4.0021 a 4u 0 1 0 0 0 0 0 0
Tbll.v4.0030 a 2u 1 0 0 0 1 0 0 0
Tbll.v4.0036 b Su 0 0 0 0 0 1 0 0
Tbll.v4.0040 a 2u 1 1 0 0 0 0 0 0
Tbll.v4.0065 A 2u 0 0 0 1 0 0 0 0
Tbl1.2S.0001 A 2u 0 0 0 0 1 0 0 0
Tbl1.40.0007 A lu 0 0 0 1 1 0 0 0
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7.2.3 C-terminaJ type 5 domain alignment
Alignments were performed with clustalX, then edited with Bioedit. The edited sequences
were realigned using ClustalW at Poly bioinformatique Lyonnais (http://npsa-
pbil.ibcp.fr/cgi-binlnpsa automat.pl?page=npsa clustalw.html), for the graphical output
style.
Sex_CMI09-04-02
Sf_TbllS70028
Sa Tb092441870
Sp_Tb092440120
Sa_Tb091600160
Sp_Tb09v40079
Sp_Tbl10930
sf Tbllv40029
Sp_Tb0924417S0
Sp_Tb091420100
Sa_Tb927S4920
sa_Tb092441790
Sa_TblOv40022
Sa_TblOv40023
Sp_TblOV40179
Sa_Tb92754670
Sa_Tb92754690
Sp_Tb927SS100
Sp_Tb092441260
Sa_Tb0827P2S30
Prim. cons.
GDNKTNAAACKGTEEGKCDTKl)OAWDKDNKECKVKEGAAVISYLMKVPLLLAFLLL-
GDNKTNADAOKGTEEGKCDTK5.OAWDKDNKECKAKEGAAVISYLMKVPLLLAFLLLQ
GDNKTNAAACKGTEEGKCDTK~OTWDKDKNEOKVKEGTFFISAVMKAPLLLAFLLL-
GDNKTTAADOKASSETNODKT CDWNAEKKQCKVKEGAAVISAVIKSPLLLEFLLLA
DTVA- -TTD8AATEADKODTT CTWNKEKEK ,KVKDGAFIISAVIKSPFALFLLLP-
HNKA--ATEOLATEEKDCDKT CNWNKEKSEOKVKEGVFIISAVIKTTLLLAILFLY
GDKK--DEEOKGKLETN DTT CTWNKEENECKVKKGAAVISAVlKAPLLPAFLLF-
OEWNKEKNEOKVKESAFIISVSlKAILLLKYFGFS
EQNK--AEVCTATEEKDODTK~CDWNAENKQ KVKEGTVIISALMKAHLLLAFLIL-
GDNKTTAADFTGTEED CDKT CDWNKEKNE KVKEGAVVISAVINAPLLLAFLlLA
GETK---EECTGTVETD DKT CTWNKEKNECKVKES-AYISSVTKVPLLLAFLLL-
GEKK---EECTGTVETDCDKT CTWNKEKNEOKVKES-AYISSVTKVPLLLAFLLL-
DDKT--GAEOTATEEGKCDKNKCTWDKEKNQOKVKEGA-VISAVIKVLLVLAVLLF-
GDNKTTAAECKATEEG CDKT CTWNAEKKQFKVKEGAAVISAVlKAPLLLAFLLI-
GDNKTTTAD TGTEEG CDKTI)CDWNAEKKQOKVKEGAAVISAVlKAPLLLAVLLP-
GDNKTTAAEOKATEEGKCDKN~pDWDKEKNECKVKIA-VVISAVTKVPLLFLQLFLE
GSKE--KNECTATEEGKYDKN CTWDKEKNECKVKEGAVVISAVTKAPLLLAFLLF-
GDNKAIATDOKATEEGKCDKEKWTWDKEKKE ,KVKEG-AVLLAVIKVPLLFAFFLLA
* * *: ::.: *.*
GDNKTTA2ECTGTEEGKCDKTK TWNKEKKEOKVKEGAAVISAVlKAPLLLAFLLLA
Figure 7.1: Alignment of novel type 5 C-terminal domain silent copies with the C-terminal
domain of expressed VSG CMI 09-04-02.
Cysteines are highlighted in yellow. The cleavage site is unknown, but could occur after the
last glycine, as glycine is a known acceptor of GPI anchors. Each VSG is given the GeneDB
identifier, preceded by 5ex, 5f, 5a, 5p (expressed, putative functional, atypical and
pseudogene, respectively).
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7.3 Supplementary material to Chapter 4
7.3.1 Primers
Table 7.4: Primers used in Chapter 4 experiments.
Primername sequence
CloningofexpressedVSGs
Splicedleader GTTTCTGTACTATATTG
16mer GTGTTAAAATATATCA
InternalprimersforVSG sequencing
2-1 Nifor CGCAAACGCAACTATTAGCC
2-1 Cirev CAAGTGCAACAGCCTTCTTG
3-1Nifor CAACAGCCAAATAAACGCCC
3-1 Cirev TCAAGCTTATTGCACTCGGC
3-4Nifor AAGCTGCACCTACTAAGCGC
3-4 Cirev GCAGTTAGCGTCTGTGCAAG
4-1 Nifor GAGCTAGCAGGCTGCTTAAC
4-1 Cirev GCATCCCTTACCCTCAAGGT
4-2 Nifor AATGGCTGAATGCTGCATCA
4-2 Cirev TTGCCATGTCGCTAGAAGAG
5-1Nifor AAAAGCGGACACGGCCGCAG
5-1 Cirev GATGGTTGTGCGCAGAAGAA
5-2Nifor TAAATTTCTAACGGCGATCG
5-2 Cirev CGCTAAATCAGCCTTGCCTC
7-1Nifor AGCAGACTCGCCGACTTAAA
7-1 Cirev GCAGTATCAGTGCGCCTTCT
7-2Nifor CTATCAACAAACAACGCGGC
7-2 Cirev CGGGCTAGCAGTACATGTCA
7-3Nifor CGAGCACAAAAACGGCATAA
7-3 Cirev2 CGTGGCTAGGGGCTCTAGAT
7-4Nifor AGTAACAGACAGGGCCAACG
7-4 Cirev2 AAGCTGCTTAATGAAGTCATCGT
8-3Nifor GCTCTCAGCCTAGGAAGCAA
8-3 Cirev TCAGTGTTGGCGCTATTGTT
10-2Nifor GCATAGCAGCAGCACAGAAA
10-2Cirev GTTCCTGTTGCTGGGTTTGT
10-3Cirev GTTGGTTCGCCTTTCACTGT
10-7Nifor CGCTGAAAAATTTACTCGGC
10-7Cirev TTGTGTTATCTGCGTCGCA
10-10Nifor TGAAGTCGAACGGACAATTG
10-10Cirev TTGTGTTATCTGCGTCGCA
11-1Nifor CACTCAATGGACAAGTGCGG
11-1Cirev TTGGAGCTGTAGTGCCTCCT
11-2Nifor AGCAAGCCTCCAGGTATTCA
11-2Cirev GTATTGGTAGTGGCGCTTGG
11-9Nifor AAAACTCAAAAGGGTCGTGA
11-9Cirev GTTCCTGTTTTGGATTTGCA
11-13Nifor CGGAGTTACTCAGGAAAGCC
11-13Cirev AGCCGCTGTTTTGCGTATAG
Testingwhetherclone28-10-02isamosaic
10-2dA 95for GACAGGCAGCGGATGACCAG
10-2dA 671for ACGGCCAAACCGGGATGAAA
10-2dB648for CGACTTAGTCTGTCTTTGTG
10-2Db 89for CCATTGTCGACGCAACCGTT
10-2dB 657rev GGCCGTCGACACAAAGACAG
10-2dB 1001rev CCAGCGGATCTCGCTGTTCC
10-2dB 1362rev TGCTTTCTATGCCAGTACAT
10-2dA 1024rev ATCGCTTCGCGGACTTCCTC
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7.3.2 Table with extended details of all sequenced clones
Table 7.5: Donor and location of each independent sequenced VSG clone.
Clone VSG donor id Donor location Donor features Dom VSG
and dom type type n
03-01-01 Tbl0.v4.0001 BES chr 10 Functional A2 I
03-01-02 Tbl0.v4.0001 BES chr 10 Functional A2 1
03-02-01 Tb10.v4.0001 BES chr 10 Functional A2 I
03-02-02 Tb10.v4.0001 BES chr 10 Functional A2 I
09-03-01 reads Minichromosome? ? A6 2
09-03-03 reads Minichromosome? ? A6 3
09-03-04 reads Minichromosome? ? B3 4
09-03-07 reads Minichromosome? ? AS 5
09-04-01 reads Minichromosome? ? A6 3
09-04-02 reads Minichrornosorne? ? AS 5
09-04-10 reads Minichromosome? ? Cl 6
14-05-01 reads Minichromosome? ? A2 7
14-05-02 Tb09.v4.0077 tryp_ IXb-217g0S.qlc Atypical B2 8
14-06-01 Tb09.v4.0077 tryp IXb-217g0S.qlc Atypical B2 S
21-0S-024> Tb09.v4.0077 tryp. IXb-217g0S.qlc Atypical B2 8
21-08-03 Tb09.v4.0077 tryp IXb-217g0S.q1c Atypical B2 8
22-07-01 Tb09.244.15S0 Chr9 Functional A3 9
22-07-02 Tb11.v4.0074 ChrIl Pseudo gene A6 A6 10
Tb10.v4.0161 tryp X-324h11.p1k Pseudogene A6
Tb11.14.0001 Chrll Pseudogene A6
22-07-03 Tb927.3.190 Chr3 Functional A2 11
22-07-04 Tbl1.30.0005 ChrU Pseudo gene A4 A4 12
Tb11.v4.0021 Chr11 Atypical A4
Tb09.354.0090 Chr9 functional B6
24-09-01 Tb09.v4.0102 tiYP: IXb-218d07.plc Atypical B2 13
28-10-02 Tbl1.09.0005 ChrIl Functional B3 14
Tb11.13.0003 ChrIl Pseudozene
28-10-03 Tb11.09.0005 Chr11 Functional B3 15
Tbl1.13.0003 ChrU Pseudoaene
Read (3'donor) AZ217061 ?
28-10-04 Same as 28-10-03 Same as 28-10-03 Same as 28-10-03 B3 IS
2S-10-07 Tbll.v4.0027 tryp. XI-339b02.q2k2024 Pseudozene A3 16
read tryp. XI-934dI2.q1k rev ?
read tryp X-334d06.plc ?
28-10-10 Read trW XI-I0S8dOl.qlk ? B2 17
Tbll.S7.0032 Chrll Pseudogene Bd
Tb09.244.0090 Chr9 Pseudo gene B 1
28-11-01 read CONTIGI0023 1100 bp ofVSG Bl IS
2S-11-02 Tb927.5.50S0 ChrS Functional A2 19
28-11-03 Tb927.S.S080 ChrS Functional A2 19
2S-11-04 Tb927.5 .S080 ChrS Functional A2 19
2S-11-0S Short contig CONTIGI0023 1100 bp ofVSG Bl IS
2S-11-07 Tb927.S.50S0 ChrS Functional A2 19
28-11-08 Tb927.5 .S080 ChrS functional A2 19
2S-11-09 Tb927.7.6S30 Chr7 Pseudozene B3 B3 20
read lAL4SS630 ?
read 2AQ660659 ?
Read (3' donor) 3AL474336 ?
2S-11-1l Tb927.5.50S0 ChrS functional A2 19
2S-11-13 TbI0.v4.0088 trYP X-206a03.plc functional A2 21
28-11-14 TblO.v4.00SS trYl) X-206a03.plc functional A2 21
43 The day 21 infection corresponds to mouse S instead of 7 because blood was not harvested on day 21, but
it was passaged in an irnmunocompromised mouse and harvested on day 23, after mouse 7 (day 22).
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7.3.3 Table listing aI/ point mutations found in VSG cDNAs
Table 7.6: All unique point mutations detected in sequenced VSG clones derived from
chronic infection study, when compared with putative donors.
VSG (clone VSG Codon Parent Aa Codon aa Syn eN)1 Base
identifier) type position Codon non syn change
(y)
03-01-02 A2 619 GCG A GAA E Y 23
03-03-01 A6 64 ATA I CTA L Y 1
03-03-01 A6 70 AAA K GAA E y 1
03-03-01 A6 82 GGT G GGG G N 3
03-03-01 A6 196 AAG K MC N y 3
03-03-01 A6 220 ATC I MC N y 2
03-03-01 A6 436 GCC A GGC G y 2
03-03-01 A6 496 GCA A GCC A N 3
09-03-03 A6 670 CTG L CTA L N 3
09-03-03 A6 820 GCA A GM E y 2
09-03-03 A6 832 ATT I ATC I N 3
09-03-04 B3 22 GTG V GGG G y 2
09-03-04 B3 127 AGT 5 AGC 5 N 3
09-03-07 AS 373 GCA A ACA T y 1
14-05-01 A2 943 MG K AGG R y 2
14-05-02 B2 1267 TTA L CTA L N 1
14-06-01 B2 127 AAA k MC N Y 3
14-06-01 B2 310 AGC 5 MC N Y 2
14-06-01 82 430 AGC S MC N Y 2
21-08-02 B2 583 GGA G AGA R y 1
21-08-02 B2 643 GCG A ACG T y 1
21-08-02 B2 688 AGC 5 GGC G y 1
21-08-03 B2 607 GCC A GAC D Y 2
22-07-01 A3 58 GM E CM 0 y 1
22-07-01 A3 472 CAC H MC N y 1
22-07-01 A3 499 CCT P GCT A Y 1
22-07-01 A3 568 MC N GAC D y 1
22-07-01 A3 607 GAT D MT N Y 1
22-07-01 A3 610 CTG L CTA L N 3
22-07-01 A3 688 GCC A GGC G y 2
22-07-01 A3 736 AAA K MG K N 3
22-07-01 A3 871 GGC G MC N y 12
22-07-02 Al 31 ATA I CTA L Y 1
22-07-02 A1 34 ACG T GCG A Y 1
22-07-02 A1 340 CGC R AGG R N 13
22-07-02 Al 343 AGC S GGC G y 1
22-07-02 A1 502 GAA/GA E/D GAG E N 3
T
22-07-02 Al 511 ACC T ACT T N 3
22-07-02 Al 517 ACC/GA TID GCC A Y 1/2,3
T
22-07-03 A2 379 CAG Q CM 0 N 3
22-07-03 A2 388 CTT L CTA L N 3
22-07-03 A2 394 CAC H CAT H N 3
22-07-03 A2 448 GGC G AGC 5 Y 1
22-07-03 A2 457 CCC P GCC A y 1
22-07-03 A2 460 TTA L TTG L N 3
22-07-03 A2 469 GCA A ACA T Y 1
22-07-03 A2 475 AGC 5 ACT T Y 23
22-07-03 A2 478 TCA 5 CCA P Y 1
22-07-03 A2 517 AAC N ACC T Y 2
22-07-03 A2 541 GTT V CTT L Y 1
22-07-03 A2 655 GCA A GCG A N 3
22-07-03 A2 790 GGC G GCC A Y 2
22-07-03 A2 820 AGC 5 MC N y 2
22-07-03 A2 925 AAA K CM Q y 1
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22-07-03 A2 1138 GCA A GTA V Y 2
22-07-04 A4 316 ACC T ACG T N 3
24-09-01 B2 571 AAC N AGC 5 y 2
24-09-01 B2 577 GGG G GGC G N 3
24-09-01 B2 637 GGA G GGC G N 3
24-09-01 B2 673 ACG T GCG A y 1
24-09-01 B2 700 TCA 5 AAA K y 12
24-09-01 B2 712 AAC N GAC D y 1
24-09-01 B2 751 CCA P CCG P N 3
24-09-01 B2 781 GCG A ACG T y 1
24-09-01 B2 835 GGG G GGC G N 3
24-09-01 B2 1240 GAA E GAC D y 3
28-10-03 B3 55 AAC N AGC 5 y 2
28-10-03 B3 226 GAC D GAG E y 3
28-10-03 B3 244 GAA E GAC D Y 3
28-10-03 B3 310 GAT D AAT N y 1
28-10-03 B3 406 GAC D GAA E Y 3
28-10-03 B3 412 GCC A GCA A N 3
28-10-03 B3 541 ACA T ACG T N 3
28-10-03 B3 550 ACC T AGC 5 y 2
28-10-03 B3 676 CAC H CAT H N 3
28-10-03 B3 859 ACC T ACA T N 3
28-10-07 A2 106 AAC N AGC 5 y 2
28-10-07 A2 145 AGT 5 ACT T Y 2
28-10-07 A2 154 ACC T ACA T N 3
28-10-07 A2 196 ATG M ATT I Y 3
28-10-07 A2 202 CAG Q CAA Q N 3
28-10-07 A2 244 AGC 5 AAC N Y 2
28-10-07 A2 373 GCC A GTC V Y 2
28-10-07 A2 433 GCA A AAA K Y 12
28-10-07 A2 472 GAA E GAG E N 3
28-10-07 A2 601 GGA G GGG G N 3
28-10-07 A2 604 AGC 5 ATC T y 2
28-10-07 A2 616 GGC G GCC A Y 2
28-10-07 A2 676 ACG T ACA T N 3
28-10-07 A2 709 GGC G GAC D Y 2
28-10-07 A2 979 AAA K ACA T y 2
28-10-07 A2 1075 ACA T GCA A Y 1
28-10-10 B2 154 ACG T GCG A Y 1
28-10-10 B2 604 AAC N AGC 5 y 2
28-10-10 B2 610 GAA E GCA A Y 2
28-10-10 B2 634 ACC T AGC 5 Y 2
28-10-10 B2 703 AAA K AGA R Y 2
28-10-10 B2 748 CCC P GCC A Y 1
28-10-10 B2 790 GGA G GGC G N 3
28-11-01 B1 583 CCG P ACG T Y 1
28-11-01 B1 681 AAG K AAA K N 3
28-11-01 B1 700 CCA P GCA A Y 1
28-11-01 B1 823 AAC N GAC D Y 1
28-11-01 B1 1261 GTG V GCG A Y 2
28-11-01 Bl 1582 AGA R AAA K Y 2
28-11-02 A2 202 GCG A ACG T Y 1
28-11-02 A2 235 TCC 5 GCC A y 1
28-11-02 A2 238 GAC D GAA E Y 3
28-11-02 A2 352 AGC 5 AGA R Y 3
28-11-02 A2 415 AGC 5 AAC N Y 2
28-11-02 A2 451 GAG E GAC D Y 3
28-11-02 A2 562 AAG K AAA K N 3
28-11-03 A2 103 CCG P CCC P N 3
28-11-03 A2 112 ATA I CTA L Y 1
28-11-03 A2 151 ACA T ACG T N 3
28-11-03 A2 241 GTC V GCC A Y 2
28-11-03 A2 301 AGC 5 AGA R y 3
28-11-03 A2 439 ACC T AGC 5 y 2
28-11-03 A2 553 ACT T GCT A Y 1
28-11-03 A2 868 GCA A GTA V Y 2
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28-11-03 A2 880 ACG T GCG A Y 1
28-11-03 A2 1450 TTG L TTA L N 3
28-11-04 A2 52 MC N GAC D y 1
28-11-04 A2 148 TAC Y TAT y N 3
28-11-04 A2 274 GCA A GCT A N 3
28-11-04 A2 316 AGC 5 MC N Y 2
28-11-04 A2 487 GAG E GM E N 3
28-11-04 A2 610 TCA 5 ACA T Y 1
28-11-04 A2 640 GGT G GCT A y 2
28-11-04 A2 1402 GGA G GGG G N 3
28-11-04 A2 1429 GCC A GCA A N 3
28-11-07 A2 67 ACC T AGe 5 y 2
28-11-07 A2 943 AAA K MG K N 3
28-11-08 A2 244 GM E GAC D y 3
28-11-08 A2 382 GCA A ACA T y 1
28-11-08 A2 493 AGA R AAA K y 2
28-11-08 A2 565 ACT T MT N y 2
28-11-08 A2 610 TCA 5 TeG 5 N 3
28-11-08 A2 640 GGT G MT N y 12
28-11-08 A2 664 Ace T Me N y 2
28-11-08 A2 676 GCC A GGC G y 2
28-11-09 83 43 GCG A GCA A N 3
28-11-09 83 85 GTG V GeG A y 2
28-11-09 83 88 eGT R GAT D y 12
28-11-09 83 94 CAG 0 CM Q N 3
28-11-09 83 97 CCG P CTG L y 2
28-11-09 83 292 TAC y CAe H y 1
28-11-09 83 298 Ace T Me N y 2
28-11-09 83 307 TCG 5 GeG A y 1
28-11-09 83 628 GCC A GM E Y 23
28-11-09 83 655 GAT D GAe D N 3
28-11-09 83 700 GTC V GTG V N 3
28-11-09 83 796 ACG T GCG A y 1
28-11-09 83 931 GCG A GAC D y 2
28-11-09 83 1357 GGG G GGA G N 3
28-11-11 A2 160 AGC 5 Me N y 2
28-11-11 A2 181 AGA T AAA K Y 2
28-11-11 A2 232 CAG 0 CGG R Y 2
28-11-11 A2 253 GCA A GCG A N 3
28-11-11 A2 445 ACC T Me N y 2
28-11-11 A2 640 GGT G GGC G N 3
28-11-11 A2 643 GCA A ACA T Y 1
28-11-13 A2 112 GCA A ACA T y 1
28-11-13 A2 322 CCT P ACT T y 1
28-11-13 A2 358 ACA T GCA A y 1
28-11-13 A2 364 GGe G GGG G N 3
28-11-13 A2 373 Gce A GGC G y 2
28-11-13 A2 424 GCT A AGT T y 1
28-11-13 A2 661 GCT A GeG A N 3
28-11-13 A2 667 ACA T GCA A Y 1
28-11-13 A2 787 AGe 5 AAA 0 y 23
28-11-13 A2 838 ACA T GCA A y 1
28-11-13 A2 859 GGA G GGG G N 3
28-11-13 A2 1294 AAA K AGA R y 2
28-11-14 A2 247 GCA A ACA T Y 1
28-11-14 A2 265 GCA A GRA V y 2
28-11-14 A2 415 AGe 5 MC N y 2
28-11-14 A2 418 GGC G GAe D y 2
28-11-14 A2 442 TCG 5 ACG T y 1
28-11-14 A2 601 GGG G GGA G N 3
28-11-14 A2 676 Gce A GGG G y 23
28-11-14 A2 727 MC N CAC H y 1
28-11-14 A2 892 GCA A CCA P y 1
28-11-14 A2 931 CTA L TTA L N 1
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7.3.4 Chi squared tests
Table 7.7: Chi squared test for non-random distribution of mutations in type A and type B N-
terminal domains of expressed VSGs.
Point mutations found in the first 1000 bp of expressed VSGs were grouped according to
domain type (type A and type B). The occurrence of mutations was recorded in 100 bp
intervals and compared to the expected random distribution. The Chi squared value for
nine degrees of freedom is 21.67 at the 0.01 significance level.
N-terminal domain Mutation Mutation o-e (o-e)£ (o-e)"/e
1000 bp, divided distribution (o) distribution (e)
into ten qrouos
Type A N-terminal domains
1-100 8 12 -4 16 1.33
101-200 12 12 0 0 0
201-300 13 12 1 1 0.08
301-400 16 12 4 16 1.33
401-500 22 13 9 81 6.23
501-600 9 12 -3 9 0.75
601-700 23 12 11 121 10.08
701-800 5 12 -7 49 4.08
801-900 9 12 -3 9 0.75
901-1000 5 13 -8 64 4.92
sum 122 122 0 366 29.57
Type B N-terminal domains
1-100 7 5 2 4 0.8
101-200 3 5 -2 4 0.8
201-300 4 5 -1 1 0.2
301-400 3 5 -2 4 0.8
401-500 3 6 -3 9 1.5
501-600 6 5 1 1 0.2
601-700 12 5 7 49 9.8
701-800 10 5 5 25 5
801-900 3 5 -2 4 0.8
901-1000 1 6 -5 25 4.16
sum 52 52 0 126 24.06
Table 7.8: Chi squared test for preferential association of point mutation with predicted non-
helical regions in the N-terminal domain of three expressed VSGs.
The Chi squared value for 1 degree of freedom is 3.84 at the 0.05 confidence level.
N-terminal domain Mutation Mutation o-e {o-er (o-et/e
secondary distribution (0) distribution (e)
structure
prediction
22-07-03, helical content 167/360 amino acids
helical 3 7 -4 16 2.28
non helical 12 8 4 16 2
sum 15 15 0 32 4.28
24-09-01, helical content 164/360 amino acids
helical 0 4 -4 16 4
non helical 8 4 4 16 4
sum 8 8 0 32 8
28-11-02 and related clones (see Chapter 4): 166/360 amino acids
helical 12 19 -7 49 2.57
non helical 29 22 7 49 2.22
sum 41 41 0 98 4.80
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7.4 Supplementary material to Chapter 5
7.4. 1 VSG-related table
Table 7.9: VSG-related (VR) gene identifiers.
The first column gives the identifier used in Chapter 5, the second column gives the
identifiers present in the sequence alignments given below (Figures 7.2 to 7.5), while the
third column gives the GeneDB identifiers. Columns four to six give the cluster number to
which VRs belong, based on full-length, N-terminal domain and C-terminal domain
alignment respectively. The last column specifies whether VRs are pseudogenes (ps) (Y or
N).
VR Old id GeneDB id FLe! Ne! Cel ps
id
1 1 VR 1013265 Tb927.1.5060 I I I N
2 1 VR 1027246 Tb927.1.5170 10 n 2 N
3 2 VR 393056 Tb927.2.2060 2.1 2.1 2.1 N
4 3 VR 374532 Tb03.IJ15.190 3 4 2 N
5 3 VR 388094 Tb03.lJl5.250 2.2 2.2 3 N
6 3 VR 394163 Tb03.IJI5.200 2.2 2.2 3 N
7 3 VR 396343 Tb03.IJ!5.350 3 4 2 N
8 3 VR 637733 Tb03.4808.310 3 3 I N
9 3 VR 1539306 Tb03.2HI5.460 2.1 2.1 2.1 N
10 5 VR 2864 Tb05.25N21.420 I I I N
11 5 VR 14812 Tb05.25N21.360 1 I 1 N
12 5 VRd 1374081 Tb05.26C7.250 1 1 1 Y
13 8 VR 2088588 Tb08.IOKI0.350 2.2 2.2 3 N
14 8 VR 2092483 Tb08.10KI0.330 2.2 2.2 3 N
15 9N VR 900592 Tb09.160.5350 2.1 2.1 2.1 N
16 9 VRd 904454 Tb09.160.5370 3 3 1 Y
17 9 VR 923603 Tb09.160.5440 I 1 I N
18 9 VR 926375 Tb09.vl.0300 3 3 I N
19 9 VR 936679 Tb09.vl.0290 I I I N
20 9N VR 2175922 Tb09.244.2330 2.3 2.3 2.1 N
21 9N VR 2184381 Tb09.244.23I 0 2.3 2.3 2.1 N
22 9N VR 2192834 Tb09.244.2280 2.3 2.3 2.1 N
23 9N VR 2201311 Tb09.244.2240 2.3 2.3 2.1 N
24 9N VR 2209783 Tb09.244.2200 2.3 2.3 2.1 N
25 9r VRd 86603 Tb09.142.0340 I 1 1 y
26 11 VRd 1268929 Tbl1.51.0003 10 n 3 y
27 11 2 VR Tbll.02.1566 2.2 2.2 3 N
28 11 VRd 462214 Tb 11.17.0003 1 1 1 Y
29 l1s VR 1122854 Tbl1.01.4560 2.1 2.1 2.1 n
30 Chr 10 30829 No id
31 Chr 10 20376 Tb 10.v4.0003
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7.4.2 VR C-terminal domain alignments
Alignments in Figures 7.2 to 7.5 were performed with ClustafX, then edited with Bioedit.
The edited sequences were realigned using ClustalW at Poly bioinformatique Lyonnais
(http://npsa-pbil.ibcp.fr/cgi-binlnpsaautomat.pl?page=npsa clustalw.html), for the
graphical output style.
9 VRc 936679
1VRc 1013265
5_VRc_2864
1l_VRcd_462214
5_VRc_1374081
3_VRc_637733
9_VRc_926375
5_VRc_14812
9 VRc 936679
1VRc 1013265
5 VRc 2864
1l_VRcd_462214
5 VRc 1374081
3 VRc 637733
9_VRc_926375
5 VRc 14812
NAITDADTAATTTTSTETDTNTNTRTKRSBRENS- TKGSGEPQKNGNTNTQTTTSATAT
DESAGGNTKPSTDGQ SMEKKPKSNTKPSTGENS- AKGLEGSQKDGNPNAQTTTSTE--
DESASGSTKPRAEGKPSME~KPNTVPSTGDNS-PAKGTEGPQNDGN~NAQATTSSE--
DESASGSTK'PSTDGKPSMEK- _-S- -KRSTGENS- PAKGSGGPQNDGKQNTQATTSTE--
DEGTSRHTKBSSDGE SMDAK!PNSNLKRSTEENS- SERSDEPREKGNPDAQTTTTTET-
QKVNKMPGSPBRQSPBEIKVQPEEDBSPEQRPKQSPSTATDGN-TNTSAATQSTTDPDLV
GKTHQQPVSQPVVQPEEQNVEEKNKBLPAQPHPQHPQTAAESEAKNTNTNTQTTTDTDPF
-ERAYSNAHPQTKETSKKEK--SDRST SKTEGPHTTARTDGSTQNERPNAQRNTTATTS
:* *
ETTGTTTRPPEEQRSFAEINSRSBWIFLFLLLYKPFHH-
-KDATTARPPEEQKSSSKIILQFLWIFLFWLFV------
-KDATTTRPEEEQKSSSKTILQFLRIFLFWLFA------
-TGATTAR EEEQKSSVKIISQSLWILFAVSVNCPTVRH
ETGLTTARPPEEQKSSTKIILQSIWVFLFWLFV------
PLGETRTNQPLRPKNVAQAISB-LVVFLLFLL-------
SSRETNTTKPL PKNETQVISP-LLVILLLLI-------
DMTNNTKRPPEEQRSCTIVASRPVTLFLLSFI-------
* . ..
Figure 7.2: VR C-terminal domain Cluster 1 alignment.
Proline residues are highlighted in gray. Conversion to current GeneDB id can be made by
use of Table 7.9.
3 VRc 1539306
9N VRc 900592
11s VRdc 1122854_ _
9N VRc 2209783
2 VRc 393056
3 VRc 1539306
9N VRc 900592
11s_VRdc_1122854
9N VRc 2209783
2_VRc_393056
GNGGDEILGSGGVEGEVNTNESTKANTNDGRAKKAGESKR-TPVDNISHKDEGYRQGKTC
RGGGSPHSGSRGAEGRNKWPGSERLEQSNGNREGISESVVGAAVKNPLLEONDYKREQTC
EGNAVPSVSKDVVENNNENSGVSNNREKRESKGELNEEKS GSEKSEEVDCDGCKPEEGC
GRGGQRGRQKRSVN ENSVPET ADBSDBTQSV HTNEKKRSVRKPISTGNGATKSYNSE
EKKLKDILRNVESIKTSKLSQMPRSGISQLKDGTTONKGRGQKGPSSGVEOSECESQAE
KSRKVETE8DWEEGT VGSAQ I ETSGKVNSIR-CSLSLFLILL
AGLKAEMG EWNGDA VAATRRRAIRSRVNNLQ-TELALFLLL-
E----EGK ESENGRHDSEGKRPRVKSHSATIIGGSLKFFLLLG
EDDSYEYE EGENSACSDS A I TVKNSKSAIN-CELGLILLLV
PLASQADKIS-V LWLFFL -
*: . . *
Figure 7.3: VR C-terminal domain Cluster 2.1 alignment (C-terminal domain cluster with
cysteines).
Proline residues are highlighted in gray, cysteine residues in yellow. Conversion to current
GeneDB id can be made by use of Table 7.9.
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* * ** * *:*: . : * * * : * *
3 VRc 388094
3 VRc 394163
8 VRc 2092483
11 2 VRc
YVFGDRRKFSFWRLWILPQEAPGHRVRYVVRGRNRDIKNIPWMRELLKVFNEMRDLKDYE
YTLGGGVGFSFWRYPIMAHSLAGHRVRYVVRGRNRDIKNIEWMRELLKVFNEMRDLKDYE
YVRGKHKKQLFWBLEFLSGYVPGPGVHYIINTRAGMVEDIPWLGELREIATLMGDSSEDN
YILGYQKRNSFWSLGLSSRGPMGPGVHYVRMGKEKTTDDIPWLKLLREVTMEMGQPAQDN
3 VRc 388094
3 VRc 394163
8 VRc 2092483
11 2 VRc
NDKRTLADAIEKLQKEFEESNRKIGNAKN
NDKRTLADAIEKLQKEFEESNRKIGNAKN
VEGRELKSAIEKLEGDLEELF TGGVRRG
VQEGEFTEALEKLEQDLEKLIQTK-----
.. *:***: ::*:
Figure 7.4: VR C-terminal domain Cluster 3 alignment.
Proline residues are highlighted in gray. Conversion to current GeneDB id can be made by
use of Table 7.9.
cl1_11_VRcd_462214
cl1 1VRc 1013265
cll 3 VRc 637733
cl1_5_VRc_1374081
cl1_5_VRC 14812
cl1_5_VRc_2864
cll_9_VRC_923603
cl1_9_VRC_926375
cl1_9_VRC_936679
c12 11s VRdc 1122854
c12_2_VRc_393056
c12_3_VRc_1539306
c12 9N_VRC_2209783
c12 9N_VRc_900592
c13_11_2_VRc
c13 3 VRc 388094
c13_3_VRc_394163
c13_8_VRc_2092483
TC_M15112_YNat11
TC_M15113_YNat13
TC_M74802_ffiVSG1
TC_M74803_ffiVSG2
TC PILNat32
TC U07141
TC U07142
TC X79399 BENAT1
TC_X79400_BeNat12
TC_X79401_BeNat13
cl1_11_VRcd_462214
cll 1VRc 1013265
cl1_3_VRc_637733
cl1_5_VRc_1374081
cl1_5_VRc_14812
.cll_S_VRc_2864
cl1_9_VRc_923603
cl1_9_VRc_926375
cll_9_VRc_936679
c12_11s_VRdc_1122854
c12_2_VRc_393056
c12_3_VRc_1539306
c12_9N_VRc_2209783
c12_9N_VRc_900S92
c13_11_2_VRc
c13_3_VRc_38B094
c13_3_VRc_394163
c13_B_VRc_2092483
TC_M15112_YNatll
TC_M15113_YNat13
TC_M74B02_ffiVSG1
TC_M74803_ffiVSG2
TC PILNat32
TC U07141
TC U07142
TC_X79399 BENAT1
TC_X79400_BeNat12
TC_X79401_BeNat13
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--ILGSGGVEGEVNTNESTKANTNDGRAK-KAGESKRT~VDNISHKCEGYRQGKTCKSRK
--GRQKRSVN~ENSV~ETPADPSDPTQSV~HTNEKKRSVRKJPISTGNGATKSYNSEEDDS
--HSGSRGAEGRNKWPGSJP LEQSNGNREGISESVVGAAVKN~LLECNDYKREQTCAGLK
--ILGYQKRNSFWSLGLSSRG~G~GVHY-VRMGKEKTT-DDIPWLKLL-REVTMEMGQ
--VFGDRRKFSFWRLWIV QEAiPGHRVRY-VVRGRNRDI-KNIPWMREL-LKVFNEMRDL
--TLGGGVGFSFWRY lMAHSLAGHRVRY-VVRGRNRDI-KNIPWMREL-LKVFNEMRDL
--VRGKHKKQLFW LEFLSGYVPGPGVHY-IINTRAGMV-EDI~WLGEL-REIATLMGDS
--EKNLRMAEGDLRGLLTAKQLVAALQAR-AEHLEDAAF-TIFNESVES-SRPPSTDANT
--LGHIKNAITALENRDKNLQRVRKLQRQ-AEAILMSAE-DALIEANSL-GGKDMV~ASE
--VKRYLDAAQSLRNAHGLTLGAQNDLTR-LEALHHSGL-DAFESESVS-SHKAA~VTTA
--YDKMRKIILKQKELDSERSNLQVLQYQ-LAHLEELAH-QAYLDEYSS-ASAPSSEATK
--ATAFLAAADELRAVDEQKRQLDSLENQ-LAALEiPLSK-TLYTGAVDN-SPRQTLKGPJ)
--LKNMIEALKLLRKAEDATSSIQADLSH-LKMLQHRAE-EVYLEAQEL-EKTNFEGPKG
--LKKlKEGLDKWQKIEETNTTIQQDIMY-LKILEARAV-EVYGEAREL-GAVSSGA~TQ
--EKRLREASWELRQIEERKREGEVLLTQ-LEMLNHSAW-ETCLEAWER-SSSTKVSGSP
--VANLRTAALELQKAEAAAQRRQIEITK-LRDVNTTAW-SIFVASLSQ-I SNGQTGHQQ
--LQKIKNGlAELEKAHKGEATIRNAITH-LKMLGTRAE-EIYEEAKDQ-ETTTSRI~TK
TS-TETGA--TTARPPEEQKSSVKIISQSLWILFAVSVNCPTVRH
TS-TEKDA--TTARPPEEQKSSSKIILQFLWIFLFWLFV------
TDPJ)LVPLGETRTNQPLRiPKNVAQAISI- LVVFLLFLL- ------
TT-TETETGLTTARPPEEQKSSTKIILQSIWVFLFWLFV------
TTATTSDMTNNTKRPPEEQRSCTIVASRPVTLFLLSFI-------
TS-SEKDA--TTTRPPEEQKSSSKTILQFLRIFLFWLFA------
TSATATETTGTTTRPP EQRSFAEINSRSPWIFLFLLLYKP HH-
TDTDPFSSRETNTTKiPf'RPKNETQVISP-LLVILLLLI-------
TSATATETTGTTTRiPPEEQRSFAEINSRSiPWIFLFLLLYKPFHH-
KCESENGRHDSEGKR VKSHSATIIGG--SLKFFLLLG------
AECTHTGCNKREGNCIDIKRiPPLASQADKISVPLWLFFLiP-----
VETECDWEEGTCVGSAQRPPTSGKVNSIRCSLSLFLILL------
YEyECEGENSACSDS~BrVKNSKSAINCiPLGLILLLV------
AEMGCEWNGDACVAATRRRAIRSRVNNLQTPLALFLLL-------
AQDNVQEG--EFTEALEKLEQDLEKLIQTK---------------
KDyENDKR--TLADAIEKLQKEFEESNRKIGNAKN----------
KDyENDKR--TLADAIEKLQKEFEESNRKIGNAKN----------
SEDNVEGR--ELKSAIEKLEGDLEELFiPTGGVRRG----------
SQKGPLQRPEKSGESSHLPSGSSHGTKAIRSILHVALLM------
VTVPNSSNPTSRQNSVVQEPTTVSAAAITPLILOOLLI------
AEPSASTPTATNQQQEQSNSASKQSHVKVLHFSTFLALTM-----
PEASLPVQSSEADTKAVQGVRGiPPAY IPICVILGLLV-------
DSKVGYTTNSSEERRINSGSSGRVGVSFMTAATVFRLFTN-----
Figure 7.5: Multiple sequence alignment of C-terminal domain of 10 Trypanosoma
congo/ense cDNAs with 18 T. Bruce; VR C-terminal domains, from clusters 1, 2 and 3.
The first part of each sequence id specifies the nature of the domain: c11, cl2 and cl3
correspond to the three VR C-terminal domain clusters, TC corresponds to Trypanosoma
congo/ense.
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7.4.3 Primers
Table 7.10: Primers used in Chapter 5 experiments.
Primername sequence
VRprimersusedin experimentsdescribedin section5.3.1and5.3.2
VRl f GCTACTGGAGCGAATGAAGG
VRl r TGCAATCCATTGCTTGTGTT
VR2 f GGCAACGTCCAAAATATGCT
VR2 r ATTCTTGCGGTTTGGATTTG
VR4 f AGCTAAGCAGCATTGGGAGA
VR4 r TCATTCGGTATTTTCTCGGC
VR5 f GCCTCGTATGAATTTGGGAA
VR5 r TTCCGGTACATCCATCAACA
VR8 f ACCAAAGGGAGTTTGACGTG
VR8 r TCTTCGGCTCTGTCCTTGTT
VR9 f AACATCAGGAAGACCAACGC
VR9 r TCTTTTGCTTTCACCAGCCT
VR11 f TGGCCAAGATAGTGGAAACC
VR11 r CGCATCCTGAATTGAACCTT
VR13 f ACAACCCGAAGTGAATCAGG
VR13 r TCAGCCCTCTTCCCTCTACA
VR15 f GGAAATTTTGGACAGGAGCA
VR15 r CGATGCACCACATAGACAC
VR18 f GGAACACAAGCAGAACAGCA
VR18 r CCTAGGTTGTTGGTGCGTTT
VSG primersusedin experimentdescribedin section5.3.2
221f ATGCCTTCCAATCAGGAGGC
221r TGTATGGGCGACAACTGCAG
121f TAACCTTTACAACAGAGCGCACAAACTTAA
121r CGCTGGCTGTGGTGCTCAGAATCATGCAGA
118f CAGGTTCAGTCGAAGTATCAAGCAACAGGC
1I8r TTCGTCTAGGACCCCGGCGGCCCTACCGGC
G4f CTAACAGCAGCAGCGATGCAAAGTAGGATG
G4r TCATCAAGGTAGTCCGTTGTGCGTGGCGTT
S8f TCCAGCAAACGAGCGGATGCGGCGCTGGTG
S8r CACGGCCTTGTCTTGTGCTGGCCCTGTTGT
V02f AGCCGCCTCGCCTGACGCAGCAACAGCGTG
V02r CGGTTCCGGCGCTGCAAAGGCAGAGCAAGT
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7.4.4 T. congolense VSGs analysed
Table 7.11: Brief description ofthe 13 T. congo/ense VSGs analysed in current study.
The contig name and coordinate of start codon are given, in the absence of GeneDB
identifiers. As for T. bruce; VSGs, the sequences are characterised by whether they are
"full-length", "intact" (no stop codons) and "functional" (putative functional). The question
marks in the last column indicate that not enough data are available for expressed T.
congo/ense VSGs to make accurate predictions based on a known consensus.
coordinate contig Full Intact functional
length
1 8988 congo502c05.plk y y ?
2 7537 conqo502c05.plk y y ?
3 5320 congo502c05.plk y y ?
4 2072 congo385g06.Q1k y n n
5 6118 congo385g06.Q lk y n n
6 27950 945999.cOO0216108 y n n
7 735 945999.COO0541607 y y ?
8 2860 Chrl0 y y ?
9 4230 Chrl0 y y ?
10 5540 Chrl0 y y ?
11 12812 Chr10 y y ?
12 15138 Chr10 y y ?
13 16858 Chr10 y y ?
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